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 Gamma (γ) -aminobutyric acid (GABA) is the major inhibitory neurotransmitter found in 
the mammalian central nervous system. Its effect stems from its ability to cause the opening of 
ion channels which causes an influx of negatively charged chloride ions or an efflux of positively 
charged potassium ions. This hyperpolarization of the neuron lowers the threshold for neuronal 
firing. This has an overall inhibitory effect on neurotransmission, decreasing the excitability of 
the neuron and diminishing the likelihood of a successful action potential occurring. There are 
two classes of GABA receptor: ligand-gated GABAA receptor (GABAAR) and metabotropic 
GABAB receptor (GABABR). The GABAAR is a pentameric receptor containing two binding 
sites for GABA and once bound, the channel opens to allow the influx of chloride ions. 
However, GABAAR not only contains GABA binding sites but also binding sites that modulate 
the actions of GABA. This includes the benzodiazepine-binding site which occurs at the α and γ2 
interface. 
 GABAARs draws a great deal of attention as pharmaceutical targets for treating anxiety, 
insomnia, epilepsy, schizophrenia, and cognitive deficiencies, among others. Benzodiazepines 
(BZD) are regularly used as sedatives and anxiolytics. Although there are many alternatives to 
treating anxiety, none have matched either the efficacy nor the rapid onset of BZDs. However, 
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these drugs have come to be associated with undesirable symptoms, most notably development 
of tolerance, addiction, as well as withdrawal symptoms.  
 Over the past decade, there has been an emerging understanding of the specific subunit 
composition which mediates the diverse spectrum of BZD pharmacological effects which has 
generated great interest in developing α-subtype selective drugs. There are at least nineteen 
different individual GABAAR subunits that assemble the 5-subunit structure into different 
combinations to form the native receptor (α1-6, β1-3, γ1-3, δ, and minor subunits). Of these 
potential combinations, the receptors containing two of the α1-6, two of any β subunits, and one 
of the γ2 subunit are the most prevalent in the brain. Receptors containing α1/2/3/5 are known as 
BZD sensitive receptors while α4/6 are BZD insensitive. Studies have shown that the subtype 
containing the α1 is responsible for sedation, anti-convulsant effects, ataxia, amnesia, and 
addiction while subtypes responsible for anxiolysis are primarily α2, α3, and perhaps α5 based 
on one report.  
Electrophysiological techniques are critical in determining the enhancement of chloride 
conductance and calculating potency and efficacy of the drugs but data collection is limited by 
slow throughput. Herein the development of higher throughput cellular assays to determine BZD 
subtype selectivity is described. First, an assay was created and optimized using transiently 
transfected cells on automated patch clamp. However, this assay suffered from variable 
reproducibility. Next, receptor subtypes were recombinantly expressed in stable cell lines using a 
single plasmid and antibiotic. These cells can be reliably used to determine subtype specificity of 
compounds. The overall potency and efficacy of the drugs were also tested on commercially 
available human neuronal induced pluripotent stem cells (IPSC) which would more accurately 
 iv 
 
reflect the mixture of receptor subtypes natively expressed on human neurons. Next a 
fluorescence assay, which utilizes an enhanced yellow fluorescent protein that quenches in the 
presence of selective anions, was optimized and tested in order to determine if the assay was 
suitable to perform structure activity relationship studies. Finally, the GABAAR was found to be 
present in leukocytes so multiple cell sources were tested to determine their subunit composition 
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CHAPTER 1: INTRODUCTION 
1.1 History of GABAA Receptor 
γ-Aminobutyric acid (GABA) is an amino acid neurotransmitter that was first discovered 
in the late 1800’s and was only known to exist in plants and microbes where it serves a metabolic 
role in the Krebs cycle 3. In 1950, Eugene Roberts isolated a significant amount of an unidentified 
ninhydrin-reactive material in extracts of fresh brains of mouse, rat, rabbit, guinea-pig, human, 
and frog. Only traces of this substance were found in other tissues, urine, and blood. The material 
was then isolated via paper chromatograms and based on the co-migration on paper 
chromatography in three different solvent systems, the substance was revealed to be GABA. 
Subsequent isotope derivative methods verified the findings 4. Ernst Florey, in 1953, independently 
observed that an unknown compound from horse brain inhibited the crayfish stretch receptor as 
well as inhibited the patellar reflex in cats 5. Florey purified the molecule from 100 pounds of cow 
brain with the help of Alva Bazemore of Merck Inc. and identified the active compound as Factor 
I (where ‘I’ represented inhibitory action). Thus, Ernst Florey proposed that GABA was an 
inhibitory neurotransmitter in the brain. However, some of the findings were in question. Firstly, 
GABAs large abundance was 1000-fold higher than known monoamine neurotransmitters. 
Secondly, its simple structure and its appearance in the Krebs cycle seemed to suggest that it was 
a metabolite rather than signaling molecule 6. In 1956, topically applied solutions of GABA 
exerted inhibitory effects on electrical activity in the brain 7. The research into GABA flourished 
during this period and 3 years later led to the first truly interdisciplinary neuroscience conference 
ever held where most of the key players in this field gathered to discuss their findings 8. However, 
its role in the mammalian CNS was largely in question until the late 1960s when GABA was found 
to be the major inhibitory neurotransmitter in the central nervous system (CNS). Research 
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demonstrated proof of postsynaptic action, presence in inhibitory nerves, release from terminals 
of nerves and the rapid inactivating mechanism at synapses which were carefully reviewed and 
extensively documented at the time 8,9.  
GABA is synthesized by the decarboxylation of L-glutamic acid in the vertebrate CNS, a 
reaction catalyzed by glutamate decarboxylase (GAD) which localizes primarily in inhibitory 
neurons 10. However there is gathering evidence of the presence of both GAD and GABA in non-
neuronal tissues and the peripheral nervous system which will be discussed further in Chapter 6: 
IMMUNOLOGICAL ROLE OF GABAA RECEPTOR ON T-LYMPHOCYTES. The reversible 
transamination of GABA with α-ketoglutarate is catalyzed by GABA-transaminase (GABA-T) 
and results in the products of succinic semialdehyde which is then converted to succinic acid by 
succinate-semialdehyde dehydrogenase (SSADH). Steady state concentrations of GABA in the 
brain is usually monitored by GAD and not by GABA-T. In many inhibitory nerves, both GAD 
and GABA-T are found throughout the neuron. While GAD is highly concentrated in the 
Figure 1. Schematic of GABA shunt metabolic pathway. 
 3 
 
presynaptic terminals, GABA-T is contained in mitochondria of all neuronal regions 11. GABA 
transporter (GAT) then removes GABA from the synaptic cleft, terminating inhibitory synaptic 
transmission and regulates spill-over to neighboring synapses 12. The entire process is known as 
the GABA shunt, shown in Figure 1, and is detailed further in a review 11.  
In the 70s and 80s, research was subsequently turned to defining the nature of the receptor 
that GABA acts on. Early electrophysiological studies on the GABA receptor showed inhibitory 
hyperpolarizing responses 13 resulting from an increased membrane chloride conductance 14 that 
were blocked competitively by the alkaloid bicuculline 15. Not long after, another study attempting 
to identify receptors on peripheral nerve terminals found that GABA reduced release of 
noradrenalin in the rat heart, this effect was not blocked by bicuculline. This action could be 
reproduced with application of baclofen, which in contrast, was unable to produce responses in 
neurons of the CNS. This new receptor was named GABAB receptor to differentiate it from the 
more familiar type which was termed GABAA receptor (GABAAR) 
16,17.  During this time, another 
bicuculline-insensitive receptor was found and termed GABAC, however it was later determined 
by the IUPHAR Nomenclature Committee to be a subgroup of the GABAA receptor class 
18,19. 
When bovine brain receptor was purified in the early 1980s 20, an analysis of the genes of the 
GABAAR and the glycine receptor the year before revealed the existence of what would later be 
called the Cys loop ligand-gated ion channel superfamily of neurotransmitter receptors, also 
known as the pentameric ligand-gated ion channels (pLIGICs) 21. With a known method of 
receptor purification, the same lab headed by Eric A. Barnard of the Imperial College of Science 
and Technology in the United Kingdom isolated two distinct GABAAR proteins 
22 which were 
later named the α and the β subunits 21. Shortly after, the presence of additional subunits was 
suggested 23,24 and molecular studies on the amino acid sequence similarities revealed that the 
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receptor subunits could be divided into eight classes which could be further divided into 
subdivisions. It would appear that the final estimate is that Homo sapiens contain six α-, three β-, 
three γ-, three ρ-, with one of each of the δ, ε, π, and θ subunits. Furthermore, splice variants for 
five subunits has been described with the best studied being γ2L (L indicated “long”) which 
includes an insert of eight amino acids between the transmembrane domains TM3 and TM4 25. 
Additional isoforms can occur in other species such as the fourth β and a fourth γ subunit identified 
in chickens, however these have yet to be described in mammals 26,27. Each subunit is comprised 
of a large (200 amino acids) extracellular N-terminal domain which putatively includes the ligand-
binding site, four hydrophobic (20 amino acids each) presumed to be membrane-spanning domains 
labeled TM1-TM4, and a small extracellular C-terminus illustrated in Figure 2. The membrane 
spanning helices are connected by short peptide sequences with the second helix expected to form 
the inner wall of the chloride ion channel. TM2 is hydrophobic in the upper two thirds of the 
channel with a funnel large enough to accommodate water molecules. Further into the channel, 
there is a narrow hydrophilic region filled with the hydroxyl groups from threonine and serine 
residues. These groups act as a selectivity filter where water molecules are sloughed from the 
chloride ions hydration shell and replaced by side chains that line the channel walls. The N-
terminal domain contains a highly conserved loop consisting of 13 amino acids due to a disulfide 
bridge between cysteine residues (C-x-[LIVMFQ]-x-[LIVMF]-x(2)-[FY]-P-x-D-x(3)-C) and are 
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therefore known as cys-loop receptors. Some subunits have a larger intracellular loop occurs 
between TM3 and TM4, contributing to phosphorylation sites as is the case of γ2L. Regardless of 
these differences, the subunits range from 50 to 60kDa and sequence homology within a subunit 
class is around 70% but between classes this number can drop to around 30% 11.  
Studies on the stoichiometry of the receptor at first yielded the assumed 2α, 1β, 2γ theory 
28, however this was replaced with the now accepted theory for the 2α, 2β, 1γ schema 29-31. Taking 
into account the number of subunits, the stoichiometry, splice variants, heterogeneity, and relative 
position of the subunits; the number of possible receptor isoforms might exceed hundreds of 
thousands of subtypes mediating different biological responses 32. However, it would appear that 
incompatibilities as well as developmental and functional transcriptional control and limitations 
by the temporal and spatial pattern of subunit expression and assembly dramatically reduces the 
Figure 2. Schematic structure of the GABAAR. LEFT: Monomeric subunit of the GABAAR imbedded 
in a lipid bilayer. The four transmembrane helices (TM1-TM4) are depicted as rods. RIGHT: Five 
individual subunits assemble to create the pentameric receptor and the central chloride anion 
conduction pore. TM2 is arranged to form the inner wall of the channel with TM1, TM3, and TM4 
form the outer wall.  
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probability of isoform expression. In fact, some studies suggest that there are less than 20 widely 
occurring combinations with the major contribution being α1β2/3γ2, α3β3γ2, and α2β3γ2 33.  
Functional GABAA receptors, upon activation, selectively conducts chloride ions across 
neuronal cell membranes. This results in a hyperpolarization of the neuron which has an inhibitory 
effect on neurotransmission by diminishing the chance of a successful action potential occurring 
and thereby decreasing the excitability of the neuron. Similarly, GABABR also causes 
hyperpolarization however these involve efflux of K+ rather than influx of Cl-. The assembled 
GABAA receptor not only contains GABA binding sites, which are believed to be at the interface 
between the α and β subunits, but also binding sites that modulate the actions of GABA. This 
includes the benzodiazepine-binding site which occurs at the interface of the α and γ2 subunit 
depicted in Figure 3.  
Benzodiazepines (BZDs) are not the only group of compounds that bind and modulate the 
GABAAR. Other compounds that interact with the GABAAR include: neuroactive steroids, 
Figure 3. Schematic representation of the GABAAR subunit arrangement in the synapse. (A) The 
directionality of the transmembrane helices (I -IV) with TM2 lining the pore; (B) The most common 
arrangement of subunits is two α, two β, and one γ. The γ subunit can be replaced by either the δ, ε, 
or θ. The GABA binding site is located between the α and β subunits so each receptor contains two 
of these sites; (C) When the subunit is γ2 and the α is either the α1, α2, 3α, or α5, a benzodiazepine 
site is formed at the interface of these subunits.  
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barbiturates, ethanol, gaseous and intravenous anesthetics, picrotoxin, and zinc, among others 34. 
It has been estimated that there are at least 12 distinct sites on the GABAAR: GABA binding site, 
picrotoxin sites, sedative-hypnotic barbiturate site, neuroactive steroid sites, benzodiazepine sites, 
ethanol sites, inhaled anesthetic sites, furosemide site, loreclezole site, Zn2+ site, other divalent 
cation sites, La3+ site and a recently discovered site between the α and β interface. However, this 
estimation is now considered conservative due to overlap and interaction between the distinct sites 
35. Most recently, a novel benzodiazepine site has been found between the α-α interface 36. Agents 
that act to increase GABA-mediated synaptic inhibition either by direct activation of the receptor 
or enhancement of the action of GABA are known as positive modulators with positive efficacy. 
These can bind allosterically at sites remote from the GABA binding site. Molecules that reduce 
the action of GABA on the receptor are known as negative allosteric modulators, known 
interchangeably as inverse agonists with negative efficacy. Finally, if a compound blocks the 
actions of both positive and negative allosteric modulators, they are referred to as neutralizing 
allosteric modulators or antagonists with no efficacy. There exists a diverse range of agents that 
act on the GABAAR and oftentimes the terminology is misused. 
An extensive review has been performed to determine the immunocytochemical 
distribution of the most common subunits in the adult rat brain 37. The summary of which is 
depicted in Figure 4 38. Presently it is estimated that 12-24 isoforms represent the most abundant 
GABAAR and according to mRNA localization and immunohistochemical staining. The α1 
subunit is the most abundant subunit in the CNS 37,39-41 with only a few regions lacking it 42. 
Colocalization of α1 with β2 has been noted using mRNA localization and double 
immunofluorescence detection 39,43. In addition, the presence of γ2 in nearly all brain regions has 
often been described as colocalizing with α1β2 39,40,44. Therefore, the most abundant receptor type 
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has been concluded to be α1β2γ2. In fact, α1, β1, β2, β3, and γ2 are found throughout the brain 
but all the others: α2, α3, α4, α5, α6, γ1, γ3, and δ are confined to specific locations in the brain. 
Relative abundances of subtypes found in rat brain is illustrated in Figure 4. Notably, 25% of the 
α1 available subunits co-assemble with different α subunits and a mixed BZD effect results. It 
should be noted that abundance does not necessarily correspond with physiological importance 
and until the whole circuitry of brain regions can be fully comprehended, even minor amounts of 
subunits cannot be ignored. Rather, a specialized function is suggested by their specific 
Figure 4. Pie chart by Paul J. Whiting, representing the approximate 
abundance of GABAAR subtypes in the rat brain. Subscript x indicates that 
the subdivision of the subunit is not known. It should be noted that these 
receptors are the most abundant ones and other subunit combinations do 
exist. Reprinted with permission from Elsevier.  
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localization in the CNS. The importance of which may be evident by the results of knock-out and 
knock-in mutations in animal models that will be discussed in 1.3 History of Subtype Selectivity. 
 
Table 1. Regional Distribution of GABAAR Subunits in the Adult Rat Brain. Table recreated from 
data. Where xxx indicates extremely high expression, ss is high, x is low, and o is very low.  
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GABAAR with different subunit composition have different physiological and pharmacological 
properties and are often differentially expressed in certain subcellular regions. For example, 
GABAA receptors composed of the α1, α2, α3, or α5 combined with β and γ subunits are 
benzodiazepine-sensitive and, with the notable exception of α5 receptors, are primarily located 
postsynaptically and mediate phasic inhibition 45-47. The α4 and α6 subunits primarily assemble 
with the β and δ subunits to form a specialized extrasynaptic receptors which mediate tonic 
inhibition and are insensitive to benzodiazepine modulation 47. Synaptic and extrasynaptic 
receptors also differ in their desensitization kinetics with synaptic receptors having rapid 
desensitization and extrasynaptic displaying slow kinetics 48. An excellent summary of the regional 
distribution of GABA published by W. Sieghart and G. Sperk can be seen in  
Table 1 49.  
It should be kept in mind, however, that the extent of expression and distribution of the 
GABAAR in rodents does not necessarily correspond to that of the human brain. For example, 
rodent hippocampus is nearly devoid of α3 while it is strongly expressed in areas of the human 
hippocampus. There are also differences in the expression of α1 which has no staining in human 
CA3 pyramidal cells while rodents have moderate immunoreactivity in the analogous CA3 
dendritic fields. Further, α1 and α2 are abundant in hilar mossy cells in humans but absent in 
rodents 50. Finally, basal dendrites of dentate granule cell show strong staining in the human brain 
while rats lack basal dendrites in the granule cells 51,52. The interspecies differences can profoundly 
influence the interpretation of findings when data gathered from animal models is translated to 
treatment of human disease. A more complete immunohistochemical study of human brain tissue 
would be greatly beneficial for the field of neuroscience, particularly in studying the brains of 
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those who suffer from neurological disorders. This would also allow further insight into how these 
diseases develop and progress. Particularly in assessing population imbalance of neurotransmitters 
and receptors (so called “Chemical Imbalance theory”) and/or the hereditary genetics, 




1.2 History of Benzodiazepines 
Chlordiazepoxide  Diazepam 
 DMCM  Zolpidem 
TPA023 TPA123 
 L-838,417  SL651498 
 FG-7142 
 Clonazepam 
 Ramelteon  Flumazenil 
Table 2. Compounds referenced in Chapter 1: Introduction 
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In 1955, Leo Sternbach, a chemist working at Hoffman-La Roche research facility at Nutley, 
New Jersey was studying heptoxdiazines in the hopes of discovering compounds with 
psychopharmacological activity. Eventually he realized that the drugs that he’d thought were 
heptoxdiazines were in reality benzoxadiazepines and synthesized about 40 benzoxadiazepines. 
He noted that “basic groups frequently impart biological activity” and performed a reaction of 6-
chloro-2-chloromethyl-4-phenylquinazoline-3-oxide with methylamine which yielded the 
 Gaboxadol  
  
SH-053-2’F-R-CH3  






Table 3. Compounds referenced in Chapter 1: Introduction, cont’d  
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unexpected rearrangement product 7-chloro-2-N-methylamino-5-phenyl-3H-1,4,-benzodiazepin-
4-oxide. Thus Ro 5-0690 had been stabilized with a methylamine, instead of a secondary or tertiary 
amine, and was then shelved. Years later, it was rediscovered after a laboratory cleanup and was 
“nicely crystalline” and thus submitted for pharmacological evaluation with a battery of animal 
tests. Surprisingly, the compound exhibited strong sedative, anticonvulsant, and muscle relaxant 
effects. Ro 5-0690 was the first anxiolytic 1,4-benzodiazepine with the generic name of 
chlordiazepoxide (Table 2) and the brand name of Librium 53. Further improvements on the 
molecular structure and the ironic removal of the basic nitrogen moiety brought about diazepam 
(Table 2) which was found to be 3- to 10-fold more potent and marketed under the name Valium 
in 1963. Given that these benzodiazepines were less toxic and less likely to cause dependence than 
other drugs on the market, competitors were quick to begin studying the drugs and popularity 
skyrocketed. From the late 1960s through the 1970s, sales of diazepam topped those of all other 
drugs in the United States. However, over-prescribing exposed the side effects and a negative 
public perception developed 54. Benzodiazepines were quickly associated with abuse and 
dependence55. Soon enough, reports in the media warned of their illicit and non-medical use among 
the youth and counter-culture; even extending to a Rolling Stones’ song as “Mother’s Little 
Helper”, referring to their widespread use among middle-class housewives 56. Reinforcing effects 
of BZDs are well studied in a variety of experimental conditions employing i.v. self-administration 
protocols in which subjects are trained to push a lever in order to receive the drug via a chronic 
venous catheter 57-61. Benzodiazepines were the center of the largest class-action lawsuit against 
drug manufacturers in the United Kingdom wherein 14,000 patients and 1,800 independent law 
firms alleged drug manufacturers were aware of the dependence potential but knowingly withheld 
this information from doctors. The court case never reached a verdict after allegations that 
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witnesses had a direct conflict of interest in their testimonies. However, the result was that 
individual benzodiazepines and soon the entire class of compounds saw the advent of guidelines 
and legislation giving guidance on their use 62. 
However, newly developed BZDs remain widely prescribed and are considered generally 
safe and an effective treatment for many anxiety disorders since abuse and dependence do not 
seem to occur in the majority of patients. Studies have also shown that tolerance to their sedative 
side-effects, but not their anxiolytic action, usually occurs after 2 weeks of continuous use 63. In 
addition, BZDs are remarkably safe in overdose due to their allosteric effect 64. Full antagonists or 
agonists are more likely to cause severe CNS effects due to obstruction of the necessary 
neurotransmission and desensitization of receptors. There are currently more than two dozen BZDs 
in clinical use in the United States. All BZDs enter the cerebral tissue rapidly with durations of 
action ranging from 2 hours (diazepam) to 72 hours (lorazepam). Although there are many 
alternatives to treating anxiety, none have matched either the efficacy or the rapid onset of BZDs 
65. 
Diazepam, also referred to as 1,4 benzodiazepine, referring to the position of the nitrogen 
in the diazepine core is the prototypic scaffold that other analogues have followed. The structure-
activity relationship for benzodiazepine anxiolytics has been described and the minimum needed 
for binding includes a heteroaromatic ring, which participates in π-π stacking with aromatic amino 





acid residues in the receptor, and a proton-accepting group that interacts with a histidine residue, 
preferably in a coplanar spatial orientation with the aromatic ring A. These components are often 
referred to as ‘ring A’ and ‘ring B’ respectively and shown in Figure 5 65.  
Molecular modeling and structure-activity relationship (SAR) studies based on rigid 
ligands in Milwaukee has resulted in the creation of a benzodiazepine pharmacophore. Pioneered 
by research members in the group of James M. Cook, the unified Milwaukee-based 
pharmacophore/receptor model was created on the in vitro binding affinities of over 150 ligands 
which bind to the benzodiazepine site on the GABAAR: benzodiazepines 
66,67, β-carbolines 68-70, 
Figure 6. The unified Milwaukee-based pharmacophore/receptor model. The pyrazolo[3,4-c]quinolin-3-
one CGS-9896 (dotted line), a diazadiindole (thin line), and diazepam (thick line) aligned within the 
unified pharmacophore/receptor model for the Bz BS.  H1 and H2 represent hydrogen bond donor sites 
within the Bz BS while A2 represents a hydrogen bond acceptor site necessary for potent inverse agonist 
activity in vivo.  L1, L2, L3 and LDi are four lipophilic regions and S1, S2, and S3 are regions of negative 
steric repulsion. LP = lone pair of electrons on the ligands (modified from the figure in Clayton, et al.). 1,2 
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triazolopyrimidines 71, pyridodiindoles 72,73, imidazo-pyridines 74, and pyrazoloquinolines 75. 
Analysis of the gathered data show that the binding site of benzodiazepine sensitive receptors are 
very similarly and a two-dimensional representation has been produced, Figure 6, with compounds 
from three separate classes (quinolinone, diazediindole, and benzodiazepine) depicted within.  
The majority of pharmacological effects of BZDs can be attributed to binding at the 
benzodiazepine site located on the GABAAR. These sites are often referred to as the 
benzodiazepine receptor (BZR). However, it should be noted that this terminology also 
encompasses the peripheral benzodiazepine receptor (PBR), also known as Bz3, ω3, mitochondrial 
benzodiazepine receptor (MBR), inner membrane anion channel (IMAC) and most recently 
referred to as translocator protein (TSPO). TSPO will be discussed in further detail within Chapter 
6.  
New research has shown that BZD compounds can bind to a novel site between the α and 
β that prevents further modulation by drugs 76. Covalent binding at this site renders it unresponsive 
at high concentrations, resulting in a bell-shaped curve; this feature has been suggested to 
contribute to the high degree of safety of the drugs. 
The most common side-effect of BZDs is sedation, evidenced by tiredness, drowsiness, 
light-headedness, difficulty concentrating, thinking or staying awake, apathy, confusion, muscle 
weakness, ataxia, dysarthria, blurring of vision, diplopia, vertigo and anterograde amnesia. These 
are generally dose-dependent and show great variability between individuals. In addition, 
pharmacokinetic changes and a reduction of baseline cognitive and motor function can result in 
worsened sedative side-effects among the elderly 77 which can increase the risk factor for falls and 
fractures. Other possible side-effects include weight gain, skin rash, nausea, headache, and sexual 
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dysfunction. Importantly, as will be discussed in further detail in Chapter 6- 6.1 Introduction, 
BZDs can also lead to reduction in the upper airway muscle tone, respiratory depression, and 
increase risk of secondary infection 78. Paradoxically, increased feelings of anxiety, anger, or 
hostility have been described with benzodiazepine use, however they appear to be very rare 79.  
The abuse and dependence liability of BZD consumption has been a matter of much 
concern and debate. In nonsubstance abusing populations, abuse of BZDs is quite rare and the 
majority of patients do not take more than the prescribed dosage 80,81. Those with a history of drug 
abuse are much more likely to abuse BZD 81. Discontinuation of BZD therapy can cause discomfort 
in individuals in the form of three types of discontinuation syndromes: recurrence, rebound, and 
withdrawal 63,82. Of the three, only withdrawal clearly manifests as physical dependence. 
Recurrence is the reappearance of the same symptoms for which the drug was prescribed while 
rebound is characterized by the return of symptoms to a higher level of intensity. Rebound occurs 
in 15-30% of BZD patients, ranging from mild to moderate severity with a generally short duration 
time 82. In contrast, BZD withdrawal syndrome is generally characterized by autonomic responses: 
sweating, tachycardia, mild systolic hypertension, tremulousness, dizziness, tinnitus, excessive 
sensitivity to light, sound or touch, altered taste, nausea, abdominal discomfort, depressed or 
dysphoric mood, fatigue, restlessness, and agitation. Infrequently there can also be confusion, 
psychotic symptoms, and seizures. The syndrome can last from 3-6 weeks followed by recurrence 
of the original disorder. Gradual tapering upon discontinuation can reduce the occurrence of these 
syndromes 63,82.  
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1.3 History of Subtype Selectivity 
The exact symptoms generated from the consumption of BZDs appears to depend on what 
regions of the brain are involved and the GABAAR therein expressed. In addition, it would seem 
that some CNS diseases are caused by either an underexpression or overexpression of the receptors 
on the nerve cells, causing them to be ‘out of balance’. Restoration of this ‘chemical imbalance’ 
is a major aim of therapies targeting GABAergic inhibition. To achieve this safely and rapidly is 
the goal of current development of new BZDs. Since the BZR on the GABAAR is located at the 
interface of the α and β subunit and there are 6α and 3γ subtypes, at least 18 different BZD binding 
sites exist. However exchange of γ2 with either of the other γ subunits can alter the BZD affinity 
and potency dramatically 83. 
The most important evidence for subtype-dependent GABAAR pharmacological effects is 
the advent of mice which had been genetically altered for the study of the roles of individual 
subunits. Advances in gene targeting such as constitutive or conditional knockout and knock-in 
techniques have improved the ability to study the possible neurobiological traits of anxiety in mice 
84. Constitutive knockout, wherein a mouse lacks a gene of interest during all stages of 
development, has greatly increased our understanding of the roles of GABAAR subtypes. A 
landmark study performed by the lab of Hanns Mohler, generated mice lacking an individual 
subunit of the GABAAR, the γ2, which rendered the mice benzodiazepine-insensitive 85. 
Homozygous mice with the knockout of both γ2 genes were not viable so heterozygotes with half 
the usual complement of the γ2 subunit were studied. These mice were not only less sensitive to 
benzodiazepines but exhibited symptoms of hypervigilance and anxiety in an elevated plus maze 
and light/dark choice tests. These mice became a genetically defined model of trait anxiety which 
reproduces the molecular, pharmacological, and behavioral features of human anxiety disorders 
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86. Following Mohler’s success, knockout mice lacking other GABAAR subunits were generated. 
Though knockout mice were the first model studied, they were soon followed by knockin mice, 
and finally triple-point-mutated knockin mice. Whereas knockout mice are generated by removing 
the gene in question but knockin mice are mutated at a specific amino acid to render the subtype 
BZD insensitive. The modification of a single amino acid is a very slight change in comparison to 
the deletion of a complete gene. Knockin mice have less genetic abnormalities during 
development, reduced lethality, and less unknown compensatory changes. Classical 
benzodiazepines bind to the α1βγ2, α2βγ2, α3βγ2, or α5βγ2 and show very little to no affinity for 
the α4βγ2 and α6βγ2 subtypes and reduced affinity towards receptors containing the γ1 and γ3. 
This selectivity is attributed to a single amino acid which is histidine in the α1, α2, α3, and α5 but 
an arginine in the α4 and α6 subunits 87. Point-mutated mice that change the histidine to the 
arginine are utilized as knockin mice to ascertain the role of individual subunits to the variety of 
effects from BZD application. Studies utilizing single point-mutated mice look at which side 
effects are lacking when a single subtype is mutated (loss-of-function) while studies with triple 
point-mutated mice search for which side effects remain when all but one subtype is mutated 
(restriction-of-function). 
Heterozygous knockout of the α1 subunit was successful despite its ubiquitous nature. The 
resulting mice exhibited a 30% loss in body weight as well as a tremor when handled 88. 
Surprisingly the mice were more sensitive to motor-impairment and sedative effects of diazepam 
89. Knockin H101R of the α1 subunit created mice that lacked drug-induced sedation and the 
diazepam-induced amnesia, suggesting that the α1 is responsible for anterograde amnesia action 
and sedative action of diazepam. Interestingly, the characteristic effect of BZD hypnotics on sleep 
electroencephalogram (EEG) remained in α1 knockin mice, indicating that the sedative action of 
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BZDs is not related to the changes in sleep EEG, in which α1 does not seem to be involved 90. In 
addition, diazepam only partially protected against pentylenetetrazole-induced myoclonic 
seizures, suggesting α1 involvement in the anticonvulsant activity of diazepam 91. DMCM 
(methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Table 2) failed to elicit convulsions 
which may indicate involvement of the α1 in the anti-seizure activity 92. Triple point-mutated mice 
exhibited impairment of motor coordination when diazepam was applied, while previous studies 
with single point-mutated mice failed to support this involvement 91,93,94. There has been 
controversy as to the involvement of the α1’s role in the addictive properties of BZDs. Unlike 
sedation, muscle relaxation, and memory impairment; abuse and dependence does not serve any 
conceivable clinical purpose and are always considered undesirable 95,96. It is estimated that 0.1-
0.2% of the adult population of the United States (300,000-600,000) abuse or are dependent upon 
benzodiazepines 97. In mice, the α1 was found to be necessary to the oral midazolam self-
administration with a two-bottle choice drinking sucrose paradigm 98. In addition, zolpidem (Table 
2), an α1-preferring compound, exhibited abuse by polydrug users 99 as well as self-administration 
in primates 100,101. The electrophysiological evidence also shows addiction-like disinhibition, 
evoking synaptic plasticity in α1 containing GABAAR in excitatory glutamatergic afferents on 
dopaminergic neurons in the ventral tegmental area (VTA), thus increasing the firing of 
dopaminergic neurons by decreasing the activity of GABAergic interneurons 98. It should be noted 
that all addictive drugs increase dopamine concentrations in the mesolimbic dopamine system 
98,102. This strongly implicates the α1 as the mediator for addiction.  
However, in direct contrast, further work done has shown that simply abolishing specificity 
towards α1 does not eliminate reward behavior. In one study, TPA023 (Table 2), a weak partial 
agonist at α2/3 but no efficacy at α1/5, with TPA123 (Table 2), a weak partial agonist of α1/2/3/5, 
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were applied to baboons in a self-administration study. TPA123 had moderate self-injection rates 
and exhibited BZD-like withdrawal syndrome 103. L-838,417 (Table 2), a compound with that is 
an agonist at α2/3 and an antagonist for the α1, however, did maintain self-administration in a 
similar primate model 61. Suggesting that abolishing the efficacy at the α1 does not eliminate abuse 
liability unless coupled with the reduction of α2/3 specificity. Zolpidem and diazepam examined 
in knockin mice using the intracranial self-stimulation (ICSS) paradigm agree with the findings 
that α2/3 are vital to the creation of abuse liability 104. The inherent difference between the two 
bottle choice paradigm and the ICSS paradigm is the ‘like’ and ‘want’ aspects of them; in which 
the latter involves active seeking of the reward instead of preference 105. The ICSS paradigm can 
be viewed as the animals’ willingness to work to obtain stimulation and is significant for 
individuals already in a high-reward state or when there is a motivational component involved 103. 
Furthermore, another experiment with zolpidem, an α1-preferring BZD agonist was given to 
knockin mutants for α1, α2, or α3 with no reward enhancing effects and showed that α1 knockin 
reduces the reward behavior but α2 knockin is capable of abolishing it 104. Further studies that state 
that physical dependence, measured with rapid precipitated withdrawal assay by inverse agonist-
induced seizures, reported that chronic treatment with zolpidem (selective 1), L-838,417 (selective 
2, 3, 5), TPA023 (selective 2, 3, 5), and SL651498 (selective 2, 3, Table 2) did not respond to 
administration of seizure inducing partial inverse agonist FG-7142 (Table 2). Considered together, 
this suggests that physical dependence does not occur with subtype-selective compounds. In 
addition, non-selective partial agonists also suppressed FG-7142 induced seizures, implying that 
high efficacy might also be a requirement for physical dependence 106,107. Taking all of this 
information into consideration indicates a group involvement of all three subtypes in creating a 
reward-enhancing genotype. It has been suggested that α1 may be required for long-lasting 
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neuronal changes of addiction, as indicated by the electrophysiological studies, while the α2 and 
α3 are responsible for the immediate reinforcing effect 104. It should be noted that although BZDs 
do produce self-administration behavior above levels seen in comparison with a vehicle, they 
appear to be relatively weak reinforcers in general compared to other drugs of abuse like 
barbiturates 108,109. 
Knockin at α2 H101R attenuates the anxiolytic action of diazepam in the light-dark choice 
test and the elevated plus maze test but exhibit normal sedative and anticonvulsant response. In 
addition, the muscle relaxant effect of diazepam had disappeared 94. These initial results seem to 
indicate that the α2 is the sole subtype responsible for diazepam’s anxiolytic effect, however 
TP003, an agonist with relative selectivity towards the α3, displays anxiolytic activity 110. In 
addition, L-838417 still had anxiolytic activity in α2 knock-in mice. Indicating possible 
involvement of the α3 in the anxiolytic effect of BZDs. However it should be noted that GABAAR 
bearing the α2 subunit require 20-25% receptor occupancy for anxiolysis 94 while α3-containing 
receptors require 75% of the receptors be occupied to elicit anxiolytic response 110. Consequently, 
α3 is considered a backup target for anxiety. 
The genetic deletion of α2 leads to behavioral despair as seen in the results of an FST and 
TST 111. In addition, single nucleotide polymorphisms (SNPs) genetic association studies have 
implicated the α2 in alcohol dependence 112,113 and illicit drug dependence 114,115. In direct contrast, 
a recent triple point-mutated mouse study found that tolerance can be avoided when only α2 
GABAAR are targeted. All other subtypes (α1/3/5) exhibit fast tolerance development with rapid 
diminishing of BZD effects during prolonged treatment of eight days 93.  
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Knockout mice lacking α3 displayed an increase of spontaneous locomotor activity in the 
open field with loss of prepulse inhibition of the acoustic startle response 116. When α3 knockin 
H126R mice were treated with diazepam there was reduction in muscle relaxant activity and 
similar deficits in sensorimotor gating from pre-pulse inhibition of acoustic startle 117. This 
suggests that an α3 selective positive modulator may be able to treat sensorimotor gating 
deficiency, which occurs in such psychiatric conditions like schizophrenia. Previously it had been 
suggested that the anxiolytic activity of diazepam was partly due to its action on α3 rich reticular 
activating systems. However, single point knockin mice had anxiolytic activity in the light-dark 
choice test and elevated plus-maze test, comparable to the wild-type mice 94. In addition, the same 
study revealed that there was no change in sedative and anticonvulsant activity of diazepam. 
However, muscle relaxant activity was slightly reduced, suggesting involvement of the subtype 
117. It is interesting to note that even though there is exclusive expression of α3 in the reticular 
nucleus of the thalamus, involved in regulating thalamocortical oscillations which generate sleep 
spindles, it seems this subtype is not involved in the sleep inducing effects of diazepam. However, 
a study into generalized absence epilepsy with knockin mice showed that anti-absence drug 
clonazepam (Table 2) showed no effect on mice with a mutated α3, suggesting that the subunit is 
involved in this particular form of epilepsy. Study of triple knockin mice suggested that, like α1, 
the α3 is involved in the impairment of motor coordination by diazepam. In addition, double point-
mutated mouse studies exhibited that both of these subunits appear to be required for tolerance 93. 
α5 subunits are primarily localized in the hippocampus and make up less than 5% of the 
total population of GABAAR in the brain. They are primarily responsible for generating tonic 
conductance and play a key role in cognition. Knockout of the α5 in mice causes better 
performance in the Morris water maze model of spatial learning 118. The knockout does not seem 
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to alter normal motor performance or coordination but show deficits in sensorimotor gating from 
pre-pulse inhibition of acoustic startle 118. Knockin at H105R reduced the muscle relaxant action 
of diazepam and recapitulated the learning and memory results from the knockout 119. Compounds 
selective towards the α5 have been capable of enhancing spatial learning 120. 
α6 knockout mice caused an inhibition of δ subunit expression and mice were significantly 
more impaired by diazepam in rotorod tests 121. Selective knockout of the α6 leads to a post-
translational loss of the δ since they are strongly coexpressed 122. Allelic variants in the α6 have 
been connected to abdominal obesity and cortisol secretion but the significance is still unknown 
123.  
Knockout of the β3 resulted in a cleft palate but 90% of the mice died within 24 hours of 
birth. The survivors exhibit an epileptic phenotype 124,125, hyperactivity, poor learning and 
memory, poor motor coordination, repetitive behavior consisting of running continuously in tight 
circles, and seizures 125. Loss of the β3 led to dramatic reduction in the levels of expressed 
GABAAR In addition, when mice with the knockout were treated with oleamide, an endogenous 
sleep promoting fatty acid, it was found to be inactive; indicating an involvement of the β3 in sleep 
126.  
The very lethal effect of knocking out the γ2 results in a defect in postsynaptic clustering 
of the GABAA receptor as well as decreased single channel conductance 
127. Morbidity was 
expected as γ2 is in 90% of all GABAA receptors 85. Heterozygous knockout results in mice with 
reduced synaptic clustering. They also displayed heightened response in trace fear conditioning 
and anxiety-related behavior which was relieved by diazepam 86. 
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The removal of the δ subunit results in mice that have spontaneous seizures and greater 
sensitivity to pharmacologically induced seizures 128. Interestingly, neurosteroid-sensitive 
extrasynaptic δ subunit is downregulated during pregnancy due to the elevated amounts of 
neurosteroids in the system. Post-partum drop in neurosteroids with the inadequate levels of δ 
GABAAR levels leads to decreased inhibitory function. Consequently, there is an increase in 
neuronal excitability until the levels of δ are reestablished. In animal studies, when there is a delay 
in δ GABAAR recovery, severe despair behavior is observed in mice which leads to mothers 
cannibalizing their offspring 129. Similar changes have been reported during puberty which could 
explain why this developmental stage is often associated with an increase in susceptibility to stress-
related disorders 130. In addition, rats that are stress-induced through social isolation have an 
upregulation of extrasynaptic δ subunits 131. The δ subunit also seems to be involved in 
schizophrenia and may offer a target to treat insomnia as discussed further in 1.3.1.6 Role of 
Genetics and Selective Targeting.  
1.3.1 GABAAR AND DISEASE 
Quantitatively, GABA is the most important inhibitory neurotransmitter in the CNS. 
Excitation and inhibition is a precarious balancing act whereupon overstimulation of the 
GABAergic system can cause sedation, depression, amnesia and ataxia while attenuation can result 
arousal, anxiety, convulsions, and insomnia. It has been suggested that GABA systems are 
involved in the pathogenesis of anxiety, depression, insomnia, cognitive dysfunction, Down 
syndrome, autism, schizophrenia, and epilepsy, among others 132. The existence of the 
benzodiazepine site is a mystery in itself with many evolutionary biologists theorizing why they 
occur. One theory proposes the existence of an endogenous agonist that is produced by the brain 
to reduce anxiety. Others theorize that, in contrast, the receptors mediate the activity of endogenous 
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inverse agonists (negative allosteric modulators) which can promote brain arousal. Another theory 
is that there are no endogenous ligands and the site is merely be a ‘fine-tuning’ feature that results 
from the particular protein conformation 133. Whatever the reason for its existence, the GABAergic 
system is one of the most important neurotransmitter networks in the mammalian CNS.  
1.3.1.1 Anxiety 
According to the National Institute of Mental Health, anxiety disorders are among the most 
common mental illnesses with nearly 40 million adults in the United States age 18 and older, or 
18%, being affected 134. In a 1999 study commissioned by the Anxiety and Depression Association 
of America, anxiety disorders cost the U.S. more than $42 billion a year, virtually one-third of the 
country’s $148 billion total mental health bill 135. A study six years later claimed that the total 
annual cost may be upwards to $60 billion 136. From an evolutionary perspective, anxiety is a useful 
and innately driven form of distress that arises in response to actual or threatened danger. Not long 
ago, it was believed that anger and harm are assessed by three levels of the triune forebrain: the 
rational (neomammalian), emotional (paleomammalian), and instinctive (reptilian). Anxiety is a 
de-escalating strategies mediated by these more primitive paleomammalian and reptilian 
forebrains 137. Since then, the triune brain model, popularized by Carl Sagan’s “The Dragons of 
Eden”, has fallen out of favor among neuroscientists in the post-2000 era but has yet to be replaced 
with another working theory.  
Anxiety can be grouped into six different models with many patients presenting multiple 
forms of the illness: social anxiety disorder (prevalence 13%), phobias in general (11%), post-
traumatic stress disorder (8%), generalized anxiety disorder (5%), panic disorder (4%), and 
obsessive-compulsive disorder (2%). Generalized anxiety disorder is defined by excessive and 
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uncontrollable worry for at least 6 months, accompanied by three of the six associated symptoms 
of restlessness, fatigability, concentration difficulties, irritability, muscle tension, or sleep 
disturbance 138. When compared to other anxiety and mood disorders, generalized anxiety disorder 
may commonly manifest at early ages, with many patients reporting an onset in adulthood as a 
result of psychosocial and emotional stress. Anxiety disorders develop from a complex set of risk 
factors, including but not limited to: genetics, brain chemistry, personality, and life events. The 
latter two being somewhat conjectural in nature and difficult to quantify. However, there is a 
gathering evidence that genetic variance causes altered expression and function of proteins that 
regulate the network of brain neurotransmitter systems (i.e. receptors, ion channels, transporters 
and enzymes) which can be associated with complex behavioral traits 139-141. 
Selective serotonin reuptake inhibitors (SSRIs), which are a mainstay for anxiety treatment, 
are too slow acting for acute situations and often require several weeks to work. So a fast-acting 
BZD with little to no side effects would present a major improvement to therapeutic treatment.  
1.3.1.2 Insomnia 
Sleep is a complicated process involving many autonomic, physiological, and biochemical 
changes that transition the brain from a state of wakefulness, slow wave non-rapid eye movement 
(NREM) sleep and paradoxic rapid eye movement (REM) sleep. In a statement released in 2005, 
the NIH has concluded that insomnia occurs, at least occasionally, for around 30% of adults and 
is a chronic problem among 10-15% of adults with 40% of insomniacs also having a co-existing 
psychiatric disorder 142. The condition affects daytime functioning, quality of life, and mental and 
physical health 143. The first historically relevant use of sedative-hypnotics in the United States 
began in the Industrial Revolution when laudanum, which was opium mixed with alcohol, was 
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packaged and marketed as sleep aids. In the early 20th century, barbiturates became the leading 
prescribed hypnotic until the 1960s when benzodiazepine receptor agonist hypnotics replaced them 
144.  
BZDs are considered much safer than barbiturates and the FDA-approved several BZR 
agonists for the treatment of insomnia. However, nonbenzodiazepine agents are toted as even safer 
and the safest being a recent targeting of the melatonin receptor by agonist ramelteon (Table 2) 
which has no abuse liability or interference in cognitive function. There are benzodiazepines that 
are specifically promoted as sleep inducers but depending on the dosage, any approved BZD may 
be employed. Studies suggest that specific stimulation of the a1 would primarily result in sedative-
hypnotic effects 145. BZDs increase total sleep, reduce nocturnal wakefulness, and decrease the 
time required to fall asleep. The effectiveness of BZDs are known to decrease after long-time use 
due to tolerance so the majority of BZDs are usually recommended for short term use 146. Rebound 
insomnia may occur following abrupt discontinuation but tapering the dose should offset the 
severity of the effect 147. 
1.3.1.3 Epilepsy 
The word “epilepsy” is derived from the Greek word epilambanein, meaning to seize, and 
was coined by Hippocrates in his famous 400BC essay On the Sacred Disease in which he 
described the disorder as a disease of the brain and promoted treatment through diet. Convulsive 
disorders have been described as a loss of the normal inhibitory control mechanisms and chemical 
super-sensitivity that increases excitability of the neurons 148. Brain-wave studies measured by 
EEG show that abnormal excessive or synchronous neuronal activity in the brain during seizure 
149. Epilepsy is defined as the occurrence of two or more seizures not provoked by any identifiable 
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cause. According to a study performed by the World Health Organization in 2012, it is estimated 
that 1% of the population currently has epilepsy with the majority, nearly 80%, living in 
developing countries.  There is an average of 180,000 new cases of epilepsy each year; 30% of 
cases are in children. There are different forms of epilepsy but they all originate in the brain due 
to irregularities in neuronal activity caused by disturbance of physicochemical function and 
electrical activity. There is very little understood about the causes of ‘true’ idiopathic epilepsy, 
which is distinct from symptomatic ‘acquired’ epilepsy, which results from brain injury, tumor, 
infection, or chronic alcohol use. In true epilepsy, around 70% of all epilepsy cases, the cause for 
the disease is unknown. In general, BZDs are not usually the first choice for long-term treatment 
of epilepsy due to tolerance development but in emergency management the short-term use during 
periods of increased, repeated, or prolonged seizure is very effective. Thus BZDs are still 
considered first-line agents for emergency management of acute seizures and status epilepticus 150.  
1.3.1.4 Schizophrenia 
In the mid-19th century, psychiatrists began taking note of a disorder progressing to 
chronic deterioration among the youth with unknown causes. In France it was called démence 
précoce, while in Scotland it was known as “adolescent insanity”. In Germany, Emil Kraepelin 
gathered all information surrounding this varied disease with the underlining pattern of severe 
cognitive and behavioral decline; he named the illness “dementia praecox”.  Initial definitions of 
the illness have changed considerably. Currently it is known that schizophrenia is a heritable 
psychiatric disorder that can impair cognition, perception, and motivation. The disease manifests 
late in adolescence or early in adulthood. The route that leads to the diseased state is unknown 
however there have been shared pathological features such as the disproportionate loss of grey 
matter 151 and the drop in dendritic spine density which help transmit electrical signals 152. 
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According to a study by the National Institute of Mental Health, approximately three 
million Americans or 1.1% of the US adult population have been diagnosed with schizophrenia 
with delusional thinking and hallucinations. Unfortunately although there is treatment available 
for the psychotic symptoms, there is not yet a method to treat or prevent the cognitive impairments 
or the deficits of normal emotional response that personifies the most constant features of this 
disorder. 
1.3.1.5 Cognitive Deficiencies 
Cognition is a highly complex construct of mental activities that includes problem-solving, 
learning and memory, reasoning and judgment, understanding, knowing, creativity, intuition, self-
awareness, and mental time-travel. Cognition and mood are closely linked however the underlying 
mechanisms appear to differ. Drugs that alleviate mood related symptoms such as depression and 
anxiety do not necessarily improve cognition, sometimes even worsening the deficit 153,154. Among 
many psychiatric and neurological disorders, cognitive impairment is associated with bipolarism, 
depression, generalized anxiety disorder, panic disorder, PTSD, OCD, ADHD, ASD, Alzheimer’s 
disease, Parkinson’s disease, Down Syndrome, autism, and schizophrenia 132.  
According to the Center of Disease Control (CDC), age-related cognitive impairment 
affects 16 million people in the United States and the impact as the Baby Boomer generation passes 
age 65 is expected to increase that number drastically. The estimated 4.7 million Americans with 
Alzheimer’s disease may rise to 13.2 million by 2050 155. Alzheimer’s disease and related 
dementias are estimated to be the third most expensive disease to treat in the United States. In 
2010, the Medicaid nursing facility expenditure per state for individuals with Alzheimer’s disease 
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is estimated to be $647 million 156, which does not reflect home and community-based care or 
prescription drug costs.  
1.3.1.6 Role of Genetics and Selective Targeting 
The role that genetics plays is well studied but complex. There is a large number of 
hereditable mutations in genes that regulate ion channel function called ion channelopathies 157.  
Anxiety appears to have a strong genetic component. Selective breeding of mice over 
generations can produce high- and low-anxiety lines, suggesting a strong genetic component to 
this behavior 158. In addition, individuals with generalized anxiety disorder appear to have high 
comorbidity rates with other psychiatric disorders including panic disorder, major depression, 
dysthymia, social phobia, and specific phobia 159-163. Analysis of multivariate genetic comorbidity 
statistics shows that generalized anxiety disorder and major depression have common genetic 
origins 164 and vulnerability to the two overlaps to a substantial extent genetically 165. When imaged 
by positron emission tomography, patients with panic anxiety exhibited reduction in GABAAR 
expression, a deficit that is most likely involved in the disease 166. When patients with panic 
disorder are intravenously given flumazenil (Table 2), a BZR antagonist, it provokes panic in most 
patients however control subjects without panic disorder exhibited no such response 167. The 
increased sensitivity may suggest an abnormality in GABAAR distribution or in the receptors 
themselves. This effect appears to be specific in patients with severe episodic anxiety since patients 
with generalized anxiety, post-traumatic stress disorder, and depression do not panic when given 
flumazenil. Interestingly, there is also a significant hereditary factor in panic disorder which may 




GABAARs play a fundamental role in sleep and BZD treatment for sleep disorders persist 
today, despite tolerance. Mutation in the β3 has been observed in a patient with chronic insomnia. 
Characterization of the mutant receptor showed a slower rate of desensitization than with the 
normal GABAAR 
126. BZDs approved to treat insomnia are estazolam (ProSom), flurazepam 
(Dalmane), quazepam (Doral), temazepam (Restoril), and trizolam (Halcion); which exhibit 
selectivity for the α1 168. Gaboxadol, a δ selective compound (Table 3), was able to promote slow 
wave sleep and increase total sleep time while simultaneously shortening sleep latency, and 
decrease wakefulness. However, due to side-effects such as hallucinations and disorientation, 
gaboxadol failed phase III clinical trials 169. The popularity and persistence of BZDs in sleep 
disorder therapy speaks for the usefulness of the GABAAR as a target. 
Epileptic heritable mutations of the GABAAR are known to occur in diseases such as 
Angelman syndrome. As a result of deletions in the β3 subunit, patients with Angelman syndrome 
develop severe mental retardation, delayed motor development, and epilepsy 170. The β3 knockout 
mice also have a phenotype similar to those with this neurodevelopmental disorder 124,171. The gene 
encoding the α1 (GABRG1) has been implicated in juvenile myoclonic epilepsy and the mutated 
γ2 (GABRG2) has also been discovered in two families with generalized epilepsy syndrome 
characterized with febrile seizures, and childhood absence epilepsy 172,173.  
Research has shown biological markers associated with schizophrenia include 
neurocognitive dysfunction, brain dysmorphology, and neurochemical abnormalities. Studies in 
genetic association have targeted multiple candidate loci and genes but failed to demonstrate that 
any specific gene abnormality, or a combination of genes, is sufficient to cause schizophrenia. 
Very recent findings have revealed that the C4 genes is associated with schizophrenia, the C4 
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protein is localized in neuronal synapses, dendrites, axons, and cell bodies and is responsible for 
synaptic pruning. Patients with an overexpression of synaptic pruning protein have a higher risk 
of developing schizophrenia 174. In schizophrenia there is a decline in the production of cortical 
GABA leading to a downregulation in cognitive function. As expected, there is a compensatory 
upregulation of GABAAR however not enough to regain normal function 
175. α3 knockout and 
partial knockout of α5 both show a deficit in sensorimotor gating which may point to potential 
involvement of these subunits in the pathophysiology of schizophrenia 176,177. Post-mortem brains 
of individuals suffering from schizophrenia have a reduced expression of the δ subunit. In addition, 
the α5 has been identified as a susceptibility locus for schizophrenia 178. Partial positive modulator 
with α5 selectivity SH-053-2’F-R-CH3 (Table 3) in the rat model of schizophrenia has 
demonstrated therapeutic potential by reducing the number of spontaneously active dopaminergic 
neurons in the VTA to those of control animals 179. Non-selective positive modulator bretazenil 
(Table 3) was shown to be effective treatment in 40% of patients exhibiting acute episodes of 
schizophrenia in a range of symptom severity levels with the most severe side-effects being 
sedation 180. Findings point to compatibility with a BZD that acts on α2, α3 and α5 which would 
have antipsychotic and cognitive enhancing qualities.  
Irregularity in the GABAergic system has also been correlated to the pathophysiology of 
autism spectrum disorders. Knock-in mice with an H105R in the α5 subunit in the hippocampus 
show improved spatial performance in the Morris water maze and enhancement of trace fear 
memory 181. Partial α5 knock-in mice exhibit improved trace fear conditioning, appetitive/food-
related conditioning, and novel object recognition 116,119,182. Development of agonists for the α5 
has had very little success but might be an option for compounds that promote memory suppression 
that may provide useful for phobias and PTSD. The use of BZDs as analgesia has seen beneficial 
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towards the anterograde amnesia which can be a useful outcome when used in invasive surgery or 
other traumatic events. L-655,708 (Table 3), a novel partial inverse agonist with heightened 
affinity for the α5, succeeded in enhancing the performance in the Morris maze 183. MRK-016 
(Table 3), an inverse agonist selective for the α5, rescued acquisition and memory consolidation 
184 and also exhibited antidepressant qualities 185. However, it was poorly tolerated in the elderly 
and was not investigated further 186. A highly selective α5 imidazotriazolobenzodiazepine called 
RO4938581 (Table 3) was able to assuage phencyclidine (PCP) induced cognitive inhibition and 
enhance performance of an object retrieval task. These selective inverse agonists would also find 
use in promoting recovery after stroke. The increase in tonic inhibition is observed after stroke, 
mediated by extrasynaptic GABAAR containing the α5 or δ subunit. Lowering the number of the 
these subunits genetically improved recovery after stroke and administering BZD inverse agonist 
specific for α5 produced early and sustained recovery of motor function. However, the timing of 
drug delivery is very important as a GABAAR agonist given during the stroke can decrease stroke 
size 187. Tests in mice have proven that early administration can exacerbate stroke damage but 
when treatment is delayed by 3 days, functional recovery is promoted without affecting stroke size 
188. This evidence suggests that a selective α5 inverse agonist may be useful as the first clinical 
treatment for promoting recovery after stroke or other devastating brain injuries. Selective inverse 
agonist also have therapeutic potential in patients with Down syndrome. Down syndrome, though 
clearly caused by trisomy 21 linked to Olg1 and Olg2 genes, is connected to increased presynaptic 
GABA release which leads to excessive inhibition and obstruction of synaptic plasticity 189. α5 
selective partial inverse agonist RO4938581 was capable of improve deficits in synaptic plasticity 
and neurogenesis without affecting motor coordination or sensorimotor abilities. Interestingly, the 
compound exhibited anxiolytic properties and suppressed hyperactivity 190. A related compound, 
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RG1662 (Table 3), by Hoffmann-La Roche has entered into clinical trials for the treatment of 
cognitive disabilities associated with Down syndrome. Cntnap2 knockdown, a mouse model for 
syndromic autism spectrum disorder (ASD) there is reduction in GABAergic interneurons and 
abnormal network activity 191. Increasing evidence has indicated that dysfunction of GABAergic 
neurotransmission is related to ASD 192. In Scn1a heterozygous knockout mice, which is a model 
of a syndromic form of ASD (Dravet’s syndrome), mice display hyperactivity, social interaction 
deficits, impairment of context-dependent spatial memory, and decreased GABAergic 
neurotransmission 177.  Application of clonazepam in these knockout model rescues abnormal 
social behavior and deficits in fear memory 193.  GABAAR subtypes involved are unknown but 
postmortem study has observed reduced expression of α4, α5, and β1 194. The absence of the α5 
subunit in ASD patient brains has also been verified through PET scans 195.  
In addition to the five diseases that have been linked and treated with GABAAR drugs, 
there are other possible applications. The hypothesis that targeting the GABAergic system to treat 
depression is a new prospect that has not yet been sufficiently verified. Global brain gene 
expression analysis links the GABAergic dysfunction to suicide and major depression disorder 
(MDD). Studies have shown that patients suffering from MDD have reduced CNS GABA 
concentrations 196,197.  In addition, there is differential expression of GABRA5, GABRB1, 
GABRD, GABRG1, GABRG2 198. The γ2 subunit has shown possible involvement as the 
heterozygous knockout increased behavioral despair in immobility in the forced swim test (FST) 
and the tail suspension test (TST) 199.  
In conclusion, therapeutics aimed at GABAAR are various and wide-ranging and drugs 
which target specific subtypes can elicit specific behavioral effects. Due to the receptors 
 37 
 
pervasiveness as the major inhibitory neurotransmitter, it is involved in many vital processes. 
Thus, dysfunction or altered expression can profoundly affect CNS function, translating to 
behavioral changes in an individual. Although BZDs have fallen out of favor due to their side 
effect profile, there remains an amazing potential in reducing these off-target effects by increasing 
subtype selectivity.  
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CHAPTER 2: ELECTROPHYSIOLOGICAL CHARACTERIZATION OF 
TRANSIENTLY TRANSFECTED HEK293T CELLS 
2.1 Introduction 
Ion channels are proteins in the lipid bilayer that selectively allow ions entrance or exit 
across cell membranes. They have been ubiquitously found in every cell membrane studied: plant 
cells, bacteria, unicellular and multicellular organisms and even in the membranes of many 
intracellular organelles. The lipid bilayer is a very hydrophobic and impermeable to charged 
molecules, despite the size. In solution, inorganic ions like Na+ and Cl- form a hydration shell and 
will not pass across the membrane without an ion channel or ion pump. The activity of these 
membrane proteins are so keenly controlled that the difference in the charge balance from the 
intracellular to the extracellular domain can generate a voltage difference called the membrane 
potential (Vm). Typically, the Vm is around -70mV to -40mV; this is known as the resting 
membrane potential. The flow of cations in or anions out makes the inside of the cell become more 
positively charged and is known as depolarization while the flow of cations out or anions in makes 
the inside more negatively charged and is called hyperpolarization. This change can make the Vm 
fluctuate between -90mV to +60mV. The plasma membrane acts as a resistor and a capacitor. Its 
resistor characteristics depends on the number of open ion channels; if many are open, the 
membrane has a lowered resistance but if they are closed, the membrane has a very high resistance. 
A capacitor is formed from the separation of charge. The intracellular side is more negative than 
the extracellular side so both sides have an electromagnetic gradient across the membrane. Anions 
in the cytosol are pulled towards the membrane and cations accumulate near the membrane on the 
outside. This scenario posits an energy state for the gathered ions and the amount of charge can be 
described as 𝑄 = 𝐸𝑚𝐶, where Q is the charge stored, Em is the potential difference across the 
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membrane and C is the membrane capacitance in farad. These differences between the two sides 
arises from the concentration differences and electrical due to the ionic charge differences. This is 
called an electrochemical gradient. The capacitance is proportional to the surface area of the 
membrane and inversely proportional to the thickness and can be described with the equation 𝐶 =
𝐴𝜀𝑟
𝑑
 where A is the area, εr is the dielectric constant and d is the membrane thickness. So capacitance 
can indicate the membrane surface area under investigation. Since the membrane is approximately 
25Ǻ, it is able to act as a very thin electrical capacitor. The resistance can be estimated applied to 
Ohm’s law (E=I*R), where E is the membrane potential, I is the membrane current, and R is the 
membrane resistance. The electrochemical equilibrium of a neuron can be estimated using the 






 , where Em is the membrane potential 
in volts, P is the permeability of the membrane to each ion in meters per second, and [ion]out and 
[ion]in are the concentrations in the outer and inner membrane. The Goldman equation is just an 
extended version of the Nernst equation and removing the permeability will collapse it back to its 






, where z is the number of moles of electrons transferred between 
membranes, [A-]o is the concentration of ion outside the membrane, [A
-]I is the concentration of 
ion inside the membrane.  
The space between the pre- and post-synaptic chemical synapses is known as the synaptic 
cleft. In the pre-synaptic terminal there are small membrane-bound organelles called synaptic 
vesicles which are filled with one or a mixture of neurotransmitters. These neurotransmitters bind 
and potentiate a postsynaptic electrical response. Though neurons generate electrical signals to 
transmit information, they are not intrinsically good conductors of electricity. So neurons evolved 
to produce action potentials which acts as a booster system to propagate a signal through the 
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nervous systems. A signal is sent by achieving enough stimulus that the resting potential increases 
and the voltage reaches a threshold to trigger an action potential. Excitatory signals (postsynaptic 
potentials) increase the likelihood of the action potential firing while inhibitory signals (inhibitory 
postsynaptic potentials) lower the resting potential and reduce the likelihood of an action potential. 
GABAAR thus have an inhibitory effect as the influx of chloride anions lowers the resting potential 
from the threshold for neuronal firing. 
It was not until 1952 that a technique was invented to study ion channel function. Sir 
Andrew Huxley and Sir Alan L Hodgkin studied the workings of the squid giant axon 200. For their 
work, they used Kenneth Cole’s technique called a voltage clamp and were able to measure 
changes in the conductance of ions of the membrane of the squid axon in response to modification 
of the membrane voltage. In order to measure the membrane potential, two electrodes were placed 
across the membrane. The first electrode is placed outside the cell and the second must be inside. 
However, the cell membrane’s central function is the hold the contents of the cell so as not to leak, 
thus it was a central concern as to how to access the intracellular space. It was discovered that 
squid giant axons could be cut at the end and dried (air gap). By doing this, a wire electrode could 
be inserted into the cytoplasm through the cut end without leakage between the two spaces. Huxley 
and Hodgkin’s experiments and calculations proved the ionic theory of nerve impulses and led to 
a set of ground-breaking differential equations which are still essential for describing neuronal 
circuits 201. Huxley and Hodgkin were awarded with a Nobel Prize in Physiology and Medicine in 
1991 and has defined our understanding of how the central nervous system and the brain works. 
After this landmark study, Erwin Neher and Bert Sakmann created a voltage-clamp recording 
method in 1976 and called it patch-clamp. Neher discovered that by applying negative pressure 
inside the pipette, a high seal resistance could be attained 202. After formation of the giga-ohm seal, 
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the membrane patch was broken by applying high negative pressure and the cytoplasmic side is 
connected to the pipette to allow for readings. This technique enables the study of the real-time 
current fluctuations through single ion channels 203. The patch-clamp technique uses a thin glass 
pipette and fuses it to the cell membrane through gentle suction. This technique was further 
improved by scientists in 1981 when a team was able to resolve changes as small as 0.5pA.  
There are many different recording modes in patch clamp. Whole-cell mode indicates that 
when a cell is patched, the cell-attached part is ruptured to gain access to the intracellular domain. 
Important features of this mode includes several factors. First, the pipette tip must be wide enough 
to allow washout of the cytoplasm by the intracellular solution filling the pipette. The washout can 
make readings more uniform by controlling the intracellular contents; but relevant cytosolic factors 
that may be vital to function could be lost. Secondly, leak resistance Rleak represents seal quality 
between the glass of the pipette and the membrane. This value should be higher than the current 
input resistance of the probe to ensure that no significant amounts of current will leak away. In 
manual patch-clamp, the Rleak should be higher than 10GΩ. A high seal resistance is important 
since it allows the resolution of minute current changes from background noise. Third, to perform 
manual patch-clamp, an elaborate rig is required to procure good results. A stable platform is the 
foundation to successful current readings, quick movements and vibrations can break seals so 
isolation of the rig in the building or the lab can enhance data collection. A microscope in the rig 
will be helpful in the visualization of the preparation but some skilled electrophysiologists have 
been known to work without one. Stable manipulators are needed to position the micropipette and 
introduce or position the tip onto the cell membrane in a controlled environment. Finally, the 
electronics to perform the recording and analysis are necessary 204.  
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Next, the solutions used should be carefully considered. The range of intracellular and 
extracellular ion concentrations appears to be relatively constant in cell types, organs and across 
species 204. There are large differences between sodium, potassium, and calcium concentrations 
seen in Table 5. This range roughly translates to those typically used, Table 4, when performing 
Table 5. The intracellular and extracellular concentrations found in animal fluids.  
Table 4. Typical concentrations used in patch clamping of a mammalian cell. pH is set in the ECS 
using NaOH and the ICS by using KOH.  
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whole-cell patch clamp. Besides the ionic concentrations, the pH and the osmolarity play a big part 
in obtaining good seals and thus good current readings. Physiological pH is about 7.4 in the 
extracellular solution (ECS) while the intracellular solution (ICS) is slightly more acidic at 7.2-
7.3. Osmolarity can affect the volume of the cells and the osmotic force on the membrane. The 
cell membrane will be effected if the difference is large but increasing the ICS osmolarity can 
swell and smooth the wrinkled membranes of cells to improve successful seal formation of the 
patch. Normally sucrose or glucose are used for this purpose since they don’t interfere with channel 
function. However, the addition of calcium and glucose can facilitate the growth of 
microorganisms in the stock solutions. In addition, if perishable ATP is used in the intracellular 
solution then solutions must be kept frozen. These factors should all be carefully considered when 
choosing the buffer stocks and storage conditions. 
2.2 Instrumentation 
Electrophysiological techniques are critical in determining the enhancement of chloride 
conductance and calculating potency and efficacy of the drugs but data collection is limited by 
slow throughput. Several types of automated patch clamp (APC) systems have been developed to 
allow for high-throughput data collection. The IonFlux System uses plates with microfluidic 
channels underneath the wells to enable high-throughput electrophysiology measurements. Plates 
are divided into experimental patterns in which specific wells are designated for cells, compounds, 
and recording buffer solution. The 96 well plate contains 8 experimental patterns with 12 wells: 
one cell suspension well (inlet), one well for waste (outlet), two cell recording wells (traps) and 
eight compound addition wells. Once the reagents and cells are loaded and placed in the 
instrument, a pneumatic interface seals against the top to regulate the air pressure and vacuum into 
the wells. The interface contains an array of electrodes that lower into the recording wells, ensuring 
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enough volume in these wells to reach the electrode is important. The plate is primed with fluid 
by applying positive pressure to all the channels. Once priming is complete, positive pressure is 
used to introduce the cells into the main flow channel. Trapping begins by applying negative 
pressure to the wells of the trapping zones where cells are attached and sealed similarly to manual 
patch pipettes. Whole cell voltage clamp is achieved once the cells are attached. Each of the 
trapping zones captures 20 cells which are used to make one patch clamp recording. There are two 
trapping zones per experimental pattern so there are 16 parallel recordings total in a 96 well plate. 
Once trapped, the IonFlux software can be programmed to apply voltage sweeps across the 
electrodes and measure the ionic current through the cell membranes. Open channel resistance 
should drop to approximately 1MΩ or less. After recordings are established, up to 8 different 
compounds or concentrations can be applied in rapid succession. Fast compound addition, 
washout, and exchange with simultaneous and continuous recording makes this system an 
accelerated system for drug discovery and development. The system itself reduces lab space 
required for manual forms of patch-clamp to a small benchtop footprint. The disadvantage is that 
the speed of data collection is countered by the expense of the microfluidic plates which are 
hundreds of dollars per plate. In contrast, manual patch clamp is time-consuming but very cost 
effective once the rig is set up. Giga ohm seal formation is very difficult to achieve in high 
throughput systems, and accordingly the IonFlux 20 cell trap has resistance seals consistently in 
the 7MΩ range which compares to a 140MΩ seal for a single cell. However, Molecular Devices 
has recently released a single cell trapping plate that is capable of establishing a gigaseal to produce 
high quality recordings with slightly lower success rates. Coming from a technical aspect, manual 
patch clamp requires a very fastidious and experienced hand while IonFlux’s plate reader setup 
can be learned comparatively quickly and eliminates most human-related errors. In a plate reader 
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format, cells are brought to the patching site rather than having the pipette get brought to the cell. 
Therefore, there is no optical access to the cells in the microfluidic plate and no ability to choose 
the best cell to patch. However, there are many additional advantages such as the ability for precise 
temperature control and uniform control of compound applications. In addition, the summation of 
the population of captured cells greatly improves success rates and uniformity of recordings 205. It 
should be noted that the IonFlux utilizes Ag/AgCl electrodes that only performs well in solutions 
containing chloride ions. It is vital to replenish the chloride ions on the electrode, if the AgCl is 
exhausted by the current flow, bare silver could come in contact with the solution and silver ions 
can leak and poison proteins. 
The IonFlux experiment can be divided into four different phases which can be 
programmed in the software with different well pressures, voltage applied to the cells, and signals 
recorded. The phases are: priming the microfluidic channels, capturing the cells, breaking the cell 
and gaining whole-cell recording, and the data acquisition phase. During the priming, compound 
and trapping pressure values should be kept from 10-15psi and the main channel pressure value at 
1 psi for a 2-4 minute duration. This flushes out any storage solution left in the channels and any 
bubbles that may be in the microfluidic channels. These are high pressure settings since there’s 
not yet cells patched. The compound/trapping pressures and main channel pressure should not 
exceed a factor of 20:1 or the compound will flow upstream into the cell suspension inlet well and 
contaminate the readings. Trapping phases introduce the cells into the main channel and suction is 
applied to pull the cells to the pipette series. Because the velocity of the main channel is quite high, 
trapping protocol necessitates a dwell, or a pause, to stop the flow in the main channel and allow 
the cells to be drawn to the trap openings. This docking period can take multiple cycles to ensure 
that all the traps are filled with cells. Main channel pressure should be kept at 0.1-0.2psi while the 
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compound pressures are inactive, the main channel is pulsed for 0.5sec with 3-5sec dwells. This 
should be cycled 10-15 times. The trapping vacuum should be 5inHg, too low and the traps may 
not fully fill, too high and the cells may be damaged. The breaking period is characterized by a 
burst of suction to break the cell and gain whole-cell patch. Though many cells break 
spontaneously during the trapping phase, it is necessary to ensure that all cells are in the same 
patch-clamp configuration. The main channel pressure should continue to hold at 0.1psi with a 
trap pulse value of 8-10 in Hg and duration of 5 sec. The dwell value should be 5inHg to hold the 
cells in place and the dwell time should be 5 secs. This series should be repeated 3-5 cycles to 
ensure that all the cells are opened. The most important and tunable phase of the experiment is the 
data acquisition phase. To minimize diffusive mixing that will dilute the compounds, a ratio of 
200:1 between compound pressure and main channel pressure should be maintained. This will 
deliver 90% of compound and 10% flow of cell suspension. It is incredibly important that the cell 
suspension main channel flow be kept active at all times. If the main channel is off then compound 
will start to flow upstream and contaminate the cell suspension which is the wash buffer that rinses 
the patched cells. The main channel pressure should be kept at 0.1-0.3 psi, adjusting this can speed 
the compound delivery though it should not be raised above 0.3 psi because the seal can degrade. 
Compound pressure pulse value is 10-15 psi, higher pressures can lead to faster compound 
delivery. To reiterate, the ratio of the compound pressure to main channel flow must be kept 
between 60:1 and 200:1, breaching this range can lead to diluted compound delivery or compound 
contaminating the cell suspension well. Compound delivery duration can be modified to as fast as 
100 msecs depending on the ion channel under study and the experiment performed. The trap dwell 
should continue to hold at 3-5 in Hg to keep the cells sealed in place.  
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2.3 Assay Format 
The original format of the assay for testing compounds recommended by the IonFlux was 
to split the compound ensemble into 2 halves. The first half would contain GABA EC3 and 
compound while the second half would only contain the compound. The wells would then open to 
preincubate the cells with just compound, followed by a burst from wells containing both GABA 
and compound. This method was very reliable and took into account slow kinetics of the 
compounds which may require longer exposure times to bind to the receptor. However, data 
collection was limited to 3 data points which does not result in a dose-response curve, the scheme 
is depicted in Figure 7.  
Figure 7. Plate layout and Depiction of Data Acquisition Phase of the Original 
Method Used for Drug Testing. A) illustrates a single ensemble of the IonFlux 
16 plate, O indicates the outlet, I is the inlet, C denotes compound wells, and T 
are the trap wells. GABA is kept constant while testing the compound but the 
modulator increases in concentration across the plate from left to right. B) 
illustrates the current readings during such an experiment. The bars above the 




2.4 Assay Optimization 
2.4.1 INTRODUCTION 
To study the GABAAR, transient transfection was used to generate the receptors in human 
embryonic kidney cells (HEK293T). Transfection allows the negatively charged phosphate 
backbones of DNA to enter cells with a negatively charged membrane. This can be done by coating 
the DNA with cationic lipid based reagents which can fuse with the lipid bilayer 206. Transient 
transfection coupled with automated patch clamp is capable of providing maximum flexibility with 
high throughput capabilities. Initial experiments were performed with positive modulator HZ-166, 
Figure 9, and competitive antagonist bicuculline, Figure 8.  
 
2.4.2 EXPERIMENTAL 
Plasmid Propagation Reagents 
Plasmids containing the Mus musculus genes for α1-6, β3, and γ2 GABAAR subunits were 
generously received from the Werner Sieghart Lab in Austria. These plasmids arrived on paper 
disks eluted with RNase Free Water (Fisher, BP24701). 1 µL of the elution was added to a tube of 
NEB 5-alpha competent E. coli cells (New England BioLabs, C2987H) and flicked to mix. The 
Figure 9. Structure of the HZ-166 
imidazobenzodiazepine synthesized 
by the Cook Lab at UWM.  




mixture was placed on ice for 2 minutes, undisturbed and immediately heat shocked at exactly 
42°C for 30secs. The tube was moved to ice for 2min, after which 950 µL of SOC was added to 
the mixture. 50 µL and 100 µL were spread onto a 100 µg/mL carbenicillin (GoldBio, C10325) 
plate and grown overnight at 37°C. A colony was chosen and used to inoculate LB broth (Fisher, 
BP9733-500) containing carbenicillin. The resulting culture is centrifuged at 6,000 x g for 15 min 
at 4°C to pellet the bacteria and the supernatant removed. The plasmid DNA is then extracted using 
a gravity-flow anion-exchange HiSpeed Plasmid Maxi Kit (Qiagen, 12663). The pellet was 
resuspended in buffer and an alkaline lysis is performed before the lysate is cleared by filtration. 
The lysate is then added to a primed HiSpeed tip to bind DNA, wash, and finally elute. Isopropanol 
was added to the elution to precipitate the DNA and collected using the QIAprecipitator. The final 
elution from the QIAprecipitator yields ultrapure plasmid DNA. The DNA concentration was 
determined by UV at 260 nm using the Tecan Infinite M1000 plate reader. Protein impurities were 
assessed at 280 nm.  
Cell Culture Reagents and Instrumentation 
A commercially available human embryonic kidney (HEK 293T) cell containing the simian 
vacuolating (SV) virus 40 T-antigen origin of replication 207 was used in all the stable cell lines. 
HEK 293T cells were purchased (ATCC) and cultured in 75 cm2 flasks (CellStar) coated in 
matrigel (BD Bioscience, #354234), a gelatinous protein secreted by mouse sarcoma that 
facilitates cell adhesion to the flask. Cells are grown in DMEM/High Glucose (Hyclone, 
SH3024301) media to which non-essential amino acids (Hyclone, SH30238.01), 10 mM HEPES 
(Hyclone, SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone, SV30010), and 
10% of heat-inactivated premium US-sourced fetal bovine serum (FBS) (Biowest, SO1520HI) 
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were added. Cells were rinsed with phosphate buffered saline (Hyclone SH30256.01) without 
calcium or magnesium. Cells are harvested using 0.05% Trypsin (Hyclone, SH3023601) or 
Detachin (Genlantis T100100) which both disrupts the cell monolayer and proteolytically cleaves 
the bonds between the cells and flask. The latter is more gentle and used for patch-clamp study. 
The media utilized in transient transfections contains the same components only the FBS was heat-
inactivated and dialyzed FBS (Atlanta Bio, S12650H), then cells were rinsed and shaken in Serum 
Free Media (Hyclone, SH30521.01). 
Cell transfection was conducted by lipid-based methods using Lipofectamine with PLUS 
reagent (Life Technologies, #15338020). Hygromycin was used for clone selection (Invitrogen 
10687-010). Cells were counted on a hemocytometer, 20 µL of cell suspension are aliquoted onto 
the slide and 3 counting areas whose volume is 100 nL are averaged and multiplied by 1x104 to 
give a concentration of cells in cells/mL.  
Electrophysiological Reagents and Instrumentation 
The following concentrations were optimized for study of GABAARs. The extracellular 
and intracellular solutions recommended by the manufacturers of the IonFlux. The extracellular 
solution contains: 238 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5.6 mM Glucose, and 
10 mM HEPES at pH 7.4. The intracellular solution contains: 60 mM KCl, 15 mM NaCl, 70 mM 
KF, 5 mM HEPES, and 5 mM EGTA at pH 7.25. These buffer components and concentrations 
were later altered slightly during the troubleshooting phase of creating the recombinant cell lines 
see Chapter 3: GENERATION OF GABAA STABLE RECOMBINANT CELL LINES. 
Buffer components contained: NaCl (Fisher, BP358-1), KCl (Fisher, BP366-1), MgCl2 
(Sigma, M8266), CaCl2 (Acros Org, 123350025), Glucose (Sigma, G0350500), KF (Sigma, 
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229814), HEPES (Fisher, BP410-500), CsCl (Sigma, 203025), EGTA (Tocris, 28-071-G), and 
Mg2+ATP (Sigma, A9187). Intracellular solutions pH was adjusted with KOH and extracellular 
with NaOH.  
2.4.3 RESULTS AND DISCUSSION 
Initial tests were run using α1β3γ2 stably-expressing cells provided by Fluxion (Millipore, 
CYL3053). These cells were tested using the agonist GABA (Figure 10) and competitive 
antagonist Bicuculline (Figure 11).  




Initial tests with transiently transfected cells yielded very poor results when compared to 
the Millipore cells: with transfected cells having current readings ranging from -500pA to -
5,000pA (Figure 12) compared to Millipore’s recombinant cell response which ranged from to -
4,000pA to 20,000pA (Figure 13).  
Figure 11. Stable Recombinant Millipore cells exposed to 10uM GABA EC 80 and 
increasing concentrations of negative modulator Bicuculline . N=4 
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A series of extensive experiments optimizing the lipofection transfection method and 
cellular preparation is summarized in Table 6. All transfections were performed between 40-80% 
confluency as too few cells cause the culture to grow poorly with no cell-to-cell contact and too 
many cells result in contact inhibition and make the cells resistant to uptake of foreign DNA, 
resulting in lower transfection efficiencies 208. In general, actively dividing cells take up introduced 
DNA better than quiescent cells. In addition, 1 volume of DNA was considered to be 5µg. A range 
of DNA concentration is usually suitable for transfection but anywhere below or above the range 
Figure 12. The maximum inhibitory current achieved in transiently 
transfected cells expressing the α1β3γ2 GABAAR exposed to GABA. 
Pattern (P) and trap (T) of each of the sweeps is seen above.  
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and transfection efficiencies will decrease. Too little DNA can result in very little gene production, 
too much DNA can be toxic to cells. The α1, β3, and γ2 plasmids were used for the transient 
transfection so as to be able to compare results with the stably-expressing α1β3γ2 Millipore cells. 
Initial conditions yielded very poor current response when cells were patch-clamped and exposed 
to increasing concentrations of GABA. In order to assess the optimal expression levels and 
functionality, the number of responding traps and the intensity of current response were studied. 
It was found that growth in media containing dialyzed FBS (Atlanta Bio, S12650H) followed by 
Figure 13. The maximum inhibitory current achieved in the stable 
recombinant Millipore cells expressing the α1β3γ2 GABA AR exposed to 
GABA. Pattern (P) and trap (T) of each of the sweeps is seen above.   
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rinsing and shaking cells in Serum Free Media (Hyclone, SH30521.01) greatly improves the seal 
and reduces background noise (conditions 7-9); possibly by removing excess proteins and lipids 
from the cell surface. The duration of transfection and the ratio of the plasmids matters less than 
Table 6. Optimization of transient transfection and cellular preparation  
Figure 14. Optimized transiently transfected α1β3γ2 cells exposed to GABA  
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the time needed for the cells to begin expressing large quantities of the GABAAR (condition 9-10) 
making the recovery time in fresh media unnecessary and proving cells can instead be left with the 
lipofection reagent still in solution. Transfections using 5000ng of each plasmid with a 1:1:1 ratio 
of α:β:γ yielded synonymous results; despite logic dictating that the optimal ratio should be 2:2:1 
since receptors assemble with 2α:2β:1γ; the amounts used can be reduced to 1:1:1 without 
significant effects. The final result seen in condition 11 where plasmids were transfected with a 
1:1:1 ratio for 24hrs in media containing dialyzed heat-inactivated FBS and a 30min wash in SFM 
led to maximal success in trapping and current response. The dose-response curve from this 
transfection condition (Figure 14) yielded data similar to those of the stably-expressing Millipore 
cells.  
The same optimized transfection protocol was utilized for the 6 different subtypes with 
measurable current response in all of them. Figure 15-Figure 21 shows the current sweeps of the 
entire run and the corresponding dose-response curve from each of the six subtypes. The α2β3γ2 
(Figure 16) and α3β3γ2 (Figure 17) subtypes exhibited robust GABA responses comparable to the 
Figure 15. Dose-response curve and current sweeps of α1β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. 
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α1β3γ2 (Figure 15) with current reaching a maximum of -10,000pA. The α4β3γ2 (Figure 18) 
transfected cells performed the worst and exhibited a high level of background synonomous with 
Figure 17. Dose-response curve and current sweeps of α3β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. 
Figure 16. Dose-response curve and current sweeps of α2β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. 
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its low maximum current responses at -1,000pA. The high background and low current response 
of the α4β3γ2 GABAA receptors may be indicative of failure of the receptor to assemble correctly 
in the membrane, compromised expression of the α4 protein, or a characterisitic of the receptor 
Figure 18. Dose-response curve and current sweeps of α4β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. 
Figure 19. Dose-response curve and current sweeps of α5β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. 
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subtype itself. The α5β3γ2 subtype (Figure 19) exhibited robust response but at slightly lowered 
maximum readings at -4,000pA. Transfection of the α6β3γ2 (Figure 20) had a robust response to 
GABA but was oversaturate at the lowest amount of GABA which was not observed with any of 
the other subunits. This is in line with what is observed in other electrophysiological studies where 
α6 is consistently reported as the most GABA sensitive 83. When the range of the GABA 
application was lowered from 100 µM to 33 µM (Figure 21), an intermediate response was 
observed. In retrospect, an even lower concentrations of GABA should have been used to produce 
a more sigmoidal shape. The lowest concentration is already part of the linear portion of the curve 
Figure 20. Current sweeps showing oversaturation at the lowest concentration of GABA 
(0.4µM) in HEK293T cells transfected with the α6β3γ2. 
Figure 21. Dose-response curve and current sweeps of α6β3γ2 
transiently transfected HEK293T cells exposed to successively larger 
concentrations of agonist GABA. After reduction of the GABAMAX 
from 100µM to 33µM.  
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and the maximum response level (EC100) is already achieved at concentrations as low as 1.23 µM 
so lowering the maximum concentration of GABA to 5-10 µM may be acceptable for additional 
experiments.  
After GABA dose response curves were studied, testing proceeded to other types of 
compounds: positive allosteric modulator BZD HZ-166 (Figure 22) and competitive antagonist 
bicucculine (Figure 23). 
Figure 22. Transiently transfected α1β3γ2 cells exposed to 2µM of GABA and 
increasing concentrations of positive modulator HZ-166. 
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 The throughput of the assay itself when testing modulators is a major obstacle to  
overcome.  Taking into consideration that the GABAAR is a fast action ionotropic chloride ion 
channel and the rapid rate of onset known to benzodiazepine is a result of high affinity binding 
with rapid kinetics 209, we surmised that it may be possible to utilize all compound application 
wells to increase data output. With this modified method, a constant amount of GABA and an 
increasing concentration of positive modulator is placed in 7 of the compound wells, saving a 
single channel solely for GABA application to set a baseline. The ensemble layout is depicted in 
Figure 24. This would double the number of data points aquired from each trap. However, proof 
Figure 23. Bicuculline dose response curve in transiently 
transfected α1β3γ2 cells with 10µM GABA. 
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of concept was important since it was possible that the acquired EC50 would be shifted right if the 
rate of binding of the BZD is delayed due to simultaneous exposure to both an agonist and positive 
modulator. Thus the same experiment was performed but with lowered GABA concentrations to 
the calculated concentration for agonist EC3 and EC80. Previously published studies perfomed by 
a collaborator have exhibited very similar results with EC50 values around 1µM for HZ-166 seen 
in Figure 26 210. Study of the other GABAAR subtypes using transient transfection yeilded a similar 
Figure 25. Dose response curves from improved assay forma. EC 3 concentrations taken as 0.1µM and 
EC80 as 3µM. 
Figure 24. Ensemble setup for utilization of all compound wells 
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range of EC50 concentrations between 100 nM-1.0 µM This cooresponds with the theory that the 
potency of positive modulators has a strong coorrelation between the slow infusion of drugs in 
manual patch clamp of frog oocytes and our format using ultra fast application of compounds on 
HEK293T cells using the microfluidic technology of automated patch clamp. Analysis of the 
efficacy, seen in Figure 28, presented heightened potentiation towards the receptor subtypes 
containing the α2/3 and lowered effects towards the α1/5. Unusually high results of traditionally 
benzodiazepine-insensitive subtypes α4/6 were observed. This may be due to the recorded 
sensitivity of βγ2 constructs which have been known to assemble with expression systems of α4 
Figure 26. Results of HZ-166 performed in frog oocytes injected 
with GABAAR subunit plasmid DNA via manual patch clamp. 
Figure modified from Rivas 2009, referenced in text.  
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and are stongly potentiated with diazepam with high potency 211. The efficacy and potency 
observed for α1/2/3/5 appear to be in satisfactory agreement to proceed with further analysis using 
the fast application strategy for other positive modulators.  
With the issue concerning low data output having been resolved, another shortcoming was 
the method of data analysis. Initial analysis strategies for modulators called for normalization of 
Figure 27. GABA dose response curves of transiently transfect cells 
containing differing alpha subunits, N=8 
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the data and automated export by the IonFlux software. Normalization naturally ignores the 
efficacy (potentiation) in favor of determining compound potency (EC50). Creating a drug with 
maximum efficacy not potency appears to be the most important quality to determine subtype 
selectivity 212. Examination of the manner in which data is exported from the IonFlux also revealed 
some problems.  Figure 29 is a screenshot which illustrates the limitations of using the software’s 
automated data export program when quirks and shifts in response are present. The blue bar 
indicates the area in which the lowest reading is exported for analysis. Notice that not all traps 
respond simultaneously and the Imin of the sweep occurs at different times for many of the readings. 
Automated export of the data in the blue bar ignores this behavior. 
Figure 28. Graph of the efficacy of HZ-
166 in different α subtypes transiently 
transfected into HEK293T cells 
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Manual export using the raw sweep data is time consuming but necessary in order to gain 
more genuine response curves. Since each one of the raw sweep files contains 10,260 data points 
per sweep, processing speeds of the computer used for analysis is limited; particularly if using 
Microsoft Excel. Thus sweeps must undergo initial smoothing whereupon 342 data points are 
averaged into 1. This yield 30 data points per sweep. These sweeps are loaded into a customized 
32-sheet Excel sheet where Event of the sweep is reorganized into data collected per trap. For 
Figure 30. Smoothed sweeps before and after baseline correction  
Figure 29. Real time view of the sweeps viewable from the 
IonFlux software.  
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baseline correction, the first 6 points and the last 6 points of the sweep are averaged and a slope 
and intercept are calculated. From this data, a line is constructed and subtracted from the smoothed 
sweep. The results from this step can be seen in Figure 30. The minimum currents of each entire 
sweep is then isolated and divided by the minimum current achieved with GABA alone and 
multiplied by 100. This established % potentiation. When a normalized GABA dose response is 
needed, the sheets are altered in such that the minimum current of each sweep is subtracted from 
the minimum current elicited with just GABA and then divided by the difference between the 
lowest current achieved in the trap and the lowest current from GABA application alone. This 
process is illustrated in Figure 31. 
A well-timed opportunity involving work with a pharmaceutical company allowed for the 
testing of this new method. The pharmaceutical company Concert Pharmaceuticals provided a 
known subtype selective, non-benzodiazepine that has been reported to exhibit partial agonism at 
A 
Figure 31. Improved method of data analysis. A) is the original output of data sweeps assembled by 
the IonFlux software. B) Smoothing of the data points reveals the individual swee ps. After the Imin 






α2 and α3 and antagonism at α1 called L-838417. However, this compound, synthesized by Merck, 
was not advanced into clinical development due to poor preclinical pharmacokinetic profile. They 
had created an analog of L-838417 by incorporating deuterium atoms in place of hydrogen at key 
positions (Figure 32) in hopes of improving metabolic stability but retaining pharmacological 
selectivity. Initial tests, seen in Figure 33, with the two compounds on the biologically relevant 
subtypes of α1/2/3/5 did not reveal any significant differences between the deuterated and non-
deuterated compounds. In addition, neither did they exhibit subtype selectivity with antagonism 
towards the α1 receptor subtype. Previous studies performed using human GABAAR transiently 
expressed in Xenopus laevis oocytes revealed that efficacy towards the α1/2/3 were +0%, +11%, 
and +21% respectively when tested with EC20 GABA 
213. Since initial tests were performed at 
EC3, this parameter was replaced with GABA EC20 concentrations to allow for better comparison. 
This change brought a much higher variance of results between the two compounds, as seen in 
Figure 34. For example, observation of drug response at α1 containing receptors reveals two very 
different profiles. The L-838417 would appear to be unchanged from the previous results in EC3 
GABA concentrations; with an efficacy in the 200s range. However the deuterated compound 
Figure 32. CTP-354 containing 9 deuterium atoms. 
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CTP-354 exhibited bell shaped curve with a heightened response followed by a steady trend 
Figure 33. Dose response curves of non-deuterated L-838417 vs deuterated CTP-354 in 
transiently transfected HEK293T cells with GABA EC 3 of 0.1µM, N=4 
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downwards. This may be indicative of desensitization, high concentrations of the compound 
Figure 34. Dose response curves of non-deuterated L-838417 vs deuterated 




directly blocking the chloride channels, or compound non-specifically interrupting membrane 
function. Comparison with manual patch clamp experiments, results provided by Concert 
Pharmaceuticals, offered a very different dose response profile, seen in Figure 35 214. The α2/3/5 
has equal efficacy while the α1 subtype remained at the baseline with mild antagonism at the 
highest concentration. Given these results, the company withdrew interest in further testing.  
Despite this unusual result, the high-throughput screening campaign of compounds 
synthesized by Dr. Cook was launched. The compounds under interest were anticipated to be a 
series of α3 selective drugs. In order to asses this, preliminary testing was performed on one of the 
compounds which had exhibited on transiently transfected cell lines containing differing α 
Figure 35. Dose response curve for L-838417 using oocytes transfected with 
human GABAAR. Figure used with permission from Nature Neuroscience, 
reference cited in text. 
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subtypes. In addition, our method of using transiently transfected cells makes it necessary to test 
compounds in parallel with a control to assess the relative difference.  
It was critical to determine what concentration to use of the GABA when determining the 
effect of a BZD since the BZD has no intrinsic affect without the agonist present. Experiments 
were, at first, going to be performed at EC30, however the results would most likely not be 
comparable to experiments performed by our collaborators who tested at EC3 concentrations. It 
should be pointed out that transient transfection might generate a second low affinity BZD site that 
Table 7. Structures of the drugs utilized in the high throughput screening campaign. HZ-
166 and diazepam were used as controls while compounds beginning with the initials MP 
were test compounds.  
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reacts toward µM concentrations of BZD in combination with low EC3-8 concentrations of GABA 
215. So in order to reduce the effect of the second binding site but keep results comparable, GABA 
EC10 concentration was applied in unison with the modulators. 
Along with two control compounds, HZ-166 and diazepam, 6 experimental compounds 
were tested in parallel to assess their relative efficacy. Their structures can be seen in Table 7. The 
MP-II-0XY compounds were similar to HZ-166 scaffold but differ in the ethyl ester functional 
group on the imidazole. MP-II-064, which contains a nitrile group, was tested by the Sieghart Lab 
in Austria and exhibited lowered efficacy towards the α1. Thus this compound was tested first on 
the α1/2/3/5 to compare the results. MP-II-064 showed lowered efficacy and potency for all 
subtypes when tested by our collaborator, seen in Figure 36. When the same experiment was tested 
using our experimental methods, the transient cells had a much higher current response in general 
with potentiation values in the thousands range, seen in Figure 37. Overall, the compound had 
Figure 36. Manual patch clamp experiments on 
frog oocytes performed by the Sieghart Lab. The 
HZ-166 was tested in the presence of GABA EC20 
while the MP-II-064 was tested with GABA EC3. 
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lower efficacy than HZ-166 on all but the α3, which was slightly higher though had a significantly 
higher standard deviation than the other experiments. It was also noted that accompanied GABA 
agonist concentrations differed greatly. While the Sieghart Lab performed their tests with HZ-166 
and MP-II-064 with GABA EC3, ours were performed in mid-range at EC10. In addition, we had 
tested our compounds at a maximum of 100µM instead of 10µM and since the MP-II-064 curves 
in Figure 36 had not reached saturation, higher concentrations may have revealed differences in 
the efficacy.  




Similar experiments were performed with other experimental compounds, seen from 
Figure 38 to Figure 42, though these lack manual patch clamp data for comparison. 
Figure 38. Dose response curve comparing HZ-166 and MP-II-065 using 




Figure 40. Dose response curve comparing HZ-166 and MP-II-067 using 
transiently transfected cells.  
Figure 39. Dose response curve comparing HZ-166 and MP-II-068 using 




Figure 41. Dose response curve comparing HZ-166 and MP-II-070 using 
transiently transfected cells.  
Figure 42. Dose response curve comparing HZ-166 and MP-II-073 using 
transiently transfected cells. 
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This series of compounds were tested in 7 independent experiments with transiently 








Figure 43. Dose response curves from seven independent assays for the high -throughput screening 
campaign of the Cook Lab compounds using α1β3γ2transiently transfected cells.  
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results, show in Figure 43, have been normalized to the highest achieved current result per 
experiment and then baseline corrected. The curves show a high variation in results from an 
experiment to experiment basis. The relative efficacy values from each experiment, seen in Table 
8, illustrate the variation between experiments. The top table, highlighted by column to show the 
range by experiment, shows how particular experiments such as the first and third, which are dark 
green, will exhibit a higher general efficacy for all compounds. The bottom table, highlighted by 
row to show the range by compound, shows an overall pattern occurs where a particular compound 
will test repeatedly high among the group (MP-II-073 dark green) while another will consistently 
produce low results (MP-II-064 light yellow). Though this information may be useful for strongly 
specific compounds, the ones that test within mid-range are indeterminable.  
Table 8. Relative efficacies of the compounds tested by experiment. The above table has highlighted color 
scale by experiment (column) while the lower table is highligh ted by compound (row) with green showing 




From these findings, it can only be concluded that the method of testing transiently 
transfected cells on automated patch clamp is not a feasible approach to generating reproducible 
numerical values for determining compound efficacy. In addition, assaying many different batches 
of transfected cells for data with low reproducibility had very low efficiency to the high cost of 
plates and reagents.  
The formation of heteromeric, dimeric, or homomeric receptors different from the typical 
2α:2β:1γ can dramatically vary in their level of expression depending on the recombinant 
expression system. And despite optimism that the deviation would be stifled by averaging of the 
cellular population when cells are patched in series, the reproducibility remained lower than 
expected. Even assuming that the receptor successfully forms a pentameric formation with the α, 
β, and γ, there is a possibility that the order of assembly is altered. Figure 44 illustrates the possible 
pentameric assemblies when all subunits are involved 31.  
Since the expression of the genes varies from cell to cell and the transfection is not 
successful in every cell, the variability of expression and the statistical nature of cell capturing in 
the instrument plates creates an environment in which one has a chance of capturing both high 
expressing cells, low expressing cells, untransfected cells, or debris. In addition, it is difficult to 
assess whether the high expressing cells have functionally assembled the biologically relevant 
pentameric receptor. The ability of recombinant systems to assemble both βγ and αβ receptors has 
been elucidated and even homomeric receptors containing only β3 subunits have been found to be 
robustly expressed 216,217. Despite the statement that γ2 is necessary for diazepam sensitivity of the 
GABAAR, there have been studies whereupon the combination of αβ elicited a significant 
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potentiation from diazepam within the µM range 215. Additionally βγ assembly has been shown to 
occur in oocytes and diazepam potentiated these receptors with high potency at an EC50 of 50nM 
and efficacy of +76% 211.  
In any case, despite efforts to optimize cell preparation, viability, transfection, patch-
recordings, data-throughput, and data analysis; the low reproducibility of results remains a major 
point of contention. To overcome these shortcomings, a proposed solution takes us to Chapter 3: 
GENERATION OF GABAA STABLE RECOMBINANT CELL LINES.  
Figure 44. The possible assembly of recombinant α1β3γ2 formed in HEK 293T cells transfected. The 
most likely arrangement formed is (A) and (B) configurations. Conformation (C) has a low probability 
of formation and would be unresponsive to BZDs. (D) would be improbable but if formation occurs 
then multiple BZD sites would be present.  
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CHAPTER 3: GENERATION OF GABAA STABLE RECOMBINANT CELL LINES  
3.1 α1β3γ2 GABAAR Recombinant Cell Line 
3.1.1 INTRODUCTION 
Transiently transfected cells express the gene of interest but do not integrate it into their 
genome so the new gene will not be replicated. During transient expression, target gene expression 
is temporary (24-72 hours for RNA, 48-96 hours for DNA) and the foreign gene is lost through 
cell division or other factors. In contrast, stable transfection introduces genetic materials with a 
marker gene for selection and sustain expression even after the host cells replicate as illustrated in 
Figure 45 218. The integration is usually non-specific and only occurs in a small number of cells. 
The descendants of DNA-altered cells will carry and express the gene resulting in a stably-
transfected cell line. Stable, long-term expression of a gene is achieved when a plasmid is 
introduced to the cell, travels to the nucleus, and finally integrates into the chromosomal DNA. 
Figure 45. Diagrams of the two different types of transfections. A) Stable transfection: whereupon the 
foreign DNA (red wave) is delivered to the nucleus and is integrated into the host genome (black wave) 
and expressed sustainably. B) Transient transfection: following delivery  of the DNA or mRNA into the 




Since this chromosomal integration is a rare event, successful stably-transfected cells have to be 
selected and cultured with a selection agent. Only cells with the plasmid integrated will survive in 
the presence of the selection reagent. In the case of antibiotic selection, only the cell which have 
integrated the antibiotic resistant gene, contained on the plasmid with the gene of interest, will 
survive. 
GABAAR contains multiple protein subunits to form the pentameric receptor and thus 
transfection necessitates multiple genes of interest. Cotransfection with multiple plasmids can 
leads to heterogeneous cell populations with very variable expression levels of each protein. In 
addition, the use of multiple antibiotics to select for the expression of multiple plasmids can 
negatively affect the recovery and proliferation of some cell lines. Common chemical transfection 
methods such as lipofection can be used for plasmid delivery into the cell. Choosing a clone with 
appropriate expression levels for all genes can be time-consuming. For the isolation process, single 
cells are isolated by plating into multi-well plates to obtain 100% clonal purity. Stably-transfected 
cells, in contrast to transient expression, express a gene of interest long-term at defined and 
reproducible levels. For the selection process, the antibiotic concentration is crucial since cells 
differ in their susceptibility to antibiotics and the activity of the antibiotic can vary considerably 
from batch to batch. So generating an antibiotic kill-curve is necessary if a new stock is used. After 
transfection, the cells grow and develop the proteins for antibiotic resistance during the initial 
selection. This step can take up to four weeks to extensively eliminate any contamination with 
non-resistant cells. After 1-2 weeks, the antibiotic concentration can be lowered. The optimal 
confluency for the time of transfection is normally 60-80%. Variation in cell densities can result 
in lower transfection efficiencies 208.  
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Using a stably-transfected cells line has several benefits. Firstly, discontinuing use of 
lipofection reagent is fiscally beneficial and would lead to a better intact cell membrane which is 
crucial for electrophysiological measurements. As a result, this would lead to a better seal with 
high resistance and less noise. Furthermore, since all cells are a genetically homogenous and clonal 
population, they maintain the same levels of GABAAR protein expression and thus offer high 
reproducibility of results.  
The pJTI destination vector used in this study contains a φC31Integrase to mediate stable 
integration of the gene into the genome of the cell line. φC31 integrase, unlike recombinases such 
as Cre and Flp, does not have a corresponding excisionase enzyme, making the integration 
virtually irreversible 219. Furthermore, the integration is site-specific for attB and attP phage 
attachment sites on extrachromosomal vectors and in human cells the integration will be 
distributed among a set of pseudo attP sites 90% of the time which is dramatically specific over 
random integration. These degenerate pseudo sites have partial sequence identity to attP and is still 
recognizable by the enzyme and may randomly present in large genomes like those of mammals 
220. The CMV promotor was added to generate the highest gene expressions possible, this has been 
reported as the best promotor for recombinant protein production in HEK293T cells with high 
efficiency long term transgene expression 221. 
3.1.2 MOLECULAR CLONING 
3.1.2.1 Introduction 
Gateway technology utilized in the molecular cloning of the multi-gene system is based on 
the bacteriophage lambda site-specific recombination system which integrates lambda DNA into 
the E. coli chromosome. This process involves DNA att site recombination sequences with proteins 
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that mediate the selective recombination reaction. At the att sites, attB on the E. coli chromosome 
and attP on the lambda chromosome. These sites serve as binding sites for recombination proteins 
222. After recombination occurs between the attB and attP sites, attL and attR sites are formed; 
facilitated by the bacteriophage λ integrase (Int) and E. coli integration host factor (IHF) proteins, 
a mixture called the lysogenic BP reaction. The recombination of the attL with the attR creates an 
attB expression clone catalyzed by Int, IHF, and Excisionase (Xis) proteins, a mixture called the 
LR Clonase enzyme mix. The recombination reactions are very specific for the sites. Invitrogen’s 
Multisite Gateway technology manipulates this strategy to generate donor vectors. The three 
fragment system employs the following PCR fragments to donor vectors: aatB1 and attB4 react 
Figure 46. Multisite gateway 3-fragment recombination system assembling the target expressio n 
construct. Open Access cited in text.  
 86 
 
with attP1 and attP4, attB4r and attB3r with attP4r and attP3r, attB3 and attB2 with attP3 and attP2. 
These newly created sites are the attL1 and attL4, attR4 and attR3, and attL3 and attL2 
respectively. These sites reassemble with the final destination vector which contains an attR1 and 
attR2. This final reaction regenerates the attB1, attB4, attB3, and attB2 sites. This process is 
illustrated in detail in Figure 46 from 223. 
3.1.2.2 Experimental 
Plasmid Propagation 
Plasmids, BP clonase, and LR clonase were acquired from a kit for the Multisite Gateway 
Technologies (ThermoFisher, 12537100). The ccdB effects of the DONR and DEST (donor and 
destination) vectors meant that propagation of the plasmid has to be done in ccdB Survival 2 T1R 
E. coli stain (ThermoFisher, A10460). Then plated on LB (IBI, IB49120) containing 50 µg/mL 
kanamycin (GoldBio, K12025) and 20µg/mL chloramphenicol. The destination vector should be 
cultured on LB plates containing 100µg/mL carbenicillin (GoldBio, C10325) and 20µg/mL of 
chloramphenicol (GoldBio, C1055). The plasmid DNA is then extracted using a gravity-flow 
anion-exchange HiSpeed Plasmid Maxi Kit (Qiagen, 12663). The pellet was resuspended in buffer 
and an alkaline lysis is performed before the lysate is cleared by filtration. The lysate is then added 
to a primed HiSpeed tip to bind DNA, wash, and finally elute. Isopropanol was added to the elution 
to precipitate the DNA and collected using the QIAprecipitator. The final elution from the 
QIAprecipitator yields ultrapure plasmid DNA. The DNA concentration was determined by UV 




One Shot Mach1 T1 Phage-Resistant chemically competent cells (ThermoFisher, 
C862003) were used to generate DONR plasmids. PCR fragments were generated with flanking 
attB sites seen in Table 9 and ordered from Integrated DNA Technologies (IDT). The template 
DNA was combined with 1 µL of 20µM of each of the primers, 1 µL of 10 mM dNTP mix, 2 µL 
of 50 mM MgSO4, 5 µL of 10X High Fidelity PCR Buffer, add 0.2 µL Platinum Taq DNA 
Polymerase High Fidelity (ThermoFisher, 11304-011) and the reaction mixture was diluted to 50 
µL reaction. The thermal cycler was set for 30 PCR cycles with an initial denaturation step 94°C 
for 2 minutes, denaturing step at 94°C for 15secs, annealing step at 55°C, and an extension phase 
at 68°C for 2 minutes.  
Gene fragments containing the attB sites were purified using 150 µL of TE, pH 8.0 
(Qiagen, 12662) to a 50 µL amplification reaction containing the product. 100 µL of 30% PEG 
8000 with 30 mM MgCl2 (Fisher, BP233-1/Fisher, AB-0359) were added and vortexed to mix and 
centrifuged immediately at 10,000 x g for 15 minutes at room temperature. The supernatant was 
removed and the clear pellet was dissolved in 50 µL of 1 x TE, pH 8.0. The recovered product was 
run on a 1% agarose gel with 0.5 g of agarose (MidSci, BE-A500)  with 50 mL of 1xTBE buffer, 
microwaved in bursts of 30 secs until the agarose was dissolved. 5 µL of an ethidium bromide 
replacement, Bullseye DNA Safestain (MidSci, C138) was added to visualize the DNA under 
Table 9. Primers used to integrate recombination sites. 
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ultraviolet light. The agarose was poured into a small gel tray with a well comb. The gel was 
allowed to solidify at room temperature for 20-30 min. The gel was run at 80-150 V for around 30 
min until the dye line was 50-75% down the gel. 
50 fmoles of the attB PCR product was added to a mixture with 150 ng of pDONR vector, 
in 8 µL of TE buffer. 2 µL of BP Clonase II enzyme mix (ThermoFisher, 11789100) was added 
and vortexed to mix and incubated at 25°C for 1 hour. Afterwards, 1 µL of Proteinase K 
(ThermoFisher, 25530049) solution is added to the reaction and incubated for 10 min at 37°C.  
The BP reaction is transformed using One Shot Mach1 T1 Competent Cells (ThermoFisher, 
C862003). 2 µL of the BP recombination reaction was added to a vial of One Shot Mach1 T1 
chemically competent E. coli and incubated on ice for 30 min. The cells were heat-shocked for 30 
sec at 42°C without shaking and immediately transferred to ice for 2 min. SOC medium, 250 µL, 
was then added and incubated at room temperature. The tube was secured and shaken horizontally 
at 225 rpm at 37°C for 1 hr before being spread on pre-warmed Kanamycin (GoldBio, K-120) 
selective plates (20 µL and 100 µL) which were incubated overnight at 37°C. Colonies were 
isolated and grown in LB broth containing Kanamycin and purified using the IBI High Speed 
Plasmid Mini Kit (MidSci, IB47101).  
The DONR entry clones were combined at 10fmoles each with the destination vector at 20 
fmoles with 1X TE buffer, pH 8.0 added to 8 µL. The LR Clonase II Plus enzyme (ThermoFisher, 
11791100) was thawed and vortexed before 2 µL were added to the reaction vessel and vortexed 
for 2 seconds twice. The reaction was then incubated at 25°C for 16 h. The reaction was then 
incubated with 1 µL of Proteinase K (ThermoFisher, 25530049) for 10 min at 37°C to discontinue 
the reaction. 2-3 µL of the reaction mix was used to transform into One Shot Mach1 T1 competent 
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cells (ThermoFisher, C862003) or MAX Stbl2 Competent Cells (ThermoFisher, 10268019). The 
cells were plated onto Carbenicillin (GoldBio, C10325) selective plates (20 µL and 100 µL) which 
were incubated overnight at 37°C. Colonies were isolated and grown in LB broth containing 
Kanamycin and purified using the IBI High Speed Plasmid Mini Kit (MidSci, IB47101).  
3.1.2.3 Results and Discussion 
pDONR plasmids were replenished using a Qiagen Maxi prep in OneShot ccdB survival 
2T1 competent cells. PCR product was run on a 1% agarose gel. Initial results to generate Entry 
Clones from the DONR plasmids exhibited integration of the α1 and β3 but not the γ2 gene. When 
the quality of the PCR product was assessed during genetic sequencing at GeneWiz, the product 
was found to be of poor quality. Multiple colonies were purified but attempts yielded the same 
results. A repeat with the PCR reaction with subsequent PEG purification followed by BP clonase 
and transformation led to a successful recombination of γ2 into the DONR plasmid. Jump-In LR 
Clonase II Plus recombination reaction was performed using 10 fmoles of each Entry Clone 
plasmid and 20 fmoles of the destination vector, DEST. The reaction was transformed into Mach1 
T1 competent cells and plated onto Carbenicillin (Carb) plates. Growth yielded >200 colonies, all 
of which failed to grow in LB broth with Carb. When fresh plates were poured, growth was around 
20 colonies. Two colonies were sequenced but lacked the γ2 gene. Re-sequencing the γ2 Entry 
Clone led to a failed priming so the original source plasmid, pCI-GABAAR-γ2, PCR was 
performed again with >200 colonies growing on a Kanamycin selective plate. 5 colonies were 
isolated with all exhibiting high background or poor quality DNA. Repeating the transformation, 
colony isolation, LB growth and purification yielded sufficient DNA quality and sequencing 
within the γ2 gene fragment showed a successful insertion. The LR recombination reaction was 
repeated and mixture was transformed and plated out onto Carb plates. Around 15 colonies grew 
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and were sequenced with no priming at the α1 or β2 genes. Repeating the reaction resulted in 
formation of >20 colonies but Mini-prep of five colonies yielded negligible amounts of DNA 
except for 1 which only contained the γ2 insert. 8 more colonies were selected, grown and purified 
via mini-prep. The fifth plasmid yielded all three inserts which were verified with genetic 
sequencing with GeneWiz. The sequence of the entire construct can be found in the supplementary 
material. 
A maxi-prep was performed to amplify the plasmid with growth kept below 30°C. Since 
the plasmid is large, it is unstable and has a low copy number and needs to grow for longer periods 
of time. It may be prone to mutate in regular competent cells so Stbl2 cells can be used instead. 
3.1.2.4 Conclusions 
DONR plasmid construction presented little trouble as long as the PCR product was of 
sufficient quality. The efficiency of the recombination of the three DONR plasmids was lower than 
expected despite reports that the combined success frequency of producing the correct clone was 
reported to be 51.8% in other publications 223. However it should be noted that such numbers 
represent single-fragment Gateway cloning and multi-fragment success was not reported 
separately. 
3.1.3 TRANSFECTION AND CLONE ISOLATION 
Stable cell lines are an essential tool in research for mass production of recombinant protein 
and antibodies as well as for assay development, functional studies, and for gene editing CRISPR 
experiments. Currently most biopharmaceutical companies employ the methotrexate (MTX) 
amplification technology or the Lonza glutamine synthetase (GS) system for selection, using 
Chinese hamster ovary (CHO) cells due to their robust growth in suspension cultures. MTX 
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inhibits the dihydrofolate reductase enzyme necessary for cellular metabolism while methionine 
sulphoximine in the GS system inhibits glutamine synthetase 224,225. If transfection of multiple 
genes on different plasmids is involved, cell clones obtained will have multiple random genome 
integration with highly heterogeneous results. Choosing a cell clone expressing all genes of interest 
in edition to having high, stable expression can be costly and time-consuming, taking 6 to 12 
months at a time. Thus, advancements in this area to increase speed and efficiency of generating 
and picking stable cell clones is at the forefront of concern for many companies 226.  
The pJTI destination vector employs site-specific recombination to develop clones with 
more reproducible and predictable efficiency. The vector also contains a hygromycin 
phosphotransferase gene which confers hygromycin B resistance. Though there are automated 
methods of picking cell clones such as fluorescence-activated cell sorting (FACS)-based 
screening, ClonePix fluorescence halo system, or Cell Xpress laser fluorescence detection; the 
traditional method is the serial limiting dilution approach. This approach is simple and ensures 
monoclonal purity but is time and labor intensive. It involves sequential diluting in well-plates 
with single cells selected from the survivors of multiple rounds of selection and expansion. This 
traditional method was utilized for selection of the clones discussed further. 
3.1.3.1 Introduction 
Generating a stable cell line with the use of antibiotic selection necessitates the 
optimization of the antibiotic concentration used. The concentration is cell type dependent and 
antibiotic batch dependent. A kill curve is a dose-response experiment whereupon cells are 
exposed to increasing concentrations of antibiotic to determine the minimum concentration 
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required to kill all the cells over the course of one week. Two different assay formats were tested 
to determine the optimal antibiotic concentration. 
Trypan Blue is a 960 Dalton molecule that enters cells with compromised membranes and 
binds to intracellular proteins. Trypan Blue has a very high affinity for serum proteins in media so 
the cells must be pelleted and resuspended in serum-free media or salt solution. Cells are physically 
counted instead of using an automatic instrument measurement so human error can be a problem. 
However, this assay is quick and commonly used as standard dye exclusion technique for viable 
cell counting.  
CellTiter-Glo determines the number of viable cells though quantification of the ATP 
present in the well. ATP (adenosine triphosphate) indicates living, or metabolically active, cells. 
The mixture results in the cell lysis and the generation of a luminescent signal indicative of ATP 
presence. The reaction that converts luciferin into oxyluciferin, generates luminescence as a 
byproduct. For this reaction to occur, the presence of Mg2+, molecular oxygen, and ATP are 
necessary. Promega’s luciferase (LucPpe2m) is a stable form of the luciferase found in the firefly 
Photuris pennsylvanica (LucPpe2) and is pH and detergent resistant.  
10µg total DNA was used for the transfection. After transfection, 48-72 hours passed to 
allow for sufficient recovery and to avoid low cell viability. Cells were then transferred to 6-well 
plates containing fresh medium at a less than 25% confluency. After cells successfully adhered to 
the culture dish (3-5 h), antibiotic pressure was applied with Hygromycin B. Visual toxicity of the 
cells were noted daily and media was replaced every 2-3 days. The surviving polyclonal line was 
then processed further using the limiting dilution method to expand single cells into colonies in 
separate wells. Only those cells with single, well-defined colonies and identifiable foci were 
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manually picked and expanded for further analysis. Very low survival rates are a hallmark of this 
method as secreted factors from neighboring cells are absent 227. 
3.1.3.2 Experimental 
Cell Culture Reagents and Instrumentation 
A commercially available, human embryonic kidney (Hek 293T) cell containing the simian 
vacuolating (SV) virus 40 T-antigen origin of replication 207 was used for all the stable 
transfections. Human embryonic kidney (HEK) 293T cells were purchased (ATCC) and cultured 
in 75cm2 flasks (CellStar) coated in matrigel (BD Bioscience, #354234), a gelatinous protein 
secreted by mouse sarcoma that facilitates cell adhesion to the flask. Cells are grown in 
DMEM/High Glucose (Hyclone, SH3024301) media to which non-essential amino acids 
(Hyclone, SH30238.01), 10 mM HEPES (Hyclone, SH302237.01), 5x106 units of penicillin and 
streptomycin (Hyclone, SV30010), and 10% of heat-inactivated premium US-sourced fetal bovine 
serum (FBS) (Biowest, SO1520HI) were added. Cells were rinsed with PBS or phosphate buffered 
saline (Hyclone SH30256.01) without calcium or magnesium. Cells are harvested using 0.05% 
Trypsin (Hyclone, SH3023601) or Detachin (Genlantis T100100) which both disrupts the cell 
monolayer and proteolytically cleaves the bonds between the cells and flask; the latter is more 
gentle and better suited for patch-clamp studies due to the proprietary mixture of proteases and 
collagenases. The media utilized in transient transfections contains the same components only the 
FBS was heat-inactivated and dialyzed (Atlanta Bio, S12650H).  
Transfection Reagents and Instrumentation 
15 µg of the pJTI-constructs were used for transfection reactions. Cell transfection was 
conducted by lipid-based methods using Lipofectamine with PLUS reagent (Life Technologies, 
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#15338020). Hygromycin was used for clone selection (Invitrogen 10687-010). Cells were 
transformed at 60-70% confluency and the population was thinned for accurate clone isolation. 
Clone Selection Reagents and Instrumentation 
After lipofection for 24 h in the 75cm2 flask, cells were redistributed onto a 60cm2 petri 
dish (MidSci, TP93100) and allowed to adhere overnight. 300µg/mL of hygromycin was added to 
the dish after 24 h. Media was exchanged every 2-3 days over a period of 10-15 days until 90% of 
the cells were dead. Large, well defined and separated colonies were chosen and placed in a 
matrigel-treated Nunc 384 well-plate (ThermoSci, 12-566-1) containing 80 µL of media. Once the 
well had sufficient growth of 50-60% confluency, the cells were moved to a matrigel-treated Nunc 
96 well-plate (ThermoSci, 12-566-71) containing 150 µL of media. The wells that met 50-60% 
confluency were again moved to a matrigelled 24 well-plate (Corning, 3738) with 500 µL of media 
and 300µg/mL Hygromycin. Cells were again allowed to come to confluency before being moved 
to a 6 well-plate (MidSci, TP92006) with 2 mL of media and continued exposure to 300 µg/mL 
hygromycin.  
Cells were centrifuged at 1000 rpm for 2min before being resuspended in PBS (Hyclone 
SH30256.01). 200 µL of the suspension was added to 300 µL and 500 µL of 0.4% Trypan Blue 
solution (Sigma, T8154) and mixed thoroughly. The mixture was incubated for 10 min before 
being counted with a hemocytomer. Cells were counted by adding 20 µL of cell suspension onto 
the slide. Three counting areas whose volume is 100 nL are averaged and multiplied by 1x104 to 
give a concentration of cells in cells/mL. 
CellTiter-Glo cell viability assay was performed in a 96 or 384-well plate. Cells in the 96-
well plate (ThermoSci, 12-566-71) were cultured with 100 µL of media while the 384-well plate 
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(ThermoSci, 12-566-1) should contain 25 µL of media. Control wells without cells were prepared 
to obtain a value for background luminescence. 1 volume of CellTiter-Glo reagent is added to the 
wells and the plate is placed on an orbital shaker for 2 minutes to induce cell lysis. The plate is 
further incubated at room temperature for 10 min before reading the luminescence. The 
luminescence was recorded using the Tecan Infinite M1000 plate reader with an integration time 
of 1000 ms. Since the plates are clear on the bottom to provide viewing of the cells, an adhesive 
bottom seal was applied prior to reading to maximize the luminescence intensity of each well 
(Perkin Elmer, 6005199).  
qRT-PCR Reagents and Instrumentation 
Cells were lysed using the QIAshredder (Qiagen) and RNA was isolated using the 
RNAeasy kit (Qiagen). RNA concentration was determined by UV at 260 nm using the Tecan 
Infinite M1000 plate reader. The Quantifast SYBR green RT-PCR Kit (Qiagen) was used for the 
real time PCR following the manufacturer’s instructions. Primers used are listed in Table 10. 
Primers were ordered from Integrated DNA Technologies as 25nmole DNA oligos with standard 
desalting. qRT-PCR experiments were carried out on the Mastercycler 4 (Eppendorf) in 96-well 
twin.tec PCR plates (Eppendorf) with 20 µL reaction volumes.  
qRT-PCR Protocol 
Table 10. qRT-PCR primers used for recombinant stable cell lines containing the α1β3γ2  
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Cells were harvested once 80% confluent using 0.05% Trypsin or Detachin solution and 
pelleted by centrifuging at 1000 rpm for 2 minutes. Media was aspirated and the cell pellet was 
resuspended in RTL buffer. The mixture was pipetted into the QIAshredder spin column and spun 
for 2 minutes at max rpm. One volume of 70% ethanol was added to the homogenized lysate and 
mixed well by pipetting. The solution was then transferred to an RNAeasy spin column and spun 
down for 15 sec at 10,000 rpm. Then washed with buffers to purify the bound RNA with the flow 
through discarded. After the column is washed and dried, RNA is eluted by addition of 30-50 µL 
of RNase-free water. Total RNA concentration was determined by UV at 260 nm and protein 
contamination was assessed at 280 nm. The RNA was then diluted and used for qRT-PCR with 
the QuantiFast SYBR Green RT-PCR Kit (Qiagen). The cycling conditions used was 10 min at 
50°C (reverse transcriptase), 5 minutes at 95°C (PCR initial activation step), 10 sec at 95°C 
(denaturation), and 30 sec at 55°C (annealing and extension) for a total of 50 cycles. Data was 
taken in triplicate and the relative mRNA expression levels were calculated using wells containing 
no template and normalizing to housekeeping gene GAPDH. 
Automated Patch-Clamp Electrophysiology 
The buffers were made from NaCl (Fisher, BP358-1), KCl (Fisher, BP366-1), MgCl2 
(Sigma, M8266), CaCl2 (Acros Org, 123350025), Glucose (Sigma, G0350500), HEPES (Fisher, 
BP410-500), CsCl (Sigma, 203025), and EGTA (Tocris, 28-071-G). The extracellular and 
intracellular solutions recommended by the manufacturers of the IonFlux. The extracellular 
solution contains: 238 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5.6 mM Glucose, and 
10 mM HEPES at pH 7.4. The intracellular solution contains: 60 mM KCl, 15 mM NaCl, 70 mM 
 97 
 
KF, 5 mM HEPES, and 5 mM EGTA at pH 7.25. These concentrations were later optimized twice, 
see 3.2.1.3.2 Experimental.  
To record GABAA currents, cell arrays were voltage clamped at a hyperpolarizing holding 
potential of -80mV. Cells were centrifuged at 380 g for 2 min and gently resuspended in ECS. This 
was repeated two more times before the cells were dispensed into the plate.  
3.1.3.3 Results and Discussion 
The kill curves generated were assessed. The curve generated using Trypan Blue studied various 
concentrations on a single time axis, Figure 47, with HEK293T cells exposed to hygromycin B for 
seven days in culture. The Trypan Blue assay seen in Figure 47 determined that after a week of 
Hygromycin B exposure, nearly all cells were dead at a concentration of 400 µg/mL. The Trypan 
Blue assay relies on visual assessment and counting of cells by the experimenter, while this method 
Figure 47. HEK293T cell viability after 7 days in culture with Hygromycin B. Assessment using 
Trypan Blue dye where the % viable cells = [1.00 - (number of blue cells/number of total cells)] x 100. 
Data was collected in duplicate and averaged. 
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is low-cost and simple, it is also time-consuming. When ‘time’ is added as an additional factor, it 
is faster and more convenient to use an instrument to record measurements such as absorbance, 
florescence, or luminescence. The Cell-Titer Glo assay is one such option; a luminescence based 
cell viability assay designed for multi-well plates. Using this method, various concentrations of 
antibiotic over a long period of time could be tested.  
The result of the Cell-Titer Glo assay, seen in Figure 48, shows an incubation time at less 
than five days is insufficient to produce cell death as high as at 500 µg/mL. At ten days, the cell 
viability plummets at the lowest concentration (100 µg/mL) of antibiotic, however the curve does 
not flatten out until reaching 200 µg/mL. The curve at ten days was above the baseline- most likely 
caused by residual ATP after the single media exchange over five days, however it was expected 
Figure 48. Cell viability over a period of 20 days. Assessment using CellTiter -Glo assay in a 96 well 
plate. Media and antibiotic was exchanged every 5 days. Data taken in doublet and averaged.  
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the luminescence of 2x106 RLU corresponded to nearly complete cell death. After fifteen days, 
cell viability is low even without the presence of antibiotic due to the overgrown conditions in the 
well. Both the exposure time and the antibiotic concentration can affect the quality and purity of 
clones chosen; high selection stringency generates surviving clones with high transcript levels 
while insufficient incubation times can lead to the survival of cells which have not incorporated 
the gene of interest. Thus, in order to minimize overuse of antibiotic yet keep the high selection 
stringency, the selection window was chosen to be 10 days with 300 µg/mL of Hygromycin B. 
This concentration yielded almost no surviving cells within the shortest period of time. 
In order to assess that the cloned plasmid would result in expression of the subunits, qRT-
PCR was performed on cells which were transiently transfected with the plasmid. The results, seen 
in Figure 49, shows the successful expression of the cassettes in the cell line via mRNA 
quantification.  























Figure 49. qRT-PCR of transiently transfected HEK293T cells 
containing the α1β3γ2 plasmid construct. 
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The electrophysiological response of the transiently transfected cells were also recorded. 
The GABA dose response, seen in Figure 50, confirmed that the transfection with the plasmid 
resulted in functional GABAA receptors.  
After transient transfection with the α1β3γ2 construct in a 75cm2 culture flask, cells were 
allowed to recover for 48 hours. After which, cells were separated into 6 well culture plates at a 
20% confluency, allowed 2-3 hours to adhere to the matrigel-treated surface, and exposed to 
300µg/mL of Hygromycin B. After ten days with frequent media exchange, well defined single-
celled colonies were chosen and placed in a 384-well plate without the presence of the selective 
antibiotic. After reaching an 80% confluency in a 384 well plate, the cells were expanded further 
into a 96-well plate, a 24-well plate, and finally a 6 well plate before undergoing a second round 
of antibiotic pressure. Surviving cell cultures were selected and expanded further for analysis.  
Figure 50. Transiently transfected HEK293T cells expressing the 





Kill curve generation was both fast and convenient using the Cell-Titer Glo assay but 
pricing can be a limiting factor. In comparison, the Trypan Blue was inexpensive but necessitated 
removal of the cells from the plate, staining, incubating, and manual counting. Cell-Titer Glo also 
eliminates most of the human error of manual counting of the cells and would only have possible 
inaccuracies of pipetting error.  
Transient transfection with the α1β3γ2 construct resulted in high mRNA expression levels 
and large current changes (-8000pA) in response to the application of GABA during 
electrophysiological recordings. In the future, these large plasmid constructs can be reliably used 
if transient transfection of cells with the GABAAR, in place of transfecting three individual 
plasmids. In addition, the maintenance and propagation of the plasmid only requires a single 
growth and purification rather than three separate; lowering the amount of consumables used. 
Selection of the cells was time-consuming but performed with relative ease. Separating the 
cells to an initial starting point of 20% confluency allows for well separated colonies to flourish 
but also led to a very high amount of initial cell death, making single cellular recovery take even 
longer in a 384-well plate. Quite a few colonies, which presented an extremely healthy morphology 
during the first selection, died after being moved to the solitary confinement in the 384-well plate. 
Thus, two rounds of selection was performed, an initial selection after 10 days in culture with 




3.1.4 CHARACTERIZATION OF CLONE 
3.1.4.1 Introduction 
Characterization of the cell clones was done electrophysiologically with the IonFlux 
system and also genomically using qRT-PCR. Polymerase chain reaction (PCR) is a method that 
utilizes a thermal cycling pattern that heats and cools the DNA in the presence of primers, 
deoxynucleoside triphosphates (dNTP) and the polymerase enzyme. There are three major steps 
to PCR: denaturation into single stranded DNA, cooling to allow annealing of the primers to the 
strands, and extension of the copy by DNA polymerase and dNTPs. Quantitative reverse 
transcription-PCR is different in a few ways. Firstly, it is real-time, meaning the process can be 
monitored with the fluorescent dye in parallel to the experiment (qPCR). Secondly, instead of 
Figure 51. Reverse transcription polymerase chain 
reaction. Created by Jpark623 and used with permission. 
CC BY-SA.  
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DNA polymerase, reverse transcriptase is added in order to reverse transcribe the RNA of interest 
(RT-PCR) into its complementary DNA (cDNA) as seen in Figure 51. The combined technique is 
known as qRT-PCR. Qiagen uses the SYBR Green probe which binds to the minor groove of 
double stranded DNA and produces a fluorescent signal, illustrated in Figure 52. Reverse 
transcriptase of reverse transcribes mRNA to cDNA results in an increase of double stranded 
cDNA. The SYBR Green binds to the increasing product, leading to an increase in fluorescence 
after each cycle 228. 
3.1.4.2 Experimental 
qRT-PCR Reagents and Instrumentation 
Refer to 3.1.3.2 Experimental 
Figure 52. Biochemical illustration of the SYBR Green dye process. SYBR green binds to double -
stranded DNA and the resulting DNA-dye complex absorbs blue light (λmax=497nm) and emits 
green light (λmax=520nm). During PCR, DNA polymerase amplifies the target sequence which 
creates new copies of double-stranded DNA so there is an increase in fluorescence intensity 




Refer to 3.1.3.2 Experimental 
Automated Patch-Clamp Electrophysiology 
Refer to 3.1.3.2 Experimental 
3.1.4.3 Results and Discussion 
Isolated clones were grown to 80% in a single well of a 6-well plates before being separated 
into three wells of the 6-well plate. One well was used in the qRT-PCR and the second well, if 
expressing sufficient quantities of the mRNA, would electrophysiologically examined with the 




Among the hundreds of cells selected for the expansion, six cell lines quickly reached the 
appropriate confluency for examination. qRT-PCR was performed to ascertain that expression of 
the subunits. The data is seen in Figure 53. Interestingly, the β3 expression prevailed in all the cells 
while the lowest expression was consistently the γ2 subunit. The cell line 1, 2, 4, and 5 were 






































Figure 53. mRNA quantification of six recombinant cell lines (CL) containing the GABA AR 
α1β3γ2 construct. Results normalized to GAPDH (1.0 indicated by dashed line).   
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The normalized current response to GABA application, seen in Figure 54, exhibits nearly 
identical curve shapes with similar EC50 values. The current sweeps for these dose response curves 
can be seen in Figure 55. The largest response was from cell line 5 which, with four traps, averaged 
a maximum response of 14,250pA, cell line 2 responded with an average response of 9,875pA, 
cell line 4 had an average response of 8,375pA, and finally cell line 1 which responded with an 
average of 5,000pA. Incidentally, cell line 5 was the slowest growing clonal line while cell line 1 
was the fastest. Thus these two cell lines were further characterized with testing of positive 
modulators diazepam and HZ-166.  
The first trial with the BZD compounds elicited potentiation within the range of 200% for 
both compounds in both cell lines, Figure 56 with the sweeps shown in Figure 57. The responses 





























Figure 54. Isolated cell line (CL) clones expressing the GABAAR α1β3γ2 construct 
exposed to increasing concentrations of GABA. N=4  
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from both cell lines corresponded well to each other but the response to diazepam was lower than 
Figure 55. Recombinant stable cell lines (CL) expressing the GABA AR 
α1β3γ2 exposed to increasing concentrations of GABA 
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anticipated. Upon further inspection it was discovered that the compound solutions and patch 
clamp buffers had been created months prior to the experiment. Fresh extracellular, intracellular, 
Figure 56. Stable cell lines 1 and 5 containing the GABAAR α1β3γ2 exposed to increasing concentrations 
of diazepam and HZ-166 in combination with a constant concentration of GABA EC 20 or 0.1µM. 
Compounds were solubilized in 1% max DMSO. N=6 
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and DMSO solutions of the compounds were prepared and the assay was repeated. This 
Figure 57. Current sweeps of recombinant stable cell lines (CL) 
expressing the GABAAR α1β3γ2 exposed to increasing 
concentrations of modulator with constant concentration  of GABA 
EC3 of 0.1µM. The maximum DMSO concentration was 1%.  
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modification had significant effects on the both the potency and efficacy of the compounds, Figure 
58, with the current sweeps shown in Figure 59. The calculated potentiation for cell line 1 rose to 
Figure 58. Stable cell lines 1 and 5 containing the GABAAR α1β3γ2 with new solutions exposed to 
increasing concentrations of diazepam and HZ-166 in combination with a constant concentration of 
GABA EC20 or 0.1µM. Compounds were solubilized in 1% max DMSO. N=6  
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a range in the thousands, with cell line 5 not far behind. The efficacy of diazepam rose 
Figure 59. Current sweeps of recombinant stable cell lines (CL) 
expressing the GABAAR α1β3γ2 exposed to increasing concentrations 
of modulator with constant concentration of GABA EC3 of 0.1µM. 
The maximum DMSO concentration was 1%. 
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significantly, surpassing that of HZ-166 in both cell lines. Whether this was the result of 
Figure 60. Retention of GABAAR subunit gene 
transcripts in the α1β3γ2 expressing cell lines 
(CL1-3) over a series of ten passages. Passage 1 
(P1) to passage 10 (P10) mRNA levels were 
assessed via qRT-PCR.  N=3 
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degradation of the active compound over time or change in the buffer solutions (evaporation or 
mold growth) is unknown. The former is more likely as latter as diazepam was far more effected 
than HZ-166. As far as comparison of cell lines, it would appear that the dose response of cell line 
1 had not reached saturation by the final concentration of 100µM. In contrast, the response of cell 
line 5 plateaued for both compounds at around 1-3µM. It would almost appear as if the dose 
response curve for cell line 5 was offset and shifted towards the right to produce the response seen 
for cell line 1. This shift in potency was also observed in the GABA EC50, Figure 54, but not nearly 
to the same degree as seen here in Figure 56.  
From this data it would appear that even among different clonal cell lines, the 
reproducibility has improved greatly from what was previously seen with transient transfections.  
After selection, all clones were expanded and frozen down to preserve their expression 
characterization. It has often been reported that clones have been known to be unstable and lose 
expression or experience transgene silencing after several passages, particularly genes that utilize 
CMV promotor 229. In order to address this concern, the cell line was characterized both 
immediately after generation and then after 10 passages which would be the equivalent of a month 
in culture. The results for these qRT-PCR experiments, Figure 60, exhibit the near negligible 
change in mRNA levels of the GABAAR subunits in the stably expressing clones.     
In addition, although the HEK293T cell line had not exhibited DMSO sensitivity, problems 
were observed with the Jurkat E6-1 cell line. So the cell lines were tested at a constant at a constant 
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concentration of DMSO at 0.3%. The α1β3γ2 CL5 was recharacterized at constant DMSO and 
GABA EC3. The results of this experiment can be seen in Figure 61. Though the potency of the 
compounds (EC50) exhibited comparable results  diazepam exhibited a vast reduction in efficacy. 
Figure 61. Current responses in CL5 isolated from HEK293T stably expressing 
the α1β3γ2. Modulators were tested with a constant concentration of GABA EC 3 
0.18µM and DMSO concentrations of 0.3%. N=8  
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The lowering in response of the cells to 100 µM HZ-166 and diazepam as well as the reduced total 
potentiation of diaazepam may be the result of solubility issues of the compounds in 0.3% DMSO. 
To combat this issue, the maximum concentration of the compounds were lowered from 
100 µM to 20 µM with the DMSO concentration kept at 0.3% DMSO. Additionally, it has also 
been reported that the diazepam produces a biphasic potentiation with distinct components in the 
nanomolar and micromolar 215. The two components become more distinct in the presence of low 
GABA concentrations from EC3 to EC10, thus we determined that testing with the modulators 
should be performed at GABA EC20 so as not to overestimate the potentiation of the compounds. 
The results of this experiment can be seen in Figure 62. 
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Additionally, the competitive antagonist bicuculline was used in the cell line 
characterization. The antagonist successfully inhibited the influx of chloride ions, Figure 63. 4µM 
Figure 62. Current responses in CL5 isolated from HEK293T stably 
expressing the α1β3γ2. Modulators were tested with a constant concentration 
of GABA EC20 1µM and DMSO concentrations of 0.3%. N=8 
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of bicuculline led to nearly complete inhibtion of the receptor ion channels. To ascertain whether 
the % DMSO effects the cell response over time, cells were dosed with GABA before and after 
three minute incubations with DMSO, Figure 64. The signal slightly increases overtime, with the 
response increasing 200pA from the first sweep to the last sweep. However this is a very slight 
change that should not interfere with analysis of modulators. 
Figure 63. Cells stably expressing the α1β3γ2 GABAAR exposed to an increasing concentration 
of bicuculline in combination with a constant concentration of GABA EC 80. Cells were 




3.1.4.4 Conclusions  
 The creation of the recombinant stable cell lines expressing the GABAAR α1β3γ2 subtype 
resulted in multiple clonal lines with high expression of the receptor. Electrophysiological 
characterization of the cell lines showed the potential for high reproducibility of results even 
among different clone lines. In addition, the CMV promotor leads to a stable expression after 
integration. The retention of the genes of interest has shown long-term stability in the cell lines 
with minimal change after 10 passages (month in culture). The methods that we have described 
for creating stable cell lines could be applied to any genes and can easily be used to a 












Figure 64. Response of cells after three minute incubations with 1% DMSO.  
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3.2 αXβ3γ2 GABAAR Recombinant Cell Line 
The three fragment constructs were planned to be completed in the following order: α4β3γ2, 
α5β3γ2, α3β3γ2, α2β3γ2, and α6β3γ2.  
3.2.1 α4β3γ2 GABAAR RECOMBINANT CELL LINE 
3.2.1.1 Molecular Cloning 
3.2.1.1.2 Experimental 
Cloning protocols 
One Shot Mach1 T1 Phage-Resistant chemically competent cells (ThermoFisher, 
C862003) were used to generate DONR plasmids. PCR fragments were generated with flanking 
attB sites seen in Table 9 and ordered from Integrated DNA Technologies (IDT). The template 
DNA was combined with 1 µL of 20 µM of each of the primers, 1 µL of 10 mM dNTP mix, 2 µL 
of 50 mM MgSO4, 5 µL of 10X High Fidelity PCR Buffer, add 0.2 µL Platinum Taq DNA 
Polymerase High Fidelity (ThermoFisher, 11304-011) and the reaction mixture was diluted to 50 
µL reaction. The thermal cycler (Eppendorf, Mastercycler RealPlex 4) was set for 30 PCR cycles 
with an initial denaturation step 94°C for 2 minutes, denaturing step at 94°C for 15 secs, annealing 
step at 55°C, and an extension phase at 68°C for 2 minutes.  
PCR fragments were created using Q5 polymerase (NEB, M0491). The reaction mixture 
contained 10 µL of 5X Q5 reaction buffer, 1 µL of the 10 mM dNTPs, 1 µL each of 20µM forward 
and reverse primers, template DNA, 0.5 µL of Q5 High-Fidelity DNA Polymerase, 10 µL of 5X 
Q5 High GC Enhancer, and nuclease-free water to 50 µL. The PCR tubes were transferred to the 
thermocycler (Eppendorf, Mastercycler RealPlex 4) with an initial denaturation step at 98°C for 
30 secs, with 30 cycles containing a denaturing step at 98° for 10secs, annealing phase at 55°C for 
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25secs, and extension step at 72°C for 45secs with a final extension at 72° for 2min. PCR products 
were purified by use of Diffinity Genomics RapidTip2 (Diffinity Genomics, RR050) which 
removed dNTPs, primers, primer-dimers and DNA polymerase from the sample. These pipette tips 
are added to a 100 µL Eppendorf Pipettor. The PCR products is aspirated into the pipette tip and 
mixed by pipetting up and down for one minute. The purified sample is dispensed into a PCR 
grade tube. 
Antarctic Phosphatase (NEB, M0289) prevents self-ligation. Dephosphorylation of the 5’-
ends involves 5µg of DNA in 1/10 volume of 10X AnP reaction buffer. 5 units or 1 µL of Antarctic 
Phosphatase was added before being incubated for 60min at 37°C. The mixture was heat 
inactivated for 5min at 70°C before moving to ligation. 
T4 DNA Ligase (ThermoFisher, EL001) catalyzed the formation of a phosphodiester bond 
between 5’-phosphate and 3’-hydroxyl. Linearized vector DNA at 50ng was combined with insert 
DNA at 150ng. 2 µL of 10X T4 DNA ligase buffer with 1 µL ligase was added and nuclease-free 
water was added to a total reaction volume of 20 µL. The reaction mixture was incubated for 10min 
at 22°C and 5 µL of the mixture was used to transform One Shot Mach1 T1 Phage-Resistant 
chemically competent cells (ThermoFisher, C862003). The cells were incubated on ice for 30 min. 
The cells were heat-shocked for 30 sec at 42°C without shaking and immediately transferred to ice 
for 2 min. SOC medium, 250 µL, was then added and incubated at room temperature. The tube 




Restriction enzyme digestion was performed with 50 ng/µL of DNA with 4 µL of CutSmart 
buffer and 2 µL of ApaI. The reaction was incubated at 25°C for 60 min. 2 µL of BbvCI was added 
before the temperature was raised to 37°C for 60 min.  
A series of control experiments involving multireactions were performed: reaction 1: 
pENTR L1-pLac-LacZa-L4/R4-pLac-Spec-R3/L3-pLac-Tet-L2/Dest, reaction 2: pENTR 
Alpha2/R4-pLac-Spec-R3/L3-pLac-Tet-L2/Dest, reaction 3: pENTR L1-pLac-LacZa-
L4/Beta3/L3-pLac-Tet-L2/Dest, reaction 4: pENTR L1-pLac-LacZa-L4/R4-pLac-Spec-
R3/Gamma2/Dest, reaction 5: pENTR Alpha2/Beta3/Gamma2/Dest. LR Clonase II Plus enzyme 
was added to the reaction mixture and incubated for 16 h at room temperature. Proteinase K was 
added for a 10min incubation at 37°C. 2 µL of the reaction mixture were transformed into Mach1 
T1 cells and plated onto carbenicillin selection plates. 
Refer to 3.1.2.2 Experimental for remaining cloning protocols.  
3.2.1.1.3 Results and Discussion 
The attB PCR products of all remaining alpha subunits was generated and BP 
recombination was performed with the BP clonase enzyme for insert into the DONRs for creation 
of the respective Entry Clone vectors. All BP recombination mixtures were transformed into 
competent One Shot Mach1 T1 cells. Growth on Kanamycin selection plates resulted in <100 
colonies on each plate. The Entry Clones plasmids for the α3, α4, and α5 were created within two 
attempts, the first attempt failing due to quality of the PCR product. The third attempt yielded 
Entry Clones plasmids for the α2 and α6 without much difficulty. 
The LR recombination reaction was performed with all completed Entry Clone plasmids 
in unison. Most plates yielded >10 colonies each with the exception of the α4 recombination which 
 122 
 
resulted in growth of <20 colonies on ampicillin resistance plates. These colonies were all isolated 
and purified, sequencing confirmed the insertion of the α4 in one of the samples. However, though 
insertion of the β3 was successful, the γ2 insert was not present. When the recombination was 
repeated, this happened twice more with the α4. Since many of the colonies appeared not to contain 
any insert, antibiotic concentration was increased by two times from 100 µg/mL to 200 µg/mL In 
addition the temperature of the plate incubator was lowered from 37°C to 30°C. This would slow 
the rate of growth and in effect decrease the chances of plasmid loss or mutation. Despite this 
modification, the gamma 2 gene did not insert successfully.  
The fact that the gamma 2 gene alone had a propensity to not recombine with the final 
construct could be due to instability of the insert as well as the large construct size. The γ2 Entry 
Clone quality, verified through diagnostic digest and 260/280 absorbance ratio above 1.8, did not 
appear to be the issue. To determine if a particular entry clone was flawed, control reactions were 
performed to analyze the number of colonies produced compared to the expected number in a 
given LR reaction. Control experiments with pENTR plasmids, Table 11, exhibited 30-50 colony 
growth except for reaction 5 containing all three of the inserts which had only 3 colonies. This 
may indicate that the combination of all three inserts resulted in toxicity or the accumulation of all 
three inserts is instable. When the insertion sites for the gamma 2 were examined, sequencing 
showed that they were undamaged. MAX Efficiency Stbl2 competent cells, suitable for cloning 
Table 11. Troubleshooting reactions for the LR recombination reaction.  
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large and unstable inserts, were purchased to offset instability of the plasmid. Due to the high 
background growth of colonies with an absence of entry clone, the destination vector was restored. 
A high background could be due to deletions, full or partial, of the ccdB gene in the destination 
vector so to maintain the integrity of the destination vector, the plasmid was propagated in ccdB 
Survival T1 E. coli strain in media containing carb and chloramphenicol.  
DNA quantities, duration times, temperatures, plasmid qualities, etc were all examined for 
problems but did not overtly present any reason as to the difficulties experienced. Genetic 
Figure 65. The completed α1β3γ2 construct with restriction enzyme sites.  
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sequencing, Clonase reagents, competent cells, and qRT-PCR reagents as well as other 
consumables were being repetitively and most times led to the creation of the empty DEST vector 
without recombination. As an alternative, the completed α1β3γ2 construct was used instead, shown 
in Figure 65. The finished construct contains all three fragments flanked with restriction enzymes. 
The alpha subunit is surrounded by the ApaI and the BbvCI which can be cut out and exchanged 
with alternative alpha subunits. PCR products were generated with ApaI and BbvCI sites for the 
α2 subunit (Primers ordered from IDT: AlphaApaI: 5’- 
TAAGCAGGGCCCGTGTCCACTCCCAGTTCAAT-3’; AlphaBbvCI: 5’- 
TGCTTAGCTGAGGATGTATCTTATCATGTCTGCTCGAAG-3’) and were ligated into the 
pJTI_Fast DEST_a1_b3_g2 backbone with the α1 removed. However, this resulted in the 
recircularization of the backbone with the removed alpha1 fragment. Antarctic Phosphatase was 
used to dephosphorylate the 5’ ends to prevent this phenomenon but resulted in no growth. Since 
the ApaI site is predominantly GC, Q5 polymerase was also tested since it has lower error rates 
and is renowned for its robust amplification with high GC content. Identical results were observed 
regardless. 
Due to the time-consuming nature of these experiments, the costliness of the cells and 
enzymes, and the lack of molecular cloning equipment in the lab; it was decided that the most 
prudent decision was to contract out the remaining molecular cloning steps to another lab. Science 
exchange was used as an intermediary to hire Integrated Technology Enterprise, Inc based in 
Marietta, Georgia. The α1β3γ2 construct was sent to the independent contractor and the alpha 1 
subunit was exchanged with α2, 3, 4, 5, and 6 to produce the remaining constructs. This lab utilized 
the same flanking ApaI and BbvCI sites with Gibson assembly to produce the plasmids and 
production of each one generally took one to two months for completion at an average cost of $350 
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per construct. The plasmid samples were amplified, purified, and analyzed upon receipt with no 
outstanding problems. 
3.2.1.1.4 Conclusions 
 Though research has been published stating that recombination of constructs as large as 
15-20kb is possible223 the success rate and efficiency was lower than expected. There are many 
forums (Research Gate) discussing these issues with Gateway Cloning but the problem could have 
stemmed from multiple areas. Since Integrated Technology Enterprise had also stated difficulties 
in successfully growing the plasmids and had to move to lower temperatures for growth, this could 
be indicative that the γ2 DNA fragment of interest is toxic to the cells. In addition, the size of the 
construct may have necessitated use of electroporation for transformation. Incidentally, the 
reported construction of plasmids at 15-20kb using Gateway Cloning had electroporated into all 
competent cells223. 
 In the future, in the creation of large constructs (>8,000bp) using Gateway Cloning, it may 
be fortuitous to invest in electroporation equipment as well as in electrocompetent cells. In 
addition, the linearization of the destination vector before LR recombination may be beneficial as 
the supercoiling of the vector may be preventing insertion.  
3.2.1.2 Transfection and Clone isolation 
3.2.1.2.2 Experimental 
qRT-PCR Protocol 
Refer to 3.1.3.2 Experimental. PCR primers used are listed in Table 12. Primers were ordered from 
Integrated DNA Technologies as 25nmole DNA oligos with standard desalting. 
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 Automated Patch-Clamp Electrophysiology 
Refer to 3.1.3.2 Experimental. 
3.2.1.2.3 Results and Discussion 
 The α4β3γ2 construct was transiently transfected into HEK293T cells to ensure expression 
and function of the receptors. There is very little work published on the α4β3γ2 assemblies besides 
its hightened sensitivty to GABA (in comparison to  other αXβ3γ2 subtypes) and it’s inadequate 



























Figure 66. qRT-PCR of transiently transfected HEK293T 
cells containing the α4β3γ2 plasmid construct. 
Table 12. qRT-PCR primers for GABAAR expressing stable recombinant cell lines 
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ratio of 5:1:1 for transient transfection for α4β3γ2 was required to observe consistent levels of 
expression. One publication has observed small increases in current with diazepam and GABA 
EC10 on frog oocytes expressing the α4β2γ2 and large increases in current for the β2γ2 assembly. 
Thus it was a concern using the plasmid as this would be a 1:1:1 ratio of subunit gene transcripts 
and may result in a herterogenous mixture of receptors, namely the α4β3 or the β3γ2. Both of these 
combinations respond to GABA while the β3γ2 responds strongly to diazepam. The expression of 
α4β3 has been reported to have condiderably low expression levels 230 so the major interfering 
assembly would be the β3γ2 211. The mRNA expression levels after transient transfection of the 
α4β3γ2 construct appeared to suggest there was expression of all subunits, though with lower 
expression of the alpha subunit, Figure 66. The GABA response did not reach saturation, Figure 
67, which may have been indicative of a heterogenous population of receptors.  
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When diazepam was tested, Figure 68, the compound elicited a small change in current 
despite being regarded as a benzodiazepine-insensitive receptor. However, the GABA EC3 was 
estimated to be 0.1µM which may not have been sufficient, as evidenced by the GABA dose 
response in Figure 67 and the lack of initial negative current when the cells were dosed with GABA 
EC3 prior to application of the compound in Figure 68.  
Figure 67. Cells transiently transfected with the α4β3γ2 construct exposed to 
increasing concentrations of GABA. N=4 
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This same current response was generated with the application of the 
imidazobenzodiazepine HZ-166, Figure 69. The large positive response to GABA EC3 was 
transformed to negative current at 1.23µM HZ-166 and the signal increased further at 33 to 
100µM. 
In addition, the modulator XHE-III-74 Ethyl Ester (XHE-III-74EE) was tested. These 
compounds have been shown to cause a greater change in current for oocytes expressing the α4 
Figure 68. Cells transiently transfected with the α4β3γ2 construct exposed to increasing 
concentrations of diazepam in combination with the estimated GABA EC 3. The maximum 
DMSO concentration was 1%. N=4 
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and α6 231.  The response of the transiently transfected cells to XHE-III-74EE was similar to both 
diazepam and HZ-166.  
 
Figure 69. Cells transiently transfected with the α4β3γ2 construct exposed to increasing concentrations 




The seemingly large initial positive current response to only extracellular solution and 
GABA may be the result of the small current changes near a noisy baseline. The changes in current 
reached a maximum response in a range of -500-1000pA. The reduction in the size of the current 
changes could be the result of poor transfection efficiences. These anomalous rectifying properties 
have been observed for both α4 and α6 containing receptors expressed in HEK293 cells previously 
Figure 70. Cells transiently transfected with the α4β3γ2 construct exposed to increasing concentrations 
of XHE-III-74EE in combination with the estimated GABA EC3. The maximum DMSO concentration 
was 1%.  N=4.  
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232. However, the signal can be improved by altering the intracellular and extracellular buffer 
composition. This problem was confronted with the isolation of the first α4β3γ2 clones, discussion 
of this can be found in 3.2.1.3.3 Results and Discussion. 
3.2.1.2.4 Conclusions 
 Transfection with the α4β3γ2 resulted in both mRNA expression of the subunits and a 
recordable electrophysiological response to application of GABA. This confirms the result of the 
previous work performed with the α1β3γ2. Transfection with these large three fragment constructs 
results in successful expression of the receptor subunits. Although mRNA expression levels and 
the overall current signal was low (<1000pA), isolation of homogenously pure clones with high 
expression of the receptors would theoretically resolve this problem.  
3.2.1.3 Characterization of Clone 
3.2.1.3.2 Experimental 
Automated Patch-Clamp Electrophysiology 
The buffers were made from NaCl (Fisher, BP358-1), KCl (Fisher, BP366-1), MgCl2 
(Sigma, M8266), CaCl2 (Acros Org, 123350025), Glucose (Sigma, G0350500), HEPES (Fisher, 
BP410-500), CsCl (Sigma, 203025), and EGTA (Tocris, 28-071-G). The extracellular solution 
contains: 238mM NaCl, 4mM KCl, 1mM MgCl2, 1.8mM CaCl2, 5.6mM Glucose, and 10mM 
HEPES at pH 7.4. The intracellular solution contains: 60mM KCl, 15mM NaCl, 70mM KF, 5mM 
HEPES, and 5mM EGTA at pH 7.25.  
Optimization of the solutions not only changed the concentrations of chloride ions but also 
included the addition of cesium ions which blocks potassium leak current233. The extracellular 
solution contains 140 mM NaCl, 5.4 mM KCl, 1 mM CaCl2, 10 mM D-glucose monohydrate, 10 
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mM HEPES, and pH 7.4 with NaOH. The intracellular solution contains 140 mM CsCl, 1 mM 
CaCl2, 1 mM MgCl2, 11 mM EGTA, 10 mM HEPES, and pH 7.2 with CsOH. Compounds were 
diluted to 10 mM in DMSO.  
To record GABAA currents, cell arrays were voltage clamped at a hyperpolarizing holding 
potential of -80 mV. Cells were centrifuged at 380g for 2 min and gently resuspended in ECS. This 
was repeated two more times before the cells were dispensed into the plate. 
3.2.1.3.3 Results and Discussion 
Transfection of the α4β3γ2 led to change in the morphology of the HEK293T cell line, 
Figure 71A-B. This was not observed after tranfection with any of the other GABAA receptor 
subtypes. Many of the cells appeared to exhibit loss of adherence, Figure 71B. Such changes in 
morphology of the HEK293T after transfection has been reported before 234. In addition, antibiotic 
selection led to nearly complete elimination of all cells, Figure 71C. Cells which were isolated into 
384 well plates immediately after the ten day selection perished soon after. However, if the cells 
were left to recover on the original selection plate for five more days (Figure 71D) and then 
isolated, clone survival increased and expansion of the cells could proceed. 
This morphological change and low survival rates of transfected cells may suggest that the 
α4β3γ2 is toxic to the cells as well as confirming low expression and integration levels of the gene. 
Since the selection and isolation of the α4β3γ2 was more time-consuming and inefficient than the 
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α1β3γ2, many more of the clones were isolated and expanded for analysis. The mRNA levels of 
35 clonal cell lines were evaluated, results seen in Figure 72. Cell lines 1, 5, 17, and 27, expressing 
Figure 71. Images of the HEK293T cells during clonal isolation of the α4β3γ2 expressing cell 
lines. A) Image of uhealthy HEK293T cell line. B) Image of HEK293T cells after transfection 
using the α4β3γ2 construct. C) Cells after ten day exposure to Hygromycin B. D) Cells after 
five day recovery following antibiotic selection.   
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varying levels of subunit mRNA, were examined further using electrophysiology. Experiments 
Figure 72. qRT-PCR of clonal cell lines (CL) of HEK293T cells stably expressing the α4β3γ2 plasmid 
construct. GAPDH is normalized to 1.0, designated with a dashed line. N=3 for each bar.  
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with these cell lines, Figure 73, exhibited an initial positive current which was previously observed 
in transiently transfected cells. All of the stable cell lines had a current response of <1500pA. Thus 
these low currents, despite stable and homogenous expression, must be the result of an inherent 
characteristic of the α4β3γ2.  
The pipette solution (intracellular solution) is often designed to mimic the chloride 
concentrations in the natuaral physiological level. However, delieberately using high chloride 
concentrations can increase the chloride driving force. This can facilitate the detection of small 
inhibtory postsynaptic currents 235. To test this, we switched to a cesium and chloride rich 
intracellular solution to block potassium leak currents as well as enhance small iPSCs. 
Figure 73. Cell line 1 isolated from HEK293T stably expressing the α4β3γ2. N=2 
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Figure 74 exhibits the differences in current between using the two buffer formulations. 
Though the maximum current response of the cells remained the same (~1200pA), the noise at the 
baseline changed signifantly. This was true for all of the α4β3γ2 stable cell lines tested, Figure 74-
Figure 77. Despite the fact that CL5 and CL17 have the highest overall expression of the GABAAR 
mRNA, they exhibited the same overall current response to GABA. The maximum current 
response in the first solutions averaged 925 pA while after changing the buffer it averaged 1375 
pA. To keep the results of the GABAAR cell lines uniform across all subtypes, the formulas of the 
cell solutions were permanently changed to the cesium and chloride rich buffers.  
Figure 74. Comparison of current responses in Cell line 1 isolated from HEK293T stably expressing the 
α4β3γ2. Top: The typical IonFlux solutions elicited a noisy baseline. Bottom: A cesium and chloride rich 
buffer reduced the positive current changes. N=2  
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The GABA affinity for α4β3γ2 is 2-3 fold higher for the α4 than the α1. In addition, the α4 
Figure 76. Comparison of current responses in Cell line 5 isolated from HEK293T stably 
expressing the α4β3γ2. Top: The typical IonFlux solutions elicited a noisy baseli ne. Bottom: A 
cesium and chloride rich buffer reduced the positive current changes. N=2  
Figure 75. Comparison of current responses in Cell line 17 isolated from HEK293T stably 
expressing the α4β3γ2. Top: The typical IonFlux solutions elicited a noisy baseline. Bottom: A 
cesium and chloride rich buffer reduced the positive current changes. N=2  
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is easily oversaturated during prolonged low levels of GABA to suppress the overall response and 
desensitizes rapidly to repetitive GABA application. 
In addition, since it has been reported that the diazepam produces a biphasic potentiation 
with distinct components in the nanomolar and micromolar 215. The two components become more 
distinct in the presence of low GABA concentrations from EC3 to EC10, thus we determined that 
testing with the modulators should be performed at GABA EC20 so as not to overestimate the 
potentiation of the compounds.  
As CL1 exhibited a high current response as well as the least deviation, this cell line was 
further analyzed using BZDs diazepam and HZ-166. 
Figure 77. Comparison of current responses in Cell line 27 isolated from HEK293T stably 
expressing the α4β3γ2. Top: The typical IonFlux solutions elicited a noisy baseline. Bottom: 
A cesium and chloride rich buffer reduced the positive current changes. N=2  
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Extensive experiments were performed with these two modulators, using a constant 
concentration of GABA EC20 0.3µM and a high concentration of 100µM compound, the current 
elicited resulted in high potentiation and current response of around -2000pA. 
Figure 78. Current responses in CL1 isolated from HEK293T stably expressing the 
α4β3γ2. Modulators were tested with  a constant concentration of GABA EC20 0.3µM 
and DMSO concentrations of 1%. N=8 
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As this receptor is traditionally termed a BZD insensitive GABAAR subtype, it was 
theorized that the concentrations of the compounds was too high possibly creating a problem with 
the solubility, or the percentages of DMSO was too high. Thus the concentrations of compound 
was lowered to 20µM and the DMSO percentages lowered to 0.3%. This experiment resulted in 
Figure 79. Current responses in CL1 isolated from HEK293T stably expressing 
the α4β3γ2. Modulators were tested with a constant concentration of GABA E C20 
0.3µM and DMSO concentrations of 0.3%. N=8 
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Figure 79. The cells had the same maximum current response of -2000pA with the same general 
curve shape of the dose response.  
These findings are in agreement with previous research published on the rat GABAAR 
α4β3γ2 expressed in Xenopus oocytes 236. This study observed that both diazepam and 
flunitrazepam significantly potentiated GABA-gated currents in α4β3γ2 expressing oocytes but 
not for α4β2γ2 receptors. Indicating that β3 plays some role in the observed effect. Though this 
publication attempted to express α4β3γ2 in HEK293 cells, low expression levels forced them to 
substitute the signal peptide sequence of the β3 with the β2. The resulting curves in HEK293 cells 
showed little potentiation of GABA-evoked currents. A majority of studies exhibiting the α4/6 
containing receptors insensitivity to benzodiazepines are performed in combination with the β2γ2 
211,237-240. Taking our own measurements into consideration, this may suggest that the signal 
peptide of the β3 subunit is critical in the benzodiazepine sensitivity of these assemblies and 
previous findings observing that the receptors were benzodiazepine insensitive. However, we 
cannot discount the possibility that this binding is a result of binding at the α4β3 interface, rather 




 In addition to testing the positive modulators diazepam and HZ-166, antagonist bicuculline 
was used on all the created cell lines, Figure 80. Cells were pre-incubated with bicuculline for 
three minutes prior to the application of GABA. Most cell lines were inhibited with 0.4µM 
bicuculline which was the smallest concentration of the compound. Functional studies on 
recombinant and native GABAAR have reported that subunit composition does not affect the 
Figure 80. Cell line 1 stably expressing the α4β3γ2 GABAAR exposed to an increasing 
concentration of bicuculline in combination with a constant concentration of GABA EC 80. Cells 
were preincubated with the antagonist for three minutes prior to activation with GABA.  N=6 
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antagonist action of bicuculline 242. Unlike agonists and positive modulators, it would appear that 
antagonist activity is independent of the composition 243. However, receptors which contain the α6 
subunit have been observed to be less sensitive to bicuculline 244.  
To ascertain whether the % DMSO effects the cell response over time, cells were dosed 
with GABA before and after three minute incubations with DMSO, Figure 81. The signal did not 














Figure 81. Response of cells after three minute incubations with 1% DMSO.  
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3.2.2 α5β3γ2 GABAAR RECOMBINANT CELL LINE 
3.2.2.1 Transfection and Characterization of Clones 
The α5β3γ2 construct, which was received during the clonal cell line isolation of the α4β3γ2, was 
also transiently transfected into the HEK293T cell line. The mRNA expression (primers listed in 
Table 12) confirms that transfection was successful, seen in Figure 82. The cells were also 
electrophysiologically characterized after transient transfection. This experiment was performed 
with the initial formulation of low chloride, no cesium, intracellular solution. The average current 



























Figure 82. qRT-PCR of transiently transfected HEK293T 
cells containing the α5β3γ2 plasmid construct.  N=3 
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Transfection, antibiotic selection, and clone isolation of the α5β3γ2 into HEK293T did not 
present any serious concerns on morphology or survival. Eleven cell lines were isolated and their 
mRNA levels were characterized, Figure 84. Cell lines 5 and 7 were among the clones having the 
highest expression. These two cell lines were characterized further by automated patch clamp 
using the IonFlux.   
Both cell line 5 and 7 both achieved high inhibitory current responses to the application of 
GABA. Cell line 5 had the largest current response, reaching -14,000pA as seen in Figure 86. Cell 
Figure 83. Cells transiently transfected with the α5β3γ2 construct exposed to 
increasing concentrations of GABA. N=4. 
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line 7 reached a maximum negative current of -10,000pA, as seen in Figure 85. These dose 
response curves exhibit the α5β3γ2’s low GABA sensitivity, as was previously reported 83.  
The response of the cells to positive modulators diazepam, HZ-166, and MP-III-004 were 
initially evaluated at GABA EC3 with a serial dilution of DMSO. This resulted in the curves seen 
in Figure 88, the sweeps for these curves are shown in Figure 87. Tests with MP-III-004 reported 
an α5 selectivity, perfomed by collaborator Dr. Margot Ernst on frog oocytes. These experiments 
in oocytes yielded a potentiation of ~600% at maximum 10µM, This is in high agreement to our 
results on the automated patch clamp. This compound, when tested in parallel with HZ-166 and 
Figure 84. qRT-PCR of clonal cell lines (CL) of HEK293T cells stably expressing 
the α5β3γ2 plasmid construct. GAPDH is normalized to 1.0, designated with a 
dashed line. N=3 for each bar. 
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diazepam, have nearly identical values for the maximum current response and calculated 
Figure 86. Current responses in Cell line 5 isolated from HEK293T stably expressing 
the α5β3γ2. N=2 














































Figure 88. Current responses in CL5 isolated from HEK293T stably expressing the α5β3γ2. 
Modulators were tested with a constant concentration of GABA EC3 0.7µM and maximum 
DMSO concentrations of 1%. N=2 for each curve. 
Figure 87. Current response sweeps of CL5 isolated from HEK293T stably e xpressing the 
α5β3γ2 exposed to increasing concentrations of modulator in combination with GABA EC 3. 
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In order to evaluate the current without the characteristic biphasic components of BZD 
binding, we determined that testing with the modulators should be performed at GABA EC20 so 
Figure 89. Structure and oocyte efficacy of MP-
III-004 performed by Dr. Margot Ernst.  
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as not to overestimate the potentiation of the compounds. These tests were performed with HZ-
Figure 90. Current response of CL5 stably expressing the α5β3γ2 tested with a constant 
concentration of GABA EC20 3µM and DMSO concentrations of 0.3%. N=4  
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166 and diazepam, Figure 90. The calculated potentiation was lower than previous results with 
GABA EC20. However, this is in agreement with the results of HZ-166 tested using manual patch 
clamp on frog oocytes, Figure 26. 
Lastly, the response of the cells to competitive antagonist bicuculline was evaluated for the 
α5β3γ2 containing receptors. In addition to testing the positive modulators diazepam and HZ-166, 
antagonist bicuculline was used on all the created cell lines, Figure 91. Cells were pre-incubated 
Figure 91. Cell line 5 stably expressing the α5β3γ2 GABAAR exposed to an increasing 




with bicuculline for three minutes prior to the application of GABA. The cell line exhibited almost 
complete inhibition at the lowest concentration of 4 µm.  
To ascertain whether the % DMSO effects the cell response over time, cells were dosed 
with GABA before and after three minute incubations with DMSO, Figure 92. The signal did not 
vary significantly over time, ranging from -4307pA to -4473pA. 
3.2.3 α2β3γ2 GABAAR RECOMBINANT CELL LINE 
3.2.3.1 Characterization of Clones 
The α2β3γ2 was the next plasmid to be stably expressed. Transfection, antibiotic selection, 
and clone isolation did not present any serious concerns on morphology or survival. Of the many 
clones that were isolated and expanded in 384 well plate, the ones presenting the fastest growth 












Figure 92. Response of cell line 5 stably expressing the α5β3γ2 GABAAR after three minute 
incubations with 1% DMSO. 
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levels for CL2-4 were around the same level of expression for all three subunits of the alpha 2, 
beta3, and gamma2. Interestingly, CL1 exhibited no insertion of the α2 gene. This cell line was 
the slowest growing out of the selected cells with a turnover of 4-5 days instead of 2-3 as is 


































Figure 93. qRT-PCR of clonal cell lines (CL) of HEK293T cells stably 
expressing the α2β3γ2 plasmid construct. GAPDH is normalized to 1.0, 
designated with a dashed line. N=3 for each bar.  





























Figure 94. Current responses from HEK293T stably expressing the α2β3γ2 exposed to increasing 
concentrations of GABA. N=4 for each curve. 
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electrophysiologically, seen in Figure 94. The current sweeps for these GABA dose response 
Figure 95. Current response sweeps of clonal cell lines 
isolated from HEK293T stably expressing the α2β3γ2 
exposed to increasing concentrations of GABA. 
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curves can be seen in Figure 95. Despite only containing the β3γ2 subunits, the assembled 
receptors were still responsive to GABA. This has been described before for recombinant β3γ2 
combinations 211. 
Clonal cell lines were assessed using diazepam, Figure 96. The β3γ2 combinations were 
also slightly responsive to the exposure of diazepam as was previously described 211 in 
recombinant systems in frog oocytes. The current sweeps for these curves can be seen in Figure 
97.  
The maximum current response averaged around -2500pA for all the clonal cell lines. The 
small amount of total current and the positive current elicited by GABA EC3 could have been the 










































Figure 96. Current responses in cell lines isolated from HEK293T stably expressing the α2β3γ2. 
Modulators were tested with a constant concentration of GABA EC 3 0.7µM and maximum DMSO 
concentrations of 1%. N=2 for each curve. 
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result of low expression of the receptor or a characteristic of the α2β3γ2 subtype. Cell line 3 of the 
Figure 97. Current response sweeps of cell lines 
isolated from HEK293T stably expressing the α2β3γ2 
exposed to increasing concentrations of modulator in 
combination with GABA EC3. 
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clones was chosen for further study as it appeared to reach saturation with GABA and diazepam.  
As with the other receptor subtypes, the GABA concentration was raised from EC3 to EC20 
to eliminate any biphasic mechanism of binding. In addition, the DMSO percentage was kept at 
Figure 98. Current responses in CL3 isolated from HEK293T stably expressing 
the α2β3γ2. Modulators were tested with a constant concentration of GABA EC 20 
0.3µM and DMSO concentrations of 0.3%. N=8 
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0.3% consistently. The results of this experiment can be seen in Figure 98. The two curves suggest 
Figure 99. Current responses in CL1 isolated from HEK293T stably expressing the β3γ2. 
Modulators were tested with a constant concentration of GABA EC 20 0.3µM and DMSO 
concentrations of 0.3%. N=8 
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that there is very little to no difference in the effect of both diazepam and HZ-166 on the α2β3γ2 
subtype. In addition to the α2β3γ2 containing CL3, the β3γ2 containing CL1 was also characterized 
as a control. The response of β3γ2 cell line is seen in Figure 99. 
Lastly, the response of the cells to competitive antagonist bicuculline was evaluated for the 
α2β3γ2 containing receptors. In addition to testing the positive modulators diazepam and HZ-166, 
antagonist bicuculline was used on all the created cell lines, Figure 100. Cells were pre-incubated 
Figure 100. Cell line 3 stably expressing the α2β3γ2 GABAAR exposed to an 
increasing concentration of bicuculline in combination with a constant concentration 
of GABA EC80. N=6 
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with bicuculline for three minutes prior to the application of GABA. The cell line exhibited almost 
complete inhibition at the lowest concentration of 4 µm. 
To ascertain whether the % DMSO effects the cell response over time, cells were dosed 
with GABA before and after three minute incubations with DMSO, Figure 101. The signal 
slightly diminished over time, from -855pA to -698pA from the first to the last sweep. However, 












Figure 101. Response of cell line 3 stably expressing the α5β3γ2 GABAAR after three minute 
incubations with 1% DMSO. 
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3.2.4 α3β3γ2 GABAAR RECOMBINANT CELL LINE 
3.2.4.1 Characterization of Clones 
Cells transfected with the α3β3γ2 construct posed little problem. The cells remained 
healthy and isolation after antibiotic selection produced eleven very health cell lines. Interestingly, 
many of the cells did not successfully incorporate the β3 or γ2 gene. However, the α3 appeared to 
have a higher expression than was previously observed for the recombinant cell lines. Both CL10 
and CL11 had the highest expression of the β3 and γ2 mRNA. Cell line 10 was taken further for 
electrophysiological characterization. The GABA dose response curve, seen in Figure 103, found 
that the GABA EC20 was 0.43 µM. Modulators were tested at this concentration with a constant 
percentage of DMSO 0.3%. Testing the two modulators diazepam and HZ-166, seen in Figure 
Figure 102. qRT-PCR of clonal cell lines (CL) of HEK293T cells 
stably expressing the α3β3γ2 plasmid construct. GAPDH is 
normalized to 1.0, designated with a dashed line. N=3 for each bar.  
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104, it was found that this receptor subtype exhibited the largest difference in efficacies. HZ-166 
had a significantly higher potentiation than for diazepam. This is in agreement with the reported 
selectivity of HZ-166 (ligand 2) for the α3 in frog oocytes210, though the concentration utilized in 
Figure 103. Current responses from cell line 10 stably expressing the α3β3γ2 exposed to increasing 
concentrations of GABA. N=4 for each curve. 
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our study was 10X the maximum amount used in the oocytes, was performed at GABA EC20 
Figure 104. Current responses in CL10 isolated from HEK293T stably expressing the α3β3γ2. 
Modulators were tested with a constant concentration of GABA EC20 0.43µM and DMSO 
concentrations of 0.3%. N=8 
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instead of EC3, and was recorded using automated rather than manual patch clamp. 
Lastly, the response of the cells to competitive antagonist bicuculline was evaluated for the 
α3β3γ2 containing receptors. In addition to testing the positive modulators diazepam and HZ-166, 
antagonist bicuculline was used on all the created cell lines, Figure 105. Cells were pre-incubated 
Figure 105. Cell line 10 stably expressing the α3β3γ2 GABAAR exposed to an increasing 




with bicuculline for three minutes prior to the application of GABA. The cell line exhibited almost 
complete inhibition at the lowest concentration of 4µm.  
To ascertain whether the % DMSO effects the cell response over time, cells were dosed 
with GABA before and after three minute incubations with DMSO, Figure 106. The signal did not 
vary significantly over time, ranging from -1057pA to -952pA from the first to the last sweep. 












Figure 106. Response of cell line 3 stably expressing the α5β3γ2 GABAAR after three minute 
incubations with 1% DMSO . 
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3.2.5 α6β3γ2 GABAAR RECOMBINANT CELL LINE 
3.2.5.1 Characterization of Clones 
The last cell line created was the α6β3γ2 which, like the α4β3γ2 containing receptors, are 
traditionally known as BZD insensitive. Like the α4β3γ2, the α6 GABAAR subtype containing cell 
line also presented low survival of expanded cell lines after antibiotic selection. Six of the 
healthiest cell lines were evaluated for GABAAR α6β3γ2 transcripts, Figure 107. Four cell lines 







































Figure 107. qRT-PCR of clonal cell lines (CL) of HEK293T cells stably expressing  the α6β3γ2 plasmid 
construct. GAPDH is normalized to 1.0, designated with a dashed line. N=3 for each bar.  
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highest expression of all three receptor subtypes while CL1 and CL3 primarily expressed the alpha 
6 subunit. The GABA dose response for these four distinctive clones are shown in Figure 108. The 
Figure 108. Current responses in cell lines isolated from HEK293T stably expressing 
the α6β3γ2 exposed to increasing concentrations of GABA. CL1 and CL3 were exposed 
to a maximum concentration of 100µM GABA while CL2 and CL4 were exposed to a 
maximum concentration of 20µM GABA. N=8 for each curve.  
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current sweeps for these curves can be seen in Figure 109. The average maximum inhibitory 
Figure 109. Current response sweeps of clonal cell lines isolated from 
HEK293T stably expressing the α6β3γ2 exposed to increasing 
concentrations of GABA.  
 170 
 
current from CL1 was 2100pA, CL2 had currents of 1760pA, while CL3 reached 1970pA, and 
CL4 had an average response of 1,550pA. The current response for CL1 and CL3 was higher than 
those of CL2 and CL4, despite the relative absence of the β3 subunit for both CL1 and CL3 as well 
as the γ2 subunit of CL3. However, the higher current response could be a result of the overall 
higher concentration of GABA used in the dose response. The near identical dose response curves 
for the two cell lines suggests that the α6 subunit is capable of forming homomeric receptors which 
respond to the binding of GABA.  
Similarly to the α4β3γ2, the α6β3γ2 is traditionally known as a benzodiazepine insensitive 
receptor. Extensive experiments were performed with these two modulators, using a constant 
concentration of GABA EC20 0.3µM and a high concentration of 100µM compound, the current 
elicited resulted in high potentiation and current response of around Thus the concentrations of 
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compound was lowered to 20µM and the DMSO percentages lowered to constant concentration of 
Figure 110. Current response of CL2 stably expressing the α6β3γ2 tested with a 
constant concentration of GABA EC20 0.5µM and constant DMSO concentrations of 
0.3%. N=4  
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0.3%. The resulting current response, seen in Figure 110, trended close to baseline readings with 
Figure 111. Current response of CL2 stably expressing the α6β3γ2 tested with a 
constant concentration of GABA EC20 1µM and constant DMSO concentrations of 
0.3%. N=8  
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a maximum response of -500pA for both compounds. The initial positive response in the diazepam 
sweep appears to be the result of small total current change. The GABA EC20 of 0.5 µM failed to 
elicit a response. Increasing the GABA concentration to 1 µM, which was within the standard 
deviation of the calculated EC20, was able to elicit a negative response. Despite the α6 being 
described as benzodiazepine insensitive, these conditions resulted in a potentiation. Similar to the 
α4, studies on the α6 receptor are most often performed with the β2 232,245,246 and the potentiation 
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could be due to the expression in combination with the β3. Refer to 3.2.1.3.3 Results and 
Discussion. 
In addition to testing the positive modulators diazepam and HZ-166, antagonist 
bicuculline was used on all the created cell lines, Figure 112.  Cells were pre-incubated with 
bicuculline for three minutes prior to the application of GABA. Unlike the other cell lines which 
Figure 112. Cell line 2 stably expressing the α6β3γ2 GABAAR exposed to an increasing concentration 
of bicuculline in combination with a constant concentration of GABA EC 80. N=10. 
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exhibited almost complete inhibition at 4µM bicuculline, the α6β3γ2 required higher 
concentrations of the antagonist to inhibit the GABA-evoked current. This is in line with the 
observation that receptors which contain the α6 subunit have been observed to be less sensitive 
to bicuculline 244. Unlike agonists and positive modulators, antagonist activity independent of the 
subunit composition with the exception of the α6 containing receptors 242,243.  
To ascertain whether the % DMSO effects the cell response over time, cells were dosed 
with GABA before and after three minute incubations with DMSO, Figure 113. The signal did 
not vary significantly over time, ranging from -415pA to -453pA. 
3.2.6 CONCLUSIONS  
 From our findings, it would appear that the plasmid constructs are able to successfully 












Figure 113. Response of cell line 2 stably expressing the α6β3γ2 GABAAR after three minute 
incubations with 1% DMSO.  
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of GABAAR subunit expression. The clones chosen all had around 50% or more mRNA expression 
as the housekeeping gene GAPDH. All of the cell lines were responsive to the binding of the 
agonist GABA, the antagonist bicuculline, as well as to modulation by diazepam and HZ-166.  
 The cells transfected with the α4β3γ2 and α6β3γ2 exhibited slow recovery and low levels 
of overall transfection levels, as evidenced by the widespread cell death during antibiotic selection. 
However, longer recovery times on the transfection plate allowed the cells to recuperate from the 
antibiotic exposure prior to isolation in the multi well plates.  
 By altering the formulation of the intracellular and extracellular solutions, small iPSCs 
could be enhanced and potassium leak could be inhibited with high levels of cesium. This becomes 
particularly important for receptor subtypes that do not exhibit current changes of more than -
1,500pA. The background noise at baseline can create a positive current change from resting 
potential, resulting in a rise in current rather than a lowering. Attempts to calculate a potentiation 
from these values could be a misleading representation of the data. 
 Interestingly, we have detected measurable potentiation of GABA-evoked current in the 
HEK293T cells stably expressing the GABAAR α4β3γ2 and α6β3γ2 to diazepam and HZ-166. 
Whether this is the result of the β3γ2 subunit composition or binding at a site alternative to the 
traditional αγ2 site, such as the αβ interface, has yet to be determined.  
 The clonal cell lines among stable transfections had very similar changes in current despite 
having very differing levels of mRNA expression. In general, the α5β3γ2 cells had the greatest 
current responses in the range around -10,000pA while α3β3γ2 and α4β3γ2 had a much more 
diminished current signal around -2,000pA. This would suggest that the maximum change in 
current is a characteristic of the receptor subtype rather than the extent of mRNA expression levels. 
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This recombinant stable cells system can be used to assess the selectivity of any GABAAR 
modulator. By comparing the efficacies and potencies of novel BZDs with pre-existing and FDA 
approved GABAAR modulators the alpha subtype selectivity can be determined. This method of 
comparing results is necessarily performed on a batch to batch basis for transient expression 
systems as the observed potentiation has been known to flux 247,248, however this repetitive step 
may be able to be reduced in the future with the reproducibility and clonal purity of these 
recombinant stable cell lines. From this data, structure activity relationship can be assessed and 
the compounds can be improved to create future subtype selective GABAAR modulators with any 
desired specificity.  
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CHAPTER 4: ICELL NEURONS 
4.1 Introduction 
 In his famous literary work Heart of Darkness, author Joseph Conrad perhaps best 
describes the evolution of the brain and humankind: “The mind of man is capable of anything—
because everything is in it, all the past as well as all the future”. The human brain is not exceptional 
in its cellular composition, containing as many neuronal and non-neuronal cells as any primate 
brain of its size. Thus it appears unexpectedly surprising that the cognitive abilities between 
humans and other great apes differ so greatly. The answer to this question may be found in the 
composition of neurons, neuroanatomical structure, and the function of the cerebral cortex and 
cerebellum 249. 
The central nervous system is primarily composed of two kinds of cells: neurons and glia. 
A much quoted and wide held belief was that the human brain contains 100 billion neurons and 
for every neuron there were 10 glial cells, derived from the Greek word for “glue”, which provides 
the scaffolding for neuronal architecture 250,251. However, new studies have shown that this number 
is an overestimation and that the human brain actually contains 86 billion neurons and 85 billion 
non-neuronal (glial) cells 252. Since each neuron can form connections with more than 1,000 other 
neurons, the adult human brain has been conservatively estimated to have more than 60 trillion 
neuronal connections 253. These connections are called neuronal synapses, as previously discussed 
in 2.1 Introduction.  
 When GABA is released from vesicles, it rapidly activates the postsynaptic GABAA family 
of receptors. This elicits a transient inhibitory postsynaptic current known as a phasic response. 
After release into the synaptic cleft, GABA is rapidly removed from the intercellular space by 
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specific transporters (GAT). The majority of the GABA is transported back into the synapse 254. If 
multiple vesicles from several terminals release GABA, a ‘spillover’ occurs that activates 
postsynaptic receptors as well as extrasynaptic receptors. As discussed in 1.1 History of GABAA 
Receptor, GABAAR is differentially expressed in certain subcellular regions and GABAA receptors 
composed of the α1, α2, and α3 subunits are primarily located postsynaptically and mediate phasic 
inhibition 45-47 with rapid desensitization and millimolar sensitivity while the α5, α4, and α6 
subunits form extrasynaptic receptors which mediate tonic inhibition 47 and displaying slow 
kinetics with nanomalor sensitivity 48. GABA transporters such as GAT1 and GAT3 work to 
remove the excess neurotransmitter from the synapse but if a low concentration of ambient GABA 
persists then this presence can tonically activate the high-affinity extrasynaptic receptors 255,256.  
Most neurons can be divided into four distinct parts: the cell body called the soma, the 
processes which receive a signal called the dendrites, the processes on which the signal flows 
called the axon and at the end of the axon are the axon terminals which house the neurotransmitters. 
There are two major types of neurotransmission: chemical or electrical. Electrical synapses occur 
when two neurons are physically connected to one another through protein structures called gap 
channels while chemical synapses occur between an axon and a dendrite that are physically 
separated by the fluid-filled synaptic cleft 257. Unlike electrical synapses, chemical synapses 
require neurotransmitters to act as chemical messengers. 
GABAAR expression occurs on the surface of neurons in chemical synapses and regulation 
of the receptor is highly dynamic. Receptors are synthesized and assembled into pentameric 
structures in the endoplasmic reticulum (ER) 258. Exit into the Golgi network as well as subsequent 
trafficking to the plasma membrane is facilitated by multiple associated proteins 255. Subcellular 
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localization, ie: synaptic versus extrasynaptic, appears to be orchestrated by a complex act 
involving diffusion and trapping of select assemblies 259. When GABAAR diffuse into the 
membrane, the widely expressed microtubule-binding protein, gephyrin can transiently capture 
and anchor the receptors to the membrane 260. Receptors are recycled and can leave from or be 
added into the synapse by lateral diffusion and endo- or exo-cytosis. Faulty GABA trafficking has 
been implicated in multiple diseases such as epilepsy 261, anxiety 256, Huntington’s 262, Angelman 
syndrome 263, fragile X syndrome 264, schizophrenia 265, and drug abuse 266. Just a single cell can 
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contain a highly complex population of mixed GABAAR. For example, the hippocampal pyramidal 
cell is covered with GABAergic terminals, receiving around 1700 synapses 260. An illustration 
depicting such a GABAergic synapse can be seen in Figure 114.  
When attempting to screen or design a subtype selective BZD, it is critical to keep in mind 
that selective affinity does not necessarily correspond with selective efficacy. For example, a 
compound with a high affinity but a low efficacy for a particular subtype could have a high efficacy 
Figure 114. GABA and GABAA receptor at the synaptic cleft. GABA is 
synthesized in the cytoplasm of the neuron by glutamic acid decarboxylase 
(GAD) and transported into synaptic vesicles by vesicular GABA transporter 
(VGAT). The GABA releases from vesicles into the synapse where it can bind 
to both postsynaptic (α1-3) or extrasynaptic (α4-6) receptors. GABA is 




and low affinity for another subtype, leading to a summation of response in a mixed population of 
subtypes 83,267,268. One must take into account the overall affects that a compound will make once 
exposed to a mixture of subtypes as they will be expressed in the brain.  
Taking into consideration these concerns, we propose that coupling together studies of 
small molecules in respect to recombinant subtype selectivity along with characterization with 
stem cell derived neurons would provide a more complete pharmacological profile and better 
reflect observations performed in vivo. Human-induced pluripotent stem cells (hiPSCs) provide a 
novel method when paired with an automated patch clamp instrument to allow for high-throughput 
study of benzodiazepines in a more physiologically relevant environment of mixed GABA-ergic 
receptors.  
The neurons used in this study were human-induced pluripotent stem cells obtained from 
Cellular Dynamics International (CDI, Madison, WI) termed iCell Neurons™ and assayed with 
plate format automated patch clamp. These cells represent a highly pure population composed 
primarily of GABAergic and glutamatergic neurons. The instrument used was the IonFlux from 
Molecular Devices (Sunnyvale, CA) which utilizes microfluidic compound delivery on timescales 
below 100ms, facilitating the recording of fast activating ligand gated ion channels. Using this 
platform, a large number of cells (20 per ensemble) can be under voltage clamp and exposed to a 
series of concentrations of compound within a short time period in parallel across a plate. 
Continuous recording coupled with fast solution exchange enables high-throughput screening of 
the GABAA receptor subtypes. To our knowledge, iCell Neurons have yet to be used on an 
automated “plate reader” patch-clamp platform but have been studied using conventional patch 
clamp as well as a chip-based, automated patch clamp 269. 
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The nonselective BZD diazepam and the α2/3 favoring imidizobenzodiazepine HZ-166 
were tested on the iCell neurons. In addition, CW-04-020, a drug that binds at a novel site between 
the α and β interface and is strongly influenced by the α subunit was used 241.  
4.2 Genomic Characterization via qRT-PCR 
4.2.1 INTRODUCTION 
Human induced pluripotent cells (hiPSCs) are a type of pluripotent stem cell that is able to 
be generated directly from adult cells. This technique bypasses the controversial use of embryonic 
stem cells. iPSCs were first derived from mice in 2006 from the lab of Shinya Yamanaka in Kyoto, 
Japan. With the introduction of four specific genes encoding transcription factors, adult cells were 
converted to pluripotent stem cells 270. Following this, in 2007, human iPSCs were generated from 
adult human cells through the use of four genes: Oct3/4, Sox2, Klf4, and c-Myc using a retroviral 
system 271. For this pioneering work, Yamanaka was awarded the Nobel Prize in 2012.   
 Generation of iPSCs is typically time consuming and inefficient. Furthermore, cells have 
a restricted proliferative potential meaning that new cells must be generated and characterized for 
each experiment. Commercially available iPSCs provide a convenient source of highly pure 
populations of cells at industrial quantities. However, the characteristics of the expressed receptors 
in the iCell neurons has been reported to fluctuate over time while in culture 272 so characterization 
prior to electrophysiological assay becomes necessary. 
4.2.2 EXPERIMENTAL 
Cell Culture Reagents and Instrumentation 
iCell Neurons (Cellular Dynamics, NRC-100-10-001) were provided via cryopreserved 
single-cell suspensions in 1.5 mL cryovials containing 2.5 million plateable cells per vial. iCell 
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Neuron Maintenance Medium (Cellular Dynamics, NRM-100-121-001) and iCell neuron medium 
supplement (Cellular Dynamics, NRM-100-031-001) were thawed and combined to create the 
complete media.  Poly-L-ornithine (PLO) and laminin were used to provide the base layer and 
coating for cell attachment to the 6-well plate (Costar). 1 mL of 0.01% PLO (Sigma-Aldrich) was 
added to one well of a 6 well-plate and incubated at room temperature for 1 hr. The PLO was 
aspirated and 3 mL of 3.3µg/mL laminin (Sigma-Aldrich, L2020) was added and incubated at 
37°C for 1 hr.  Cells were removed from liquid nitrogen and placed in a 37°C water bath for exactly 
3min before being sterilized and moved to the cell culture hood. The contents were transferred to 
a sterile 50 mL centrifuge tube. The cryo-tube was rinsed with 1 mL of room temperature complete 
medium which was pipetted into the 50 mL centrifuge tube dropwise to prevent osmotic shock to 
the cells. 10 mL of room temperature complete medium was then added to the 50 mL tube at 1-2 
drops/sec while gently swirling the tube. Cells were kept in a 37°C and 5% CO2 and maintained 
for 10 days with exchange of 50% of the media every 3 days. Cells were washed with Dulbecco’s 
phosphate-buffered saline, without Ca2+ and Mg2+ (Life Technologies) and dissociation of the cells 
was performed using 1X TrypLE Select (Invitrogen). Prior to use on the automated patch clamp, 
cells were centrifuged at 380 x g for 5 minutes and gently resuspended in extracellular solution. 
This was repeated two more times before dispensing the cells into the plate (8x105 cells/ml). 
qRT-PCR Reagents and Instrumentation 
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iCells were homogenized using the QIAshredder (Qiagen) and RNA isolated via the 
RNeasy kit (Qiagen). Total RNA was quantified via a Tecan Infinite M1000 plate reader (Tecan) 
in a UV-Star 384-well plate (Greiner Bio-One). A QuantiFast SYBR Green RT-PCR Kit (Qiagen) 
was used for the real time PCR following manufacturer’s recommendations. Primers used in these 
studies are as follows in Table 13. Real-time RT-PCR was carried out on a Mastercycler 
(Eppendorf). The ∆Ct method was used to measure the relative expression of target gene, GAPDH. 
Standard errors of mean were calculated from two biological independent experiments performed 
in triplicates. Significance was calculated using Dunnett ANOVA in GraphPad Prism. IonFlux 
software (IonFlux App) was used for data acquisition and exported to an Excel (Microsoft, 
Redmond, WA) for organization. The data was loaded onto GraphPad Prism 5 (GraphPad 
Software, San Diego, CA) for automated analysis of concentration dose-response curves. 
qRT-PCR Protocol 
Cells were harvested once 80% confluent using 0.05% Trypsin or Detachin solution and 
pelleted by centrifuging at 1000 rpm for 2 minutes. Media was aspirated and the cell pellet was 
resuspended in RTL buffer. The mixture was pipetted into the QIAshredder spin column and spun 
 
Table 13. Human primers list for quantitative RT-PCR of iCell Neurons. 
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for 2 minutes at max rpm. One volume of 70% ethanol was added to the homogenized lysate and 
mixed well by pipetting. The solution was then transferred to an RNAeasy spin column and spun 
down for 15 sec at 10,000 rpm. Then washed with buffers to purify the bound RNA with the flow 
through discarded. After the column is washed and dried, RNA is eluted by addition of 30-50 µL 
of RNase-free water. Total RNA concentration was determined by UV at 260 nm and protein 
contamination was assessed at 280 nm. The RNA was then diluted and used for qRT-PCR with 
the QuantiFast SYBR Green RT-PCR Kit (Qiagen). The cycling conditions used was 10 min at 
50°C (reverse transcriptase), 5 minutes at 95°C (PCR initial activation step), 10 sec at 95°C 
(denaturation), and 30 sec at 55°C (annealing and extension) for a total of 50 cycles. Data was 
taken in triplicate and the relative mRNA expression levels were calculated using wells containing 
no template and normalizing to housekeeping gene GAPDH. 
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4.2.3 RESULTS AND DISCUSSION 
 Visual observation of the iCell Neuron growth confirmed cell viability after thawing. 
Morphological inspection of developing branched networks with dendritic processes and active 
synapses corresponded with the expected appearance, Figure 115, as described by the 
manufacturer.  
The expression of GABAAR subunits in iCell Neurons was determined by qRT-PCR, . A 
moderate mRNA amount of γ2 was identified, which forms part of the binding site for 
benzodiazepines together with α GABAAR subunits. In addition, a high level of β3 mRNA was 
detected. Among the different GABAAR alpha subunits, high expression of α5 and unexpectedly 
Figure 115. Cultured iCell Neurons exhibited typical neuronal morphology with development of 
branched networks. These images were obtained using phase contrast microscopy at 2 0X. iCell Neurons 
at days 1, 3, 5, and 7 post-plating. 
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lower expression of α1 makes for an uncommon neuronal subtype distribution. It is estimated that 
α5 is part of less than 5% of all the GABAAR in the brain while α1 is part of nearly 60% 37. 
Furthermore, we observed lower but similar mRNA levels for α3 and α4 subunits and even lower 
expression of α2 and α6 subunits. 
4.2.4 CONCLUSIONS 
Quantification of receptor subtype expressions levels revealed a moderate amount of the 
γ2 which is necessary for benzodiazepine sensitivity. The high degree of α5 subunit mRNA 
expression as well as the unexpectedly low degree of α1 mRNA makes for uncommon subtype 
distribution. The expression of the α5 subytpe is mainly localized in the cerebral cortex, 
hippocampus, and olfactory bulb and serve as extrasynaptic receptors 273. iCell neurons represent 



























Figure 116. The relative mRNA expression of GABAAR in 
iCell Neurons quantified using qRT-PCR. Cells were in 
culture for 10 days prior to collection. Data includes results 
in triplicate from two independent experiments, N=6. 
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this is contributing to the high level of expression of α5 in the cells as it has been studied that these 
receptors play a role in learning and memory 38,274 associated with the cerebral cortex. 
The GABAA receptor subtype distribution in iCell Neurons may be of particular interest in 
the study of compounds that target α5 containing GABAA receptors. In humans, α5 has been 
identified as a susceptibility locus for schizophrenia 178 and depression 275. This receptor subtype 
appears to be regulated heavily by stress hormones and changes in expression are often associated 
with stress-related disorders 198 and follow traumatic brain injury 50. In addition, α5 has also been 
implicated to impede learning and memory, and development of a selective inhibitor of α5-
containing receptors may serve as a cognitive enhancer in Alzheimer’s disease patients.  
The expression of GABAARs in iCell Neurons have been compared to their expression in 
the human brain at various stages of neurodevelopment 272. Interestingly, lower expression of α1 
and γ2 were observed in brain samples of human neonates in comparison to adults. In addition, β3, 
α4, α5, α2, and α3 subunits were expressed at higher levels during the first twelve months, but less 
in the adult brain. Our results are consistent with the observation that iCell Neurons, when cultured 
for 10 days, are more similar to the GABAAR expression profile of a neonatal than a human adult. 
Thus, iCell Neurons may offer an excellent representation of the GABAA receptor 
distribution to test pharmaceuticals targeting neurodevelopmental disorders, depression, cognitive 
deficiencies, and severe brain injury. 
4.3 Proteomic Characterization via Electrophysiology  
4.3.1 INTRODUCTION 
 As with planar patch clamping, cells are randomly chosen from suspension by application 
of suction and good cell quality and viability are mandatory for obtaining good results. Earlier 
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work276 has observed successful recording of the response of GABA and antagonist bicuculline on 
an Nanion chip-based NPC-16 Patchliner Octo which traps 8 cells. Besides this work, to the best 
of our knowledge, there has been no other publications reporting use of iPS neurons on automated 
patch clamp.  
4.3.2 EXPERIMENTAL 
Electrophysiological Reagents and Instrumentation 
The buffers were made from NaCl (Fisher, BP358-1), KCl (Fisher, BP366-1), KF 
(ACROS, 212602500), MgCl2 (Sigma, M8266), 5 D-glucose monohydrate (Sigma, G0350500), 
HEPES (Fisher, BP410-500), CsCl (Sigma, 203025), and EGTA (Tocris, 28-071-G). The 
intracellular solution (ICS) contained (mM): 50 KCl, 10 NaCl, 60 KF, 20 EGTA, 10 HEPES, pH 
7.2 with KOH. The extracellular solution (ECS) contained (mM): 140 NaCl, 4 KCl, 1 MgCl, 2 
CaCl2, 5 D-glucose monohydrate, and 10 HEPES, pH 7.4 with NaOH. 
GABA (Sigma-Aldrich, A2129) was made into a 10mM stock solution and diluted in ECS 
to appropriate concentrations for use. HZ-166 277 and CW-04-020 (PZ-II-029) 278 was provided by 
the lab of Dr. James Cook, diluted to a 10mM DMSO stock. Diazepam (Sigma-Aldrich, D0899) 
was made into a 10mM DMSO stock and diluted to appropriate concentrations in ECS for use.  
 191 
 
4.3.3 RESULTS AND DISCUSSION 
Four vials of iCell neurons were received and individual experiments were performed on 
each vial separately. In each plate, 320 cells are captured for whole cell recording. Once cells were 
trapped, compound addition wells were programmed to open with 3 second duration intervals. The 
lapse between compound additions ranged from 60-120 seconds, dependent on the degree of 
expected saturation of the cells at increased concentrations of modulator. All traps yielded an 
acceptable seal resistance, Figure 117. The success rate of the assays, defined as detectable current 
(>1000pA) was 100% for all experiments.  
Seven increasing concentrations of GABA were used to determine the electrophysiological 
EC50 value of GABA. The agonistic effect of GABA was measured at a maximum concentration 
Figure 117. Seal resistance of patched clamped 
icells Neurons. Twenty individual cells are 
patched clamped in a trap channel. Seal 
resistance for the cells remained stable 
throughout the experiment.   
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of 100µM  on IonFlux ensemble plate and the GigaOhm Seal plate, Figure 118. Each GABA 
application occurred for 3000 ms. Negative current increased during that time period and reached 
saturation followed by desensitization. A rapid decrease of negative current was observed once 
GABA was washed away by ECS by closing the GABA-containing microfluidic channel. A 
change of negative current in respect to the baseline was observed at a concentration of 0.14 µM 
GABA. The maximum negative current was achieved at concentrations higher than 1 µM GABA. 
The success rate of the assays, defined as detectable negative current of more than -500 pA for the 
highest concentration of GABA, was 100%. 
The experiment was carried out with sixteen independent ensemble trap channels, Figure 
118A. The EC50 value of 0.43 ± 0.19 µM was determined using non-linear regression. 
Furthermore, a single cell electrophysiology experiment was carried out using a GigaOhm Seal 
Figure 118. GABA-induced current responses of iCell Neurons measured with the IonFlux instrument. 
A) Current recordings of different concentrations of GABA applied for 3 seconds using a trap channel 
that has twenty patched clamped iCell Neurons; B) Concentration -dependent current response curve of 
GABA using trap channels that have twenty patched clamped iCell Neurons (N = 16); C) Current 
recordings of different concentrations of GABA applied for 3 seconds using a single cell recording with 
a trap channel that has one patched clamped iCell Neuron; D) Current recordings of 100 nM GABA 




Plate in combination with the IonFlux. The success rate for this plate dropped to 25%, however, 
the resistance for iCell Neurons increased to 100 MΩ. The individual current traces for different 
GABA concentrations are depicted in Figure 118C. Similar to the multi-cell experiments, negative 
current increased and saturated during three second application periods of GABA followed by 
rapid decrease of negative current during the washout period. The overall current changes were 
smaller than those recorded for multi-cell experiments, Figure 118A.  The reproducibility of 
current change for 100 nM of GABA EC3 was established to determine the electrophysiological 
effects of positive allosteric GABAAR modulators, Figure 118D. It was demonstrated that repeated 
three second applications of 100nM GABA had a consistent negative current change when applied 
six consecutive times. 
In addition, repeated application of 100 nM GABA for three seconds preceded the 
application of increasing concentrations of positive allosteric GABAAR modulators in the presence 
of 100 nM of GABA as part of the automated patch clamp protocol to characterize the 
electrophysiological affinity and efficacy of GABAAR modulators for iCell Neurons. The average 
negative current change in the presence of 100 nM GABA equals 100% of control current at 
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GABA EC3 for Figure 119. For the compound application, GABAAR modulators were dissolved 
in ECS with a maximum of 0.3% DMSO. At a concentration of 0.41 µM diazepam in the presence 
of GABA a significant negative current change was observed, Figure 119A. Diazepam 
Figure 119. Current responses of twenty patched clamped iCell Neurons from a trap channel located 
on an IonFlux 16 plate in the presence of positive allosteric GABAAR modulators and GABA. A ) 
Current recordings of iCells Neurons in the presence of different concentrations of diazepam and 100 
nM GABA applied for 3 seconds; B) Concentration-dependent current response curve of iCell Neurons 
in the presence of diazepam and 100 nM GABA (N = 20); C) Current recordings of iCells Neurons in 
the presence of different concentrations of HZ-166 and 100 nM GABA applied for 3 seconds; D) 
Concentration-dependent current response curve of iCell Neurons in the presence HZ -166 and 100 nM 
GABA (N = 20); E) Current recordings of iCells Neurons in the presence of different concentrations 
of CW-04-020 and 100 nM GABA applied for 3 seconds; F) Concentration-dependent current response 
curve of iCell Neurons in the presence CW-04-020. 
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concentrations between 1.23 µM and 11.1 µM resulted in a higher but similar negative current 
change that enabled affinity and efficacy determination. The EC50 value calculated for diazepam 
for iCell Neurons was EC50 of 0.42 ± 0.12 µM with a potentiation of 593% in respect to the current 
observed for 100 nM GABA. The affinity of diazepam among GABAA receptors bearing different 
α-subunits using HEK293 cells transfected with GABAAR subunits decreased from 
α1>α5>α2>α3, whereas the efficacy, although very similar, decreased from α2>α1>α5>α3 279. 
Interestingly, a concentration of 33 µM diazepam induced a second component of potentiation, 
which was earlier reported by Walters et al for α1β2γ2 transfected oocytes due to the presence of 
two components of potentiation in GABAA receptors, namely binding of α1β2γ2 and α1β2.215 HZ-
166 is a novel anxiolytic compound with less efficacy toward the α1 subtype. The selectivity 
profile of this compound is α5>α2>α1>α3 for affinity and α3>α2>α5>α1 for efficacy. 280 
Investigations with iCell Neurons using the IonFlux showed a slow but steady increase of negative 
current starting at 0.14 µM of HZ-166, Figure 119C. Saturation of negative current signals were 
less pronounced at higher concentrations of HZ-166, which might be caused by occupation of 
different populations of GABAARs like diazepam. The calculated EC50 value for the most sensitive 
GABAA receptor was 1.56 ± 0.83 µM at a potentiation of 810% in respect to the current change 
observed for 100 nM GABA Figure 119D. Finally a recently discovered α6-selective GABAAR 
modulator CW-04-020 (PZ-II-029) was investigated 278. At a concentration of 0.14 µM a 
significant increase of negative current was observed Figure 119E. Negative current changes did 
not significantly change for concentrations higher than 1.23 µM and resulted in an EC50 calculation 
of 0.23 ± 0.07 µM, Figure 119F. The potentiation based on the negative current observed at 100 




 Positive modulators were tested at a maximum concentration of 100µM and serially 
diluted in a solution of ECS containing a GABA concentration of anticipated EC3 estimated at 
0.1µM, Figure 118: B-D. This established the baseline of 100% to determine % potentiation due 
to the addition of a positive modulator. The highest DMSO concentration was <1%. Vehicle 
control measured at the same DMSO concentration showed no significant response.  
4.3.4 CONCLUSIONS 
The presented preliminary results indicate that iCell neurons present an excellent means of 
testing a compounds overall efficacy on a mixed population of human GABAA receptors. The 
IonFlux microfluidic automated patch clamp platform necessitates that the cells are in suspension 
when read. The high success rate despite the nonoptimal morphology of the cells in suspension 
showed great promise. It has been a continuing struggle to develop a method to reliably screen 
compounds for GABAA subtype selectivity. 
In order to characterize a compound’s functional effects, measurements are taken via 
electrophysiological techniques expressing recombinant GABAA receptor subtypes to gain a better 
understanding of their effects in vivo. However, it is very difficult to liken a subtype occurring 
from recombinant co-expression with an in vivo subtype. This is due to the complexity and 
inaccessibility of the CNS. The co-occurrence of multiple subtypes of GABA receptors in small 
regions, or even on a single neuron gives rise to further difficulties. Therefore, analysis of a 
compound cannot be solely based on the response that comes from recombinant systems. The 
physiological and behavioral effects observed in clinical trials are a result of control by an 
amalgamation of GABA-ergic networks, not a singular subtype. In addition, in the event that 
receptor subtype selectivity is achieved and shown through study with recombinantly expressed 
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receptors, this effect could be negated by its additional interaction with a second site that is present 
in a broader range of receptor subtypes 281. 
Bi-phasic effect of midazolam has been noted when rat sacral dorsal commissural nucleus 
(SDCN) neurons are exposed to higher concentrations (30uM-300uM). Wherein current will be 
inhibited and the dose-response will have a bell-shaped curve 282. A similar effect is seen here. 
This biphasic effect is also present in recombinantly expressed receptors in the application of 
diazepam and appears only in the presence of very low GABA concentrations. In addition, the low 
affinity site does not require the presence of the γ2 subunit as it is present on the α1β1 receptors. 
However this effect appears not to have clinical relevance since most physiological effects of 
BZDs can be blocked by flumazenil 215.  
Screening on recombinant cell lines ignores the complexity which arises when multiple 
subtypes are expressed on a single cell. Screening compounds on specific receptor subtypes in 
parallel with induced pluripotent stem cells provides a valuable and unique perspective on the 
effects a GABAA receptor ligand will have in humans. Based on our findings, iCell neurons are 
capable of being used on the “plate reader” based automated patch clamp and provide an all-
encompassing view of a compounds total efficacy and potency. These readings may provide a 
more biologically relevant reflection of the effects the compound will exhibit in vivo when 
exposed to a diverse GABA-ergic network. Creating subtype selective imidizobenzodiazepines 
that target small subpopulations of the GABAA receptors should generate modulators that lack the 
major side effects associated with classic benzodiazepines. Animal models are invaluable in 
elucidating disease mechanisms and functional roles of specific genes but have been known to fall 
short when it comes to translating findings into human therapeutics 283. It is well known that the 
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expression levels of GABAA receptor subunits and their localized cellular distribution in rodents 
do not necessarily correspond with the human brain 50,52. hiPSCs capture the genetic makeup of a 
patient, making it possible to study human neurons containing a specific sets of mutations. Most 
neuropsychiatric disorders, such as autism, schizophrenia, and depression, have a strong genetic 
component. High-throughput screening of hiPSCs suggests the possibility of attaining cells with 
specific attributes that mirror the neuronal makeup of patients and could allow for more efficient 
and accurate screening to treat neuronal disease.  
The GABAA receptor subtype distribution in iCells may be of particular interest in the 
study of compounds that selectively target the α5 containing GABAA receptors. In humans, the α5 
has been identified as a susceptibility locus for schizophrenia 178 and depression 275. This receptor 
subtype appears to be heavily regulated by stress hormones and changes in expression are often 
associated with stress-related disorders. Autopsy studies of those who suffered from SMD 
upregulation of α5 with a down regulation of α1 in suicides who died during an episode of major 
depression 198. In addition, the α5 has also been implicated to impede learning and memory and 
that development of a selective inhibitor of the α5-containing receptors may serve as a cognitive 
enhancer in Alzheimer’s disease patients. Similarly, after traumatic brain injury there is an 
observed upregulation to α5 in the hippocampus which provides enhanced tonic inhibition for an 
acute neuroprotective measure 50,284. However, this enhanced tonic inhibition can impede 
functional plasticity 188. Thus, modulation of the extrasynaptic α5 that mediates tonic inhibition 
may prove to be a novel strategy to aid and enhance recovery after a stroke or devastating brain 
injury. In brief, it can be concluded that these cells may offer an excellent representation of the 
GABAA receptor distribution to test pharmaceuticals targeting depression, cognitive deficiencies, 
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and severe brain injury. These assays may provide an even better reflection of the effects in humans 





CHAPTER 5: DEVELOPMENT OF FLUORESCENCE-BASED HIGH 
THROUGHPUT SCREENING ASSAY FOR MODULATORS OF THE GABAA 
RECEPTOR 
5.1 Introduction 
Automated patch-clamp improves the throughput of manual patch-clamp, however 
microfluidic plates are expensive and yield only a limited number of data points.  
Green fluorescent protein (GFP) was first isolated from the Aequorea jellyfish 285. The wild 
type protein, crystal structure seen in Figure 120, has a complex absorption spectrum with a 
maximal excitation at 395 nm and a minor peak at 475 nm 286. Fluorescence results from 
deprotonation of the Tyr66 residue in the chromophore. The resulting ionic species exhibited 
Figure 120. Crystal structure of the Aequorea Victoria green 
fluorescent protein. PDB: 1EMA 
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excitation at 476 nm. The protonated Tyr66 reside is responsible for the major absorption peak at 
476 nm. Mutagenesis studies to fine-tune the spectral qualities of the protein has generated a wide 
variety of fluorescent proteins that range from blue to yellow 286 including substitution of the 
Thr203 in the beta-barrel near the chromophore with tyrosine (T203Y). This resulted in a 20nm 
red-shift, generating a new fluorescent protein with yellow-green emission, called yellow 
fluorescent protein (YFP). The enhanced version (eYFP) is engineered further with three more 
point mutations (S65G, V68L, S72A) to improve the efficiency of protein maturation and 
expression. The excitation and emission of this eYFP are 514 nm and 527 nm respectively, seen 
in Figure 122 286.  These mutations led to proteins with brighter fluorescence but also to heightened 
sensitivity to acidic pH and to the quench of anions. A unique feature is that eYFP is sensitive to 
chloride ions. Random mutation have identified that H148Q and I152L increases halide sensitivity 
287,288. I-, NO3
-, Br-, and Cl- anions can quench the YFP-mediated fluorescence. Chloride-channels 
such as the GABAAR, mediate an increase of chloride ions in the cell when exposed to GABA, 
Figure 121. The absorption and emission spectral profiled of wild -
type A. victoria GFP. Used with permission of the Royal Society 
of Chemistry, reference cited in text.  
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which in turn can quench the eYFP when expressed in the cytosol of a cell. An assay with 
transiently expressed GABAAR with α1β1 subunits and eYFP has been developed and verified 
with GABA as well as with channel blocker picrotoxin 289. The anion selectivity for quenching is 
ClO4
- ~ I- > SCN- > NO3
- > Cl- > Br- > formate >acetate. Recently a similar assay was developed 
that applied α2β3γ2 transiently transfected in CHO-K1 cells and determined the response to 
agonist GABA, six positive modulators, and channel blocker bicuculline 290.  
5.2 Assay Optimization 
5.2.1 INTRODUCTION 
It should be noted that in the course of studying the potential of eYFP to design an assay, 
a 2013 publication reported the development a YFP-based assay using CHO-K1 cells that were 
transiently transfected with the GABAA α2β3γ2 with the halide sensing eYFP H148Q/I152  using 
electroporation 290. However, this assay was performed using a serial dilution of GABA with a 
fixed concentration of known significant positive allosteric modulators such as diazepam, 
Figure 122. The absorption (A) and emission (B) spectral profiles of the enhanced Aequorea -GFP 
derivatives: enhanced blue fluorescent protein (eBFP), enhanced cyan fluorescent protein (eCFP), 
enhanced green fluorescent protein (eGFP), and enhanced yellow fluorescent protein (eYFP). Used with 
permission of the Royal Society of Chemistry, reference cited in text.  
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lorazepam, clobazam, and alpidem. The EC50 shifts for these modulators were estimated at 1.4 
times shift in the GABA EC50 or a difference in pEC50 or 0.15 compared to GABA. This was 
calculated to have statistical significance when averaging across 3 occasions. There was no 
detection of significant allosteric effect using weak modulators such as TPA-023 or L-838417. 
Hence it would appear that this method would not be suitable to distinguish small changes in 
efficacy among similar strong or weak modulators and thus would not be a good screening tool for 
structure activity relationship (SAR) studies. However, we continued our experimentation as to 
whether a serial dilution of compound with a constant concentration of GABA would elicit any 
discernable difference between similar modulators.  
5.2.2 EXPERIMENTAL 
Plasmid Propagation Reagents 
The eYFP-H148Q-I152L was purchased from AddGene provided the lab of Peter Haggie 
287. The plasmids arrived on paper disks and were eluted with RNase Free Water (Fisher, 
BP24701). 1 µL of the elution was added to a tube of NEB 5-alpha competent E. coli cells (New 
England BioLabs, C2987H) and flicked to mix. The mixture was placed on ice for 2 minutes, 
undisturbed and immediately heat shocked at exactly 42°C for 30 secs. The tube was moved to ice 
for 2 min, after which 950 µL of SOC was added to the mixture. 50 µL and 100 µL were spread 
onto a 100 µg/mL carbenicillin (GoldBio, C10325) plate and grown overnight at 37°C. A colony 
was chosen and used to inoculate LB broth (Fisher, BP9733-500) containing carbenicillin. The 
resulting culture is centrifuged at 6,000 x g for 15 min at 4°C to pellet the bacteria and the 
supernatant removed. The plasmid DNA is then extracted using a gravity-flow anion-exchange 
HiSpeed Plasmid Maxi Kit (Qiagen, 12663). The pellet was resuspended in buffer and an alkaline 
 204 
 
lysis is performed before the lysate is cleared by filtration. The lysate is then added to a primed 
HiSpeed tip to bind DNA, wash, and finally elute. Isopropanol was added to the elution to 
precipitate the DNA and collected using the QIAprecipitator. The final elution from the 
QIAprecipitator yields ultrapure plasmid DNA. The DNA concentration was determined by UV 
at 260 nm using the Tecan Infinite M1000 plate reader. Protein impurities were minimal by 
comparison of the 260/280 nm ratio. 
Cloning Reagents and Instrumentation  
The eYFP gene was removed from the vector via enzymatic digestion using XhoI (NEB, 
R0146) and SmaI (NEB, R0141) and treated with Antarctic phosphatase (NEB, M0289) which 
adds phosphate groups to exposed 3’OH groups to prevent self-ligation of sticky ends. 2 µL of 
digested eYFP, 4 µL of water, 0.7 µL of AnP buffer and 1 µL of Antarctic phosphatase were 
incubated at 37°C for 15 min. The mixture was heat inactivated at 65°C for 5 min. The alpha1-
Lab-pCI underwent digestion with the same enzymes and the eYFP was inserted using 1 µL T4 
ligase (NEB, M0202S), 10 µL of 2x ligation buffer, 3 µL of the fragment (purified by gel) and 1 
µL of the pCI vector (purified by gel) and incubated at room temperature for 15 min. 1 µL of the 
reaction was added to a tube of NEB 5-alpha competent E. coli cells (New England BioLabs, 
C2987H). The cells were cultured onto a 100 µg/mL carbenicillin (GoldBio, C10325) plate and 
grown overnight at 37°C. A colony was chosen and used to inoculate LB broth (Fisher, BP9733-
500) containing carbenicillin and purified using the HiSpeed Plasmid Maxi Kit (Qiagen, 12663). 
EcoRI digestion was performed using 1 µL of EcoRI (NEB, R0101S), 1 µg of DNA, 5 µL 
of CutSmart buffer and nuclease-free water to the total reaction volume of 50 µL. The reaction 
was incubated at 37°C for 1 hr. The digest was run on a 1% agarose gel with 0.5 g of agarose 
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(Fisher, BP160-500) with 50 mL of 1xTBE buffer, microwaved in bursts of 30 secs until the 
agarose was dissolved. 5 µL of an ethidium bromide replacement, Bullseye DNA Safestain 
(MidSci, C138) was added to visualize the DNA under ultraviolet light. The Bullseye 1 Kb DNA 
ladder (MidSci, BEDNA1KB) was used to measure band migration on the gel. The agarose was 
poured into a small gel tray with a well comb. The gel was allowed to solidify at room temperature 
for 20-30 min. The gel was run at 80-150 V for around 30 min until the dye line was 50-75% down 
the gel.  
Fluorescence Microscopy  
Initial imaging was performed with the Nikon Eclipse TE2000-U was connected to 
mercury-100W, Prior ProScan II, Sutter Lambda 10-3. Later imaging was performed on a Nikon 
Ti-E inverted fluorescence microscope using a 20X and 40X/NA 1.4 objective. 
Measurements of total fluorescence were taken with the Tecan Infinite M1000 plate reader 
with at 470 nm excitation, 550 nm emission, bandwidth 5 nm, and gain optimized at 245. The 
buffer used was composed of 137 mM NaCl, 2.7 mM KCl, 0.7 mM CaCl2, 1.1 mM MgCl2, 1.5 
mM KH2PO4, 8.1 mM Na2HPO4 at pH 7.4.  
Cell Culture Reagents and Instrumentation 
A commercially available, human embryonic kidney (HEK 293T) cell containing the 
simian vacuolating (SV) virus 40 T-antigen origin of replication 207 was used in all the stable cell 
lines. HEK 293T cells were purchased (ATCC) and cultured in 75 cm2 flasks (CellStar) coated in 
matrigel (BD Bioscience, #354234), a gelatinous protein secreted by mouse sarcoma that 
facilitates cell adhesion to the flask. Cells are grown in DMEM/High Glucose (Hyclone, 
SH3024301) media to which non-essential amino acids (Hyclone, SH30238.01), 10 mM HEPES 
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(Hyclone, SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone, SV30010), and 
10% of heat-inactivated premium US-sourced fetal bovine serum (FBS) (Biowest, SO1520HI) 
were added. Cells are harvested using 0.05% Trypsin (Hyclone, SH3023601) or Detachin 
(Genlantis T100100) which both disrupts the cell monolayer and proteolytically cleaves the bonds 
between the cells and flask; the latter more gently for patch-clamp study. The media utilized in 
transient transfections contains the same components only the FBS was heat-inactivated and 
dialyzed FBS (Atlanta Bio, S12650H), then cells were rinsed and shaken in Serum Free Media 
(Hyclone, SH30521.01). 
Cell transfection was conducted by lipid-based methods using Lipofectamine with PLUS 
reagent (Life Technologies, #15338020). 5 µg of each of the plasmids was combined with 25 µL 
of Plus reagent and incubated for 5 min, 75 µL of Lipofectamine was then added to the mixture 
and incubated for 30 min before being added to a 60-80% confluency 75cm2 flask. Cells were 
counted on a hemocytometer, 20 µL of cell suspension are aliquoted onto the slide and 3 counting 
areas whose volume is 100 nL are averaged and multiplied by 1x104 to give a concentration of 
cells in cells/mL When measured with the Tecan plate reader, cells were transferred to the 96-well 
plate (ThermoSci, 12-566-71) cultured with 100 µL of media while a 384-well plate (ThermoSci, 
12-566-1) contained 25 µL of media. Since the plates are clear on the bottom to provide optical 
access of the cells, an adhesive bottom seal should be applied prior to reading the plate from the 
top to reduce scattering (Perkin Elmer, 6005199). Initial buffer composition was 200 mM NaCl, 2 
mM CaCl2, 1 mM MgCl2, and 10 mM HEPES at pH 7.3. Compounds were dissolved as a 10 mM 
DMSO solution and final DMSO concentration in the assay was 1%. DMSO only controls were 




5.3.3 RESULTS AND DISCUSSION 
Initial transfections with the eYFP-H148Q-I152L plasmid exhibited low fluorescence 
signals after a 24 hour recovery. We surmised the low signal was the result of unmatured eYFP 
rather than a low percentage of successful transfection. Fluorescence imaging of individual cells 
Figure 125. Image of eYFP in HEK293T cells after 24hr transfection (20X objective)  
Figure 123. Image of eYFP in HEK293T cells after 48hr transfection (40X objective)  
Figure 124. Overall efficiency of eYFP transfection after 48 hours  (20X objective) 
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confirmed this, seen in Figure 125 after 24 hours and Figure 123 after 48 hours. The overall 
transfection efficiency was also imaged, seen in Figure 124. Using a fluorescence plate reader, cell 
fluorescence was assessed over time and it was determined that optimal maturation for eYFP 
required up to 48-72 hours to attain a high level of translation and correct folding in HEK293T 
cells at 37°C, seen in Figure 126. The fluorescent protein, once expressed, requires several steps 
before becoming functional. The protein first must be folded correctly, then a torsional 
rearrangement of the active site of the fluorophore occurs which allows a nucleophilic attack that 
results in the formation of a ring system, finally oxidation of the ring system forms the final system 
of conjugated bonds causing the formation of the mature fluorophore. This entire process is known 
as maturation 291.  
Another dynamic feature of these fluorophores is the photobleaching effect. That is, when 
the fluorophore is exposed to continuous illumination for several tens of seconds, the fluorescent 













































Figure 126. eYFP-H148Q-I152L length of protein maturation after 
transient transfection, N=12, reading performed on the Tecan M1000.  
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determined to be nonsignificant within one to three readings, Figure 127, sufficient enough to 
record the change in quench.  
In order to achieve maximal quench of the eYFP, a plasmid combining the α1 GABAAR 
(Figure 128) and the eYFP (Figure 129) was created using molecular cloning. The backbone 
containing the eYFP had an EcoRI site after the gene that could accommodate the α1 GABAAR 
gene which was flanked by two EcoRI sites. Multiple colonies were isolated from these 
experiments but always resulted in the eYFP backbone re-ligated back into the original sequence 
containing no insert. Two other restriction enzyme sites that both plasmids had in common were 
an XhoI and XbaI. Again the ligation involved the insertion of the α1 GABAAR sequence into the 
eYFP plasmid. These experiments also resulted in the original eYFP plasmid. So instead of using 
the eYFP backbone, the vector containing the α1 GABAAR gene was used as the receiver of the 
















































Figure 127. Photobleaching of the eYFP over seven 
measurements with the Tecan M1000, 50 flashes each 
reading. N=24. Significance (*) calculated using One-way 
ANOVA and Dunnett’s Multiple Comparison Test.   
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to the successful expression of the eYFP and α1 GABAAR gene. However, the two proteins were 
not fused and the eYFP contained a stop codon. Thus a site directed mutagenesis or a PCR with 
specifically designed primers would need to be performed to enable the generation of a fusion 
protein. Thus assay development was performed using an unfused eYFP and GABAAR α1 subunit. 
A Gaussia Luciferase (AddGene, pCMB-GLuc_2) was also purchased for possible creation of 
fusing a subunit with luciferase to create a bioluminescence resonance energy transfer (BRET) 
assay. 
Figure 128. The plasmid containing the alpha1 GABAAR subunit with 
restriction enzyme sites.   
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Based on earlier findings that the iodide concentration greatly affected the basal quench of 
the fluorophore as well as the potency of GABA, we modified our solution. The NaI buffer was 
composed of 130mM NaCl, 10mM NaI, 20mM Hepes, 5mM KCl, 2mM CaCl2, 1mM MgCl2 at 
pH 7.3. 
Figure 129. The plasmid containing the eYFP gene with restriction enzyme sites  
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The agonist GABA elicited a clear dose response curve with high concentrations achieving 
as much as 40% quench with low concentrations retaining a 10% quench from the addition of the 
NaI buffer, Figure 130. This corresponds with what was previously published 290 despite having 
different transfection methods and mammalian cell lines.  
The paper that was previously published perfomed a serial dilution of GABA with a 
constant concentration of 1µM modulator, citing slight differences in the shift. Instead of 
Figure 130. eYFP quench induced by GABA in 10mM I - buffer. A) The change in the relative 
fluorescence units was calculated before and after addition of GABA  in 10mM I- buffer. B) The percent 
quench was calculated as the average of the maximum signal achieved subtracted from the average of 
the background.  
A B 
Figure 131. Cells transfected with the α1 and eYFP were exposed 
to a mixture of serially diluted Diazepam with 0.1µM GABA in 
NaI buffer and fluorescence was immediately recorded. 
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recapitulating this EC50 shift, a serial dilution of compound with constant concentration of GABA 
was attempted. This method resulted in plots resembling  Figure 131.  
Though the overall graph does not appear to show a significant increase in quench, a 
comparison of average values achieved using 1mM Diazepam vs DMSO after the addition of an 
EC20 concentration of 0.1µM GABA showed statiscal significance with 95% confidence, when 





























Figure 132. Comparison of quench between the DMSO 
control and 1mM of Diazepam. Statically significant or non-
significant at p<0.05 
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In order to maximize the quench, the assay was optimized in varying ways. Firstly, the 
assay necessitated buffer and liquid exchange. The method of exchanging the liquid greatly 
effected the quench. For example, emptying the plate via flipping the plate or via aspiration using 
a vacuum resulted in varying changes in signal, Figure 134. We determined that emptying the plate 
via a flip resulted in lower change in fluorescence as well as a lower varience or deviation in 
results. A visual assessment of the cells after liquid exchange revealed that the loss in fluorescence 















Figure 134. Comparison of plate emptying methods for liquid 
exchange in the eYFP assay. 
Figure 133. Light microscope image of a well in the 96 well plate with cells plated at 20,000 
cells per well with 48 hours of maturation time before and after two  exchanges in buffer 
including the 15 minute preincubation with DMSO or compound.  
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per well in a 96 well plate which resulted in a roughly 50% confluency after the 48 hour eYFP 
maturation time. In order to cell loss, 50,000 cells were plated per well which resulted in a 100% 
confluency after the fluorophore maturation time. This high seeding density prevented the loss of 
cells, Figure 135. In addition, we changed to directional reading to a bottom read fluorescence 
confirming that the signal was not lowered after liquid exchange, Figure 136.   
Figure 135. Light microscope image of a well in the 96 well plate with cells plated at 50,000 cells 
per well with 48 hours of maturation time before and after two exchanges in buffer including the 
































Figure 136. Cells plated at 50,000 cells per well at 100% 
confluency at the time of reading saw negligible change in the 
fluorescence signal after liquid exchange. N=7 in a 96 well plate. 
 216 
 
Further optimization brought attention to the differential expression that may be due to the 
vector backbone of the plasmid. It was observed that the plasmid containing the eYFP as well as 
the α1 gene led to higher levels of fluorescence suggesting that the backbone containing the α1 led 






































Figure 137. Cells transfected with the eYFP contained in the 
pCI vector vs the pcDNA3.1(+) vector. N=24 in a 96 well 
format. 
Figure 138. Agarose gel of the eYFP-GABAAR α1 
construct. Left column is Bullseye 1Kb DNA Ladder, 
middle is the EcoRI digest of the eYFP-GABAAR α1 




(Figure 138), and ligation led to the creation of the pCI-eYFP plasmid with excised α1 gene. The 
difference between fluorescense signals is seen in Figure 137. 
As a result of these changes, the GABA dose response at low concentration of agonist was 
close to baseline with negligible quench instead of the 10% quench observed previously published 
by Johansson et al. 290, Figure 139. It should be noted that the GABA dose response curves can be 
performed with only two exchanges with buffer and the recording is immediate. In contrast, the 
testing of modulators required long incubation times in 1% DMSO and three exchanges with 
varying buffer solutions. For example, the first exchange is to get a reading with only buffer, the 
second exchange is the incubation of modulator, finally the third exchange is the a mixture of 
modulator with GABA. In addition to the liquid exchanges, it should be considered that the plate 
is read four times: after the first exchange, after the second exchange, after the incubation with the 
second exchange, and finally after the third exchange. This can alter the calculated change in 
fluorescence signal to above the baseline due to loss of cells. 















Figure 139. Cells containing the eYFP and the α1β3γ2 subtype 




The first modulator tested was the negative modulator bicuculline, Figure 140. Transfected 
cells were preincubated for fifteen minutes prior to activation with GABA in NaI buffer. Plotting 
the change in fluoresence, the cells appeared to exhibit a dramatic edge effect as every seven points 
represent a column on the plate since the serial dilution ran top to bottom. To combat this, liquid 
was added into the spaces between the plate wells. It was also estimated that the highest 
concentration range of bicuculline, from 1 µM to 1 mM, was necessary to exhibit complete quench 
of the fluorophore as exhibited by the bottom of the dose response curve. The quench at this range 
were investigated further and exhibted a clear inhibition of the GABAAR, Figure 142. It should be 
noted that the total quench was around 10%, half of what was observed with the agonist.  
Tests with the strong positive modulator diazepam exhibited very little if any observable 
trend in quench from the range of nanomolar to millimolar concentrations, Figure 141. Initial 










Figure 140. Cells transfected with the eYFP and GABAAR α1 subtype 
exposed to an increasing concentration of Bicuculline. Cells were in a 
96 well plate and serial diluted from top to bottom with the first row 
devoted to DMSO control.  
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experiments using diazepam appeared to exhibit a slight trend but had been performed without 



























Figure 142. Cells containing the eYFP and the α1β3γ2 subtype. The quench is 
lowered as the bicuculline inhibits the influx o f chloride ions to quench the 
fluorophore. N=3. 



























Figure 141. Cells transfected with the α1 and eYFP were pre incubated with 
Diazepam 15 minutes prior to addition of 0.1µM GABA in NaI buffer.  
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preincubation with the compound. To test whether this modification caused an effect, the 
experiment was repeated with the same large range in concentrations, Figure 143. This plot 
exhibited a general trend upwards but an overall change in quench of 3%. Though this again does 
























Figure 143. Cells transfected with the α1 and eYFP were exposed to a 
mixture of serially diluted Diazepam with 0.1µM GABA in NaI buffer and 





























Figure 144. Comparison of quench between the DMSO 
control and 1mM of Diazepam. Statically significant or non -
significant at p<0.05 
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1mM Diazepam vs DMSO after the addition of an EC20 concentration of 0.1µM GABA showed 
statistical significance with 95% confidence, when averaging across 7 occasions, Figure 144.  
5.3.4 CONCLUSIONS  
Previous study of diazepam in CHO-K1 cells were performed with a constant amount of 
diazepam and an increasing amount of GABA 290. Though it was initially unclear why investigators 
chose this atypical arrangement, observations of the inability of positive modulator and constant 
GABA to sufficiently cause dose-response quench appears to be the likely reason. However, this 
assay could be optimized further by the creation of fusion proteins. A prime location to test would 
be the intracellular loop located between the TM3 and TM4 of the subunits. Though functional 
testing to determine if the correct folding of the subunit protein would be critical as the assembly 
of the pentameric receptor may be compromised as well as the agonist and modulator binding sites. 
Incorporation of a luminescent protein may result in further sensitivity and might allow for BRET 
signal capture. However, the same complications as seen with a fluorescent fusion protein might 
occur with a luminescent fusion protein. The steric hindrance caused by two fluorophores attached 
to the two alpha subunits as well as the bioluminescent protein attached to the gamma subunit may 
prevent assembly and function of the receptor. 
Though there are limitations, the eYFP assay would be well-suited to screening initial hits 
for BZD compounds with significant modulatory effect. However, the insensitivity of the assay 
would suggest that it cannot reliably produce an EC50. In the work previously published, 
researchers observed no shift for weak modulators and could not distinguish strong modulators 
such as diazepam and lorazepam from each other. However, as an initial screening tool, the eYFP 
assay is a fast and inexpensive method that does not necessitate dye loading, commercial kits, or 
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expensive reagents; it has the potential to be used in the high-throughput identification of novel 
modulators of the GABAAR. In addition, certain challenges such as low assay reproducibility, also 
noted in studies with the CHO-K1 cells 290, can be overcome by use of the stable recombinant cell 
lines previously generated. 
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CHAPTER 6: IMMUNOLOGICAL ROLE OF GABAA RECEPTOR ON T-
LYMPHOCYTES  
6.1 Introduction 
An effective immune response is a crucial part of organism survival and discrete 
inflammatory response to localized areas can prevent most pathogenic invasions from spreading. 
The magnitude of the response must be well-balanced: too little and the immunodeficiency can 
cause infection and cancer, too much and morbidity and diseases such as rheumatoid arthritis, 
Crohn’s, atherosclerosis, diabetes, Alzheimer’s, MS, cerebral and myocardial ischemia can 
develop 292. If the inflammation happens to leak over to the bloodstream: sepsis, meningitis, and 
severe trauma can result and can be more dangerous than the initial stimulus 293,294.  
The immune system is known to employ ion channels in T lymphocytes and mast cells to 
mediate the cellular response against foreign pathogens. Some of the ion channels expressed are 
calcium release-activated calcium (CRAC) channels, P2X receptors, transient receptor potential 
(TRP) channels, potassium channels, chloride channels, and magnesium and zinc transporters. 
Among the expressed chloride channels are volume-regulated Cl- channels (Clswell) which open 
when the T cells swell in hypotonic environment to allow the efflux of both chloride and water to 
return to a normal cell volume 295,296. The cystic fibrosis transmembrane conductance regulator 
(CFTR) is an ATP-gated anion channel which opens and closes to allow the flow of chloride anions 
down their electrochemical gradient 297. Lastly, the GABAAR has been found to express in human, 
mouse and rat T cells 298.  
It was long believed that GABAAR would not have any activity outside the CNS since they 
would require millimolar concentrations of the neurotransmitter, unachievable without 
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concentrated synaptic release 299. However it has since become clear that extrasynaptic channels 
assemblies can be saturated by nano to micromolar concentrations 300. It may be that the majority 
of the GABAA receptors on the white blood cells are those of the extrasynaptic variety as there is 
little evidence for the large concentrations of GABA needed to achieve activation of synaptic 
channels within in the immune system. The GABA blood plasma levels in healthy individuals is 
around 100nM 301 with 99% of total body GABA and 95% of its synthesizing enzyme GAD being 
located in the brain and spinal cord 302. Metabolism of the peripheral GABA takes place by GA 
BA-T in the liver, which reaches activity almost as high as in the brain 303; platelets also  actively 
uptake GABA and have GABA-T activity but their role in peripheral GABA homeostatis appears 
to be minor 304,305. In addition, GABA does not readily cross the BBB 306. The GABA concentration 
normally detected in the blood of healthy individuals is 100 nM. The reason for the presence of 
GABA in the blood is not well understood since the molecule does not penetrate the blood-brain 
barrier and thus would be unable to access the CNS. The finding that immune cells produce and 
secrete GABA would thus explain the concentration in plasma. Interestingly, the plasma GABA 
levels can be an index of brain GABA activity and a low concentration can be a biomarker for a 
psychiatric or mood disorder such as depression 307, suicide 308, bipolarism 309, PTSD 310, and 
schizophrenia 311 as well as anxiety 312-314.  
The components of the GABA signalling network have been found to be present in the 
immune system. For example, GAD exists in two isoforms: GAD 67 and GAD 65, the numbers 
refering to the molecular mass of the enzyme. GAD 67 which is localized in the neuronal body 
and GAD 65 which is primarily in nerve terminals 315. This localization suggests that GAD 65 
plays an important role in synaptic neurotransmission and GAD 67 regulates GABA synthesis 316. 
GAD 65 is present in dendritic cells and macrophages 317 of mice while GAD 67 has been detected 
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in human peripheral monocytes 318. Intact GAD 65 and GAD 67 are also present in neutrophil 
granulocytes which may indicate that neurotphils can also produce GABA 319. In addition, GABA 
secretion has been detected from mouse macrophages and T cells 317,320 as well as the extract from 
human peripheral blood macrophages 321. Stimulation of macrophages and dendritic cells with 
lipopolysaccharide increased GAD 65 while the amount of secreted GABA. Stimulation of CD4+ 
with anti-CD3 and anti-CD28 antibodies also had no effect on the GABA concentration in the 
medium. GABA-T has also been detected in macrophages, CD4+ T cells, and peripheral human 
monocytes 317,318. Stimulation increased the expression of GABA-T in T cells but did not ater 
expression in macrophages 317. Finally, the transporter that transports GABA into synaptic 
vesicles, vesicular inhibitory amino acid transporter (VIAAT) was found to be expressed in 
peripheral human monocytes 318. So it would appear that the cells of the immune system are able 
to both synthesize and release the neurotranmitter GABA. Given that the necessary components 
of GABA signalling are expressed in immune cells, it could be possible that GABA plays either 
an autocrine or paracrine signalling role in immune cells. Evidence for this signalling role is 
mounting. GABA application results in decreased cytokine secretion and T cell proliferation 322-
324 as well as decreased the transient increase in intracellular calcium concentration that is 
associated with activation of the cells 325.  
The discovery of GABAAR, though recent, is not particularly surprising. T-cells express a 
variety of neurotransmitter receptors that appear to be upregulated and downregulated in some 
diseases. The state of the T-cell (naïve, activated, CD4/CD8/Th1/Th2/Teff/Treg) appears to be a 
deciding factor in whether the neurotransmitter will activate or suppress the cell. Macrophages 
also have a number of neurotransmitter receptors such as the nicotinic cholinergic receptor 326. 
Vagal stimulation results in the release of acetylcholine which inhibits the production of pro-
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inflammatory cytokines by macrophages. Macrophages and neutrophils can also produce 
adrenaline and noradrenaline when incubated with lipopolysaccharide 327. Elevated plasma 
norepinephrine and epinephrine can effect lymphocyte and monocyte function 328. It would appear 
that T-cells also inherently produce many of the neurotransmitters. This suggests that 
neurotransmitters play an important role in T-cell function and may even serve as the intermediary 
for communicating between the brain and the immune system.  
T-cells producing acetylcholine have also been observed and appear to inhibit cytokine 
production by vagus nerve stimulation 329. CD4+ T cells produce very high quantities of 
acetylcholine when compared to CD8+ T cells or B bells and mitogens stimulates the cells to 
produce and secrete even more of the neurotransmitter 330. The excitatory neurotransmitter 
glutamate, for example, is Glutamate receptor is found, in order of lowest to highest quantities, on 
human peripheral T-cells, human T helper clone, and human T leukemia cell line. However, though 
they are present in the naïve cells, upon activation, the cells release granzyme B which cleaves the 
receptor from their surface. The receptor is completely eliminated from the surface of the cell for 
~48 hours; after which, normal levels are restored 331. This cleavage mechanism also operates in 
neurons 332. In addition, it was found that the animal model for multiple sclerosis had high levels 
of expression for the glutamate receptor GluR3 331 and that human MS patients have an 
upregulation of GluR3 expression during relapse 333. This is reviewed by Ganor 334. 
Dopamine has direct effects on immune cells and is also endogenously produced by T cells. 
The case of dopamine receptor expression on T-cells is particularly interesting. Dopamine 
receptors have five different seven-transmembrane G-protein-coupled receptors named D1-D5. 
The receptors D2-D5 have been found to express in T-cells and appear to be responsible for 
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specific roles such as triggering adhesion to fibronectin, which was found to be mediated 
specifically by D3R and D2R 335. In addition, it has been found that dopamine induces specific 
cytokine secretion. D3R triggered secretion of TNFα, D2R of IL-10, and D1/D5R triggered both 
cytokines 336. An abnormal expression or response of dopamine-receptors on T-cells has been 
observed in in schizophrenia 337-339, Parkinson’s 340,341, Alzheimer’s 342, Migraine 343, HIV 344,345, 
MS 346-351, inflammatory bowel disease (IBD) 352-354, Rheumatoid arthritis 355-358, systematic lupus 
erythematosus 359,360. A thorough review has been published 361 on the subject.  
It is still unknown what the exact function these CNS receptors play in the T cells. GABA 
administration inhibited T cell proliferation and induced the production of IL-2 and IFNγ. In 
addition, in vivo, GABA or GABAergic agents ameliorated disease outcome in several 
autoimmune animal models such as type 1 diabetes 322, rheumatoid arthritis 362, and multiple 
sclerosis 317. Functional GABAAR act as inhibiters of antigen-specific T cell proliferation 
299 and 
inhibits the production of interleukin (IL)-6, IL-12, inducible nitric oxide (iNOS), IL-1β, and tumor 
necrosis factor (TNF)-α 363,364. Interestingly, GABAAR agonists in rodent models have been 
observed to accelerate cutaneous recovery and prevent epidermal hyperplasia in wounds 365 and 
suppress wound-induced cutaneous inflammation 363. This would perhaps suggest that the 
biological role of the receptor expression on the T cell is to inhibit the activation of the T cells 
when a GABA-secreting cell is encountered. However, the mechanisms by which expression of 
the receptors is controlled as well as the production or release levels has yet to be determined. 
It has also been found that specific subsets of the GABAAR have been identified in the 
human airway smooth muscle cells and the guinea pig tracheal smooth muscle model. The mRNA 
for α4, α5, β3, π, θ, and γ1-3 were found and immunoblots confirmed α4, α5, β3, and γ2. In 
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addition, the selective GABAA receptor agonist muscimol was able to relax a histamine induced 
contraction and appeared to facilitate relaxation in the airway, suggesting that this route may 
present novel therapeutic target for airway smooth muscle relaxation 366. Further work has been 
performed to show that the both α4 and α5 selective imidazobenzodiazepines promote airway 
smooth muscle relaxation and affects cellular calcium 367,368. 
TSPO, a protein localized primarily in the outer mitochondrial membrane, is present in 
multiple tissues and organs besides in the CNS, unlike the GABAAR, and its primary role is to 
import cholesterol through the outer mitochondrial membrane to be made into neurosteroids as 
THDOC or allopregnanolone. These neurosteroids are known to enhance GABAAR function 
369. 
TSPO may also play a role in the observed electrophysiological response; forming a complex with 
voltage-dependent anion channel (VDAC) and the adenine nucleotide transporter (ANT) 370. 
Though TSPO was originally termed a mitochondrial receptor, it was discovered that more than 
50% of the TSPO receptors were not associated with mitochondria and antibody studies have 
found that expression is found on the plasma membrane as well as the mitochondria 371,372. The 
association of these complexes forms a maxi-choride channel which has been successfully patch-
clamped for electrophysiological study 373. 
6.2 Electrophysiological Studies 
6.2.1 INTRODUCTION 
 Circa 450 BC, Hippocrates observed a respiratory illness common in anglers, tailors and 
metalworkers. The illness was characterized by laborious breathing or ἅσθμα (aazein) in ancient 
greek. The earliest treatment prescribed was owl’s blood in wine 374. Asthma is estimated to effect 
315 million persons globally 375 and is expected to increase to 400 million by 2025 376. It has been 
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extimated that 1 in every 250 deaths worldwide is due to asthma, resulting in 250,000 deaths each 
year worldwide 376 with nearly 25 million in the U.S. alone. In 2007, the health care cost burden 
to the US economy was estimated at $56 billion. With the increasing prevalence of obesity, a 
contributor to asthma severity, this number is only expected to rise. Although the morbidity is low, 
hospitalization and health care costs run upwards to $20 billion annually. Asthma is characterized 
by chronic and intermittent attacks of breathlessness, wheezing, and cough. This disease often 
presents in childhood but one in four may continue or have a recurrence of symptoms well into 
adulthood 377. 
The causes of asthma have yet to be fully understood but it appears to be a complex 
combination of environmental and genetic factors 377. Family and twin studies have suggested that 
the genetic contributions approach 60% but genome-wide analysis suggests that there is very small 
involvement from a great number of loci and no single gene has been identified with any degree 
of certainty 378,379. Air quality and endotoxin exposure have been linked to asthma development 
and symptom severity 380,381. Epidemiological studies have found that a severe viral upper 
respiratory infection occurring early in life can increase risk of developing the asthmatic 
phenotype, particularly if their families have a history of atopy 382,383. The inability to find a 
singular gene responsible for the phenotype, combined with the heterogeneity in response to 
commercial therapeutics, may be indicative that distinct subtypes of the disease exist. There 
already exists evidence of this distinction with allergic and non-allergic asthma, also called atopic 
vs non-atopic, based on the presence or absence of allergen-specific antibodies, assessed by skin 
prick serological tests 383,384 . Whether atopic and nonatopic asthma are two distinct entities is 
unknown as the mechanism of pathogenesis is still not clear. However, both forms of asthma 
exhibit the presence of bronchial mucosal infiltrate with eosinophils and elevated expression of 
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eosinophil active chemokines and cytokines, indicating local T-cell activation. There are subtle 
differences between the two forms at the mucosal and submucosal levels, however the similarities 
seem to outweigh the differences 385. The hallmark symptom of asthma is airway hyper-
responsiveness 386 as well as the presence of chronic inflammation in the lower airways which 
prevents continuous airflow, resulting in episodes of coughing, wheezing, breathlessness, and 
chest tightness 387.  
Chronic inflammation of the airway is the major marker of asthma and is caused in large 
part by Th2 cells, their cytokines, and eosinophils. Many animal models attempt to recreate these 
major symptoms 388. Il-17 associated neutrophilic airway inflammation and pauci-granulocytic 
subtypes have also been studied and appear to play some role in adult-onset cases of asthma 389. 
Frequent exposure and inhalation of allergens can cause a persistent inflammation; resulting in 
structural changes to the airway. These changes, collectively known as “airway remodeling” 
include increase in subepithelial matrix glycoproteins, smooth muscle hypertrophy, and epithelial 
mucus metaplasia. Airway remodeling is believed to be the major cause for poor airflow and 
airway hyper-responsiveness 390. 
The classic model of asthma links the disease to reaginic immune globulin (IgE). These 
IgE antibodies bind to mast cells in the airway mucosa which causes a release of mediators stored 
in cell granules and begins a cascade of mediator synthesis and release. Acute bronchoconstriction 
involves the production of histamine, mast cell activating tryptase, inflammatory leukotrienes C4 
and D4 which all accumulate to produce the “early asthmatic response”. The “late asthmatic 
response”, characterized by second sustained period of bronchial constriction caused by an influx 
of inflammatory cells in the bronchial mucosa which sensitizes bronchial reactivity for weeks after 
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the exposure to the allergen. Late phase response is believed to be a result of the cytokine 
population composed of IL-5, 9, and 13 produced by Th2 lymphocytes.  Production of the IgE 
antibodies is genetically influenced 391. 
Examination of Figure 145 from 392 illustrates the differentiation pattern of CD4 cells.  T 
lymphocyte cells are a mixture of CD4+, CD4-/CD8-, CD8+, and CD4+/CD8+ cells 393 which, under 
normal growth conditions, produces little to no IL-2. Phorbol 12-myristate 13-acetate (PMA) is 
often used to activate protein kinase C and stimulate low-level production of IL-2. 
Phytohemagglutinin (PHA) can also be used and triggers low level T-cell activation and IL-2 
production by binding to the cell surface receptor complex. The combination of PMA and PHA 
results in a strong enhancement in IL-2 production 394. This technique is often used to stimulate T 
cell activation of cells in culture. The strong IL-2 production indicates that the cells are 
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differentiated into Th1 cells. Th1 cells produce IFN-γ, tumor necrosis factor-beta (TNF-β) and 
interleukin-10 (IL-10); mediating immune response against tumor cells, intracellular viruses and 
bacteria through the activation of macrophages and cytotoxic T-cells. Secretion of IL-4 induces 
naïve CD4+ cells to become Th2, leading to the expression of transcription factor GATA3. The 
cascading production eventually leads to IL-4, IL-5, IL-13, IL-21, and IL-31 which also contribute 
to the pathogenesis of asthma and allergy 395-397. Thus a more in-depth study of Th2 cells may be 
useful in the future. Th17 cells develop in response to IL-6, IL-23, and TGF-β. IL-6 and IL-23 
then activate STAT3, increasing the expression of transcription factors RORγt and RORγ which 
promotes expression of IL-17A, IL-17F, IL-21, and IL-22. There has been evidence found that 
Figure 145. General scheme of T-helper cell differentiation. Naive T cells are activated and can 
differentiate into four effector T-helper cells: Th1, Th2, Th3, or Th17. These cells produce different 
cytokines for specialized immune function. Th-1 cells produces IFN-γ which regulates antigen 
presentation and cellular immunity. Th2 cells produce IL-4, IL-5, and IL-13 to regulate B-cell 
responses, important mediator of allergic diseases. Th3 cells produce TGF -β and IL-10 to regulate 
Th1 and Th2 cells. Th17 regulates inflammatory response by expressing IL -17, IL-21, IL-22, and IL-
26. Open Access cited in text and used with permission.  
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Th17 cells plays an essential role for host defense against invasion by extracellular bacteria 398 and 
in mediating memory CD4+ cells involved in autoimmune disease 399. Th17 cells have also been 
connected to allergic inflammation, mediating the activation of inflammatory cells in the airways, 
so common in asthma pathogenesis 400,401. Interestingly, IL-17 has been detected in the 
cerebrospinal fluid of patients with multiple sclerosis 402. It has been observed that when the 
presence of Th17 outnumbers Th1 in the brain, or drops below a certain threshold in the spinal 
cord, the result is inflammation 403. The recruitment of monocytes and macrophages to the 
inflammatory sites then leads to myelin and axonal damage 404,405. The suggestion is that IL-17 
and its producer Th17 cells, are an important regulator of CNS autoimmunity.  
 
Because the exact biochemical mechanism of asthma development has yet to be fully 
understood, finding an accurate animal model is difficult. In general, mice do not naturally develop 
asthma however it is possible to induce the symptoms using ovalbumin (OVA). OVA derived from 
chicken egg is commonly used to induce an allergic pulmonary inflammation in rodents. Though 
this produces robust results, OVA is not implicated in human asthma so there has been work in 
sensitizing mice to house dust mite (HDM) and cockroach extract 406,407.  
Acute sensitization requires exposure to the allergen with an adjuvant. The most commonly 
used adjuvant is AlOH3 or alum which promotes the Th2 phenotype in the immune system 
408. 
This model reproduces the elevated levels of IgE, airway inflammation, goblet cell hyperplasia, 
epithelial hypertrophy, airway hyper-responsiveness and some bronchio-constriction to allergen 
challenge. However, the chronic inflammation of the airway wall with persistent AHR and 
remodeling changes do not occur due to the short-lived nature of the acute model. Another problem 
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with the acute model is that some drugs have shown efficacy in acute challenge but fail to exhibit 
anything in the clinical studies such as VLA4 antagonists 409, PAF antagonists 410 and IL-4 
antagonists 411,412.  
The chronic allergen challenge model attempts to reproduce the airway remodeling and 
persistent AHR features of asthma. This model requires repeated exposure of low levels of allergen 
for up to 12 weeks and adjuvant is not always required. Long-term challenge often leads to 
development of tolerance and lowered inflammation and AHR 413. However, there are still some 
characteristics that this model lacks. Chronic asthma typically results in significant increases in 
airway smooth muscle 414 and a lack of mast cells in the airway 415 which does not occur in the 
mouse model. However, it is most likely that invention of a mouse model that completely reflects 
the complex disease is impossible and cannot be achieved in a single model.  
 There is no cure for asthma but treatment is divided into two groups: short-term relievers 
for acute bronchoconstriction relief and long-term controllers to reduce symptoms and prevent an 
attack. Short-term relief agents, such as β-adrenoceptor stimulants, relax airway smooth muscle. 
Theophylline and anti-muscarinic agents can also reduce acute airway constriction. Long-term 
controllers such as inhaled corticosteroid, can reduce inflammation. Corticosteroids can have 
profound immunosuppressive effects on the lymphoreticular system, inhibiting the trafficking 
patterns and effector functions of lymphocytes and macrophages 416,417. There are also alternative 
targeting approaches such as the leukotriene pathway antagonists or inhibitors of mast cell 
degranulation 418.  
Currently, treatment guidelines recommend the usage of inhaled corticosteroids for long-
term control of persistent asthma in combination with long-acting β2 adrenergic agonists 419. 
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Inhaled steroids help prevent asthma symptoms but do not relieve them during an attack and can 
take up to 3 months of daily use to reach the best results. Larger doses of steroids may affect 
hypothalamic-pituitary-adrenal function and bone turnover and long-term use can result in serious 
systemic adverse effects such as suppressed adrenal function, bone loss, skin thinning, growth 
impairment, and cataract formation 420,421. In addition, unbiased cluster analysis indicates that 5-
10% of asthmatics fall into the category of relative glucocorticoid insensitivity 422. This reduced 
responsiveness to the effects of corticosteroids is a major barrier to the management of asthma in 
smokers, severe asthmatics, and those with chronic obstructive pulmonary disease (COPD) 423. 
Bronchodilators are used as a quick relief rescue treatment for asthma however they are associated 
with side effects such as nervousness, increased heart rate, upset stomach, trouble sleeping, and 
muscle aches 420,424,425.  
 Taking these shortcomings into account, the need for alternative treatments exists despite 
the availability of current drug options. Targeting the GABAAR could, in theory, work dually to 
relax airway smooth muscle while also suppressing inflammatory cells. The expression of which 
has been observed on both routes. 
6.2.2 EXPERIMENTAL 
Cell Culture 
Jurkat, Clone E6-1 cells (ATCC, TIB-152) which are a T lymphocyte from a 14 year old 
boy with acute T cell leukemia were used for the studies. Cells were grown in suspension with 
RPMI-1640 Medium (ATCC, 30-2001) with 10% heat-inactivated FBS (BioWest SO1520HI), 
non-essential amino acids (Hyclone, SH30238.01), 10 mM HEPES (Hyclone, SH302237.01), and 
5 x 106 units of penicillin and streptomycin (Hyclone, SV30010) in 75 cm2 flasks (CellStar).  
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To activate the cells, 1µg/mL of phytohemagglutinin (PHA) (Sigma, L2646) and 50ng/mL 
phorbol 12-myristate 13-acetate (PMA) (Sigma, P8139) were added to the cell suspension and 
incubated for 24 hours at 37°C at 5% CO2.  
Automated Patch-Clamp Electrophysiology 
The buffers were made from NaCl (Fisher, BP358-1), KCl (Fisher, BP366-1), MgCl2 
(Sigma, M8266), CaCl2 (Acros Org, 123350025), Glucose (Sigma, G0350500), HEPES (Fisher, 
BP410-500), CsCl (Sigma, 203025), and EGTA (Tocris, 28-071-G). The intracellular solution 
contains 140mM CsCl, 1mM CaCl2, 1mM MgCl2, 11mM EGTA, 10mM HEPES, and pH 7.2 with 
CsOH. The extracellular solution contains 140mM NaCl, 5.4mM KCl, 1mM CaCl2, 10mM D-
glucose monohydrate, 10mM HEPES, and pH 7.4 with NaOH. Compounds were diluted to 10mM 
in DMSO.  
To record GABAA currents, cell arrays were voltage clamped at a hyperpolarizing holding 
potential of -80mV. Cells were centrifuged at 380g for 2 min and gently resuspended in ECS. This 
was repeated two more times before the cells were dispensed into the plate.  
Rotarod Studies 
 BALB/c mice were trained to maintain balance at a constant speed of 15 rpm on the rotarod 
instrument (Omnitech Electronics Inc) until mice were able to perform for 3 min at three 
consecutive time points. Three groups of mice containing eight mice each were divided into a 
vehicle group (10% DMSO, 40% propylene glycol, and 50% PBS), diazepam group, and test 
group. The volume of the injection was 100 µL. Ten minutes after the injection, peak time 
determined by pharmacokinetic data, mice were placed onto the rotarod for 3 min. A fail was 
assigned for each mouse that fell from the rotarod prior to 3 min. Mice were rested 2-3 days before 
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administration of another dose or a different compound. At 40mg/kg of XHE-III-74 Ethyl Ester, 
the i.p. injection volume was doubled (200 µL) due to solubility.  
qRT-PCR Protocol 
Cells were harvested once 80% confluent using 0.05% Trypsin or Detachin solution and 
pelleted by centrifuging at 1000rpm for 2 minutes. Media was aspirated and the cell pellet was 
resuspended in RLT buffer. The mixture was pipetted into the QIAshredder spin column and spun 
for 2 minutes at max rpm. One volume of 70% ethanol was added to the homogenized lysate and 
mixed well by pipetting. The solution was then transferred to an RNAeasy spin column and spun 
down for 15 sec at 10,000rpm. Then washed with buffers to purify the bound RNA with the flow 
through discarded. After the column is washed and dried, RNA is eluted by addition of 30-50 µL 
of RNase-free water. Total RNA concentration was determined by UV at 260nm and protein 
contamination was assessed at 280 nm. The RNA was then diluted and used for qRT-PCR with 
the QuantiFast SYBR Green RT-PCR Kit (Qiagen). The cycling conditions used was 10 min at 
50°C (reverse transcriptase), 5 minutes at 95°C (PCR initial activation step), 10 sec at 95°C 
(denaturation), and 30 sec at 55°C (annealing and extension) for a total of 50 cycles. Data was 
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taken in triplicate and the relative mRNA expression levels were calculated using wells containing 
no template and normalizing to housekeeping gene GAPDH. Primer sets used are listed in Table 
15 and Table 14. 
Cell metabolite extraction 
 
Table 15. Human primers list for quantitative real -time RT-PCR of immune cells. 
Table 14. Mouse primers list for quantitative real -time RT-PCR of immune cells. 
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 An excess of Jurkat E6-1 cells, 5mL of 5x106 cells/mL, were centrifuged at 380 x g at room 
temperature. The media was aspirated and the cells were washed with 5mL of PBS (Hyclone, 
SH30256.01), centrifuged at 380 x g, and the buffer aspirated. This was repeated two more times 
to ensure that residual metabolites from the media did not contaminate the extract.  
A three-phase methanol/chloroform/water extraction 426 was performed on the sample. 
Methanol/chloroform/water was added at a volume ratio of (6:6:5.4) at a total volume of 17.4 mL. 
The solution was vortex for 3 minutes and centrifuged at 10,000 x g for 10 minutes. This separates 
the mixture into three distinct phases: the upper aqueous layer contains water-soluble low-
molecular weight endogenous metabolites while the non-polar metabolites such as lipid molecules 
were found in the bottom organic phase. Biological macromolecules and proteins were precipitated 
and trapped in the solvent layer between the aqueous and organic phases. Only the upper aqueous 
phase was kept. The sample was transferred to a rotary vacuum evaporator until nearly dry and 
then moved to dry under a gentle flow of N2 gas. The sample can then be stored at -80°C until 
analysis. 
Splenocyte isolation 
 Male Balb/c mice were sensitized three times with i.p. injections of 2mg/kg/d ovalbumin 
(Ova) (Sigma) emulsified in 2 mg of Alum (Thermo Sci) on days 0, 7, and 14 in a total volume of 
100 µL. Mice were then challenge intranasally (i.n.) with 1mg/kg/d Ova for 5 days from days 23-
27. Control mice were sensitized with Ova and challenged with saline. Mice were euthanized with 
a cocktail of ketamine (300mg/kg) and xylazine (30mg/kg) (Sigma) by i.p. injection at 100 µL. 
The spleen was extracted and two frosted-end glass slides were sterilized with ethanol before 
homogenizing the spleen between the frosted ends of the slides. A single cell suspension was 
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pelleted at 360g by centrifugation and the supernatant was aspirated. The pellet was resuspended 
in 5mL/spleen of 1X Lysis Buffer (Thermo Fisher, 420301). The mixture was incubated at room 
temperature for 5 minutes. The reaction was stopped by diluting the Lysis buffer with 30mL of 1X 
PBS (Hyclone, SH30256.01). Cells were centrifuged at 360g, the supernatant removed, and the 
pellet resuspended in DMEM (Hyclone, SH3024301) containing 50mL of fetal bovine serum 
(Biowest, SO1520HI) and 5mL of 100X penicillin/streptomycin (Hyclone, SV30010). 
 Cells were challenged in culture, ex vivo, with Ova at 10µg/mL with 2 x 106 cells per mL 
overnight at 37°C at 5% CO2.  
Whole Blood Fractionation 
 The author’s blood was drawn by the Norris Health Center with the help of Clinical 
Services Director Dr. Aamir Siddiqi and lab supervisor Terry Karl. Whole blood, 5mL, was 
collected in an EDTA vacutainer (Fisher Sci, 368589). The sample was centrifuged at 1500 x g for 
15 minutes at room temperature. This separates the blood into two layers: the upper yellow plasma 
layer and the lower red blood cell layer. At the interface of these two layers is a thin film of white 
blood cells known as the buffy coat. The plasma was layer was aspirated down to ~1mm from the 
red blood cell layer. Using a circular motion, the buffy coat was carefully aspirated into a tube. 
5mL of 1X Lysis Buffer (Thermo Fisher, 420301) was added and the mixture was incubated at 
room temperature for 5 minutes. The reaction was stopped by diluting the Lysis buffer with 30mL 
of 1X PBS (Hyclone, SH30256.01). Cells were centrifuged at 360g, the supernatant removed, and 
the pellet was conserved for mRNA extraction. Taking into account the probable activity of the 
intracellular RNases that would be released in the lysis step, 1% of β-mercaptoethanol (β-ME) was 
added during the resuspension of the pellet with RLT buffer. The reducing agent irreversibly 
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denatures RNases by reducing disulfide bonds and disrupts the native confirmation of the enzyme. 
Though the RLT buffer contains guanidinium isothiocyanate which is a strong but temporary 
denaturant, addition of β-ME ensures that a majority of RNases are inactivated 427.  
6.2.3 RESULTS AND DISCUSSION 
Use of the Jurkat E6-1 cells on the automated patch clamp IonFlux was first established. 
Cells were harvested from suspension and the extracellular and intracellular solutions were 
prepared. The electrophysiological response of the cells to the agonist GABA from the first 
experiment can be seen in Figure 146. The imidazobenzodiazepine HZ-166 was also used in 
GABA GABA GABA GABA GABA
-500 pA
3 sec






























combination with an EC20 concentration of GABA to determine if positive modulation with these 
compounds was possible, Figure 147. The results suggested that the subset of receptors present on 
the Jurkat E6-1 T lymphocytes were responsive to both the agonist GABA as well as the BZD 
positive modulator HZ-166. This would also indicate that the receptors contain a gamma2 subunit 
as this confers benzodiazepine sensitivity.  
High quantities of the α4 were found in immunoblot using human airway smooth muscle 























































Figure 147. Jurkat E6-1 cells exposed to increasing concentrations of HZ-166 in 
combination with a constant concentration of GABA EC 20 or 0.1µM. HZ-166 was 
solubilized in 0.3% max DMSO. N=4  
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α4/6 subunit selectivity were synthesized using iterative computational analyses. These 
compounds, CMD-45 and XHE-III-74, were observed to have higher induction of currents in frog 
oocytes expressing the α4/6 containing receptors 231. It was also observed that pretreatment with 
these compounds inhibted histamine-induced increases in intracellular calcium concentrations 























































Figure 148. Jurkat E6-1 cells exposed to increasing concentrations of XHE-III-74 in 
combination with a constant concentration of GABA EC 20 or 0.1µM. XHE-III-74 was 
solubilized in 0.3% max DMSO. N=4  
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These α4/6 selective compounds primarily differ in the lack of a pendant phenyl. The results of 
the XHE-III-74 and CMD-45 application on Jurkat cells can be seen in Figure 148 and Figure 149. 
These results would imply that these drugs have a dual effect: 1) the airway smooth muscle 
relaxation and 2) the chloride influx and resulting inhibition of T cell function.  
XHE-III-74 Etyl ester (XHE-III-74EE or L-655,708) and its metabolite XHE-III-74 Acid 
(XHE-III-74A) was found by a collaborator to display subtype selectivity specifically for the α4 
and α5 subtype. To determine if the compounds had CNS effects due to penetration of the BBB, 
rotarod studies were performed. The rotarod test is a performance test that measures motor 























































Figure 149. Jurkat E6-1 cells exposed to increasing 
concentrations of CMD-45in combination with a constant 
concentration of GABA EC20 or 0.1µM. CMD-45 was 
solubilized in 0.3% max DMSO. N=4  
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may cause impairments 429. Compounds were delivered via i.p. injection to Male Balb/c mice, the 
results are as seen in Figure 150. Impairment was evaluated after 10 min by the ability to stay on 
a rotating rod moving at 15 rpm. Diazepam, the nonselective positive modulator, caused significant 
motor impairment as low as 5mg/kg while both XHE-III-74EE and XHE-III-74A exhibited no 
effect at these concentration. The XHE-III-74 did cause significant impairment at dosages of 
40mg/kg but the XHE-III-74A was devoid of impairing effects, consistent with its inability to 
penetrate the BBB.  
The electrophysiological effect of these compounds were evaluated using Jurkat E6-1 cells 
which were in the 30th passage (3 months in culture). Previously, experiments had been performed 
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with cells prior to their 10th passage (1 month in culture). Interestingly, the GABA dose response 
curve for the high passage cells had shifted considerably downward, Figure 151. This experiment 





















































































































































Figure 150. Effect of XHE-III-74EE and XHE-III-74A on sensorimotor 
coordination. BALB/c mice received a single i.p. injection and were tested 10 
min after application. The % success rate is expressed as mean ± SEM, N=8. 
Significance calculated by p < 0.05 compared to veh icle-treated mice. 
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The passage number, that is the degree of subculturing a cell line has undergone or literally 
the number of times cells have been transferred from vessel-to-vessel, has been shown to have an 
affect on the cell line’s characteristics over time 430-434. These effects often emerge in changes in 
morphology, response to stimuli, growth rates, and protein expression. 
Figure 151. Dose response curves for Jurkat E6-1 cells in passage 30. A) Cells were exposed to increasing 
concentrations of GABA diluted in ECS buffer, N=4, B) cells exposed to increasing concentrations of 
XHE-III-74A in combination with a constant concentration of GABA EC 20 or 1µM. Compound was 
solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of XHE -III-74EE in 
combination with a constant concentration of GABA EC 20 or 1µM. Compound was solubilized in 1% max 
DMSO, N=6  
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The change in the dose response curve for GABA can be contributed to this passage 
number-related effects. There is no straightforward method to determine how many passages are 
too many with papers reporting ranges from passage 18 to 40 for mouse insulinoma cells 435 (MIN-
6) or passage 25 to 60 for prostate cancer cell line 436 (LNCaP).  
Figure 152. Recapitulation of dose response curves for Jurkat E6-1 cells in passage 30. A) Cells were 
exposed to increasing concentrations of GABA diluted in ECS buffer, N=4, B) cells exposed to increasing 
concentrations of XHE-III-74A in combination with a constant concentration of GABA EC 20 or 1µM. 
Compound was solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of 
XHE-III-74EE in combination with a constant concentration of GABA EC20 or 1µM. Compound was 
solubilized in 1% max DMSO, N=6 
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A cyropreserved vial of cells in low passage (3) were unthawed and allowed to adjust until 
passage 5. These cells were harvested and then exposed to the same tests, Figure 153. And again 
at passage 7, Figure 154, however the shifted dose response persisted. 
Figure 153. Dose response curves for Jurkat E6-1 cells in passage 5. A) Cells were exposed to increasing 
concentrations of GABA diluted in ECS buffer, N=4, B) ce lls exposed to increasing concentrations of 
XHE-III-74A in combination with a constant concentration of GABA EC 20 or 1µM. Compound was 
solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of XHE -III-74EE in 
combination with a constant concentration of GABA EC20 or 1µM. Compound was solubilized in 1% max 
DMSO, N=6  
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Thus a new vial of Jurkat E6-1 cells were purchased from the manufacturer. These cells 
were put into culture and assayed in passage 2. The results, Figure 156, better reflect the initial 
GABA dose respone curves collected. The difference in GABA dose response may indicate some 
change in the expressed subytpe population over passage time, however this line of inquiry was 
not pursued further. The cumulative graphs for GABA dose response and modulator application 
for the experiments perfomed on the newly purchased Jurkat cells can be seen in Figure 155.  
Figure 154. Recapitulation of dose response curves for Jurkat E6-1 cells in passage 5. A) Cells were 
exposed to increasing concentrations of GABA diluted in ECS buffer, N=4, B) cells exposed to increasing 
concentrations of XHE-III-74A in combination with a constant concentration of GABA EC 20 or 1µM. 
Compound was solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of 
XHE-III-74EE in combination with a constant concentration of GABA EC 20 or 1µM. Compound was 




Figure 156. Dose response curves for Jurkat E6-1 cells in passage 2. A) Cells were exposed to increasing 
concentrations of GABA diluted in ECS buffer, N=4, B) cells exposed to increasing concentrations of 
XHE-III-74A in combination with a constant concentration of GABA EC20 or 0.1µM. Compound was 
solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of XHE -III-74EE in 
combination with a constant concentration of GABA EC 20 or 0.1µM. Compound was solubilized in 1% 
max DMSO, N=6 
Figure 155. Cumulative data sets of dose response curve for Jurkat E6 -1 cells in passage 2 . A) Cells were 
exposed to increasing concentrations of GABA diluted in ECS buffer, N=8, B) cells exposed to increasing 
concentrations of XHE-III-74A in combination with a constant concentration of GABA EC 20 or 0.1µM. 
Compound was solubilized in 1% max DMSO N=12, 
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As the presence of TSPO could be intefering with the results; BZD compounds were 
assayed without the presence of GABA. Since TSPO does not bind GABA, any effect observed 
from BZD alone may be due to the peripheral receptor which oftentimes pairs with the anion 
channel VDAC. Thus the compounds were tested with and without the presence of the agonist 
GABA, results are seen in Figure 157. Suprisingly, it would appear that a majority, if not the 
entirety, of the potentiation achieved can be attributed to the application of positive modulator 
alone. To ensure that the modulation was the effect of GABAAR, a battery of tests were performed 
using selective negative modulators of the GABAAR. The GABA competitive antagonist 
Figure 157. Dose response curves for Jurkat E6-1 cells in passage 2. A) Cells were exposed to increasing 
concentrations of GABA diluted in ECS buffer, N=4, B) cells exposed to increasing concentrations of 
XHE-III-74A in combination with a constant concentration of GABA EC20 or 0.1µM. Compound was 
solubilized in 1% max DMSO N=6, C) cells exposed to increasing concentrations of XHE -III-74EE 
without the presence of GABA. Compound was solubilized in 1% max DMSO, N=6  
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bicuculline, the GABA negative allosteric modulator picrotoxin, and the benzodiazepine receptor 
antagonist flumazenil were all tested. The unusual response from these cells can be seen in Figure 
Figure 158. Dose response curves for Jurkat E6-1 cells to negative modulators. Cells were activated (Jurkat+) with 
1µg/mL PHA and 50ng/mL PMA left overnight. 1a) Cells were exposed to increasing concentrations of bicuculline 
in combination with a constant concentration of GABA EC100 or 30µM, compound was solubilized in 1% max 
DMSO with N=2 per curve, 1b) Cells exposed to increasing concentrations of bicuculline in combination with a 
constant concentration of GABA EC3 or 0.05µM, compound was solubilized in 1% max DMSO with N=2 per curve, 
2a) Cells exposed to increasing concentrations of picrotoxin in combination with a constant concentration of GABA 
EC100 or 30µM, compound was solubilized in 1% max DMSO with N=2 per curve, 2b) Cells exposed to incr easing 
concentrations of picrotoxin in combination with a constant concentration of GABA EC 3 or 0.05µM, compound was 
solubilized in 1% max DMSO with N=2 per curve, 3a) Cells exposed to increasing concentrations of flumazenil in 
combination with a constant concentration of GABA EC100 or 30 µL, compound was solubilized in 1% max DMSO 
with N=2 per curve, 3b) Cells exposed to increasing concentrations of flumazenil in combination with a constant 
concentration of GABA EC3 or 0.05µM, compound was solubilized in 1% max DMSO with N=2 per curve. 
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158. These compounds were tested at both GABA EC100 as well as EC3. From the results, it would 
appear that these compounds were potentiating the signal rather than inhibiting it.  
It was hypothesized that this might be due to the slow onset of the negative modulators, 
which are often tested after long preincubation times. Thus a new protocol was programmed into 
the IonFlux to allow for 3 minute long incubations of the modulator compounds followed by 
application of the agonist GABA mixed with respective concentration of the modulator. This 
method however, only allows for the collection of data from 3 different concentrations of the 
compound. The results are seen in Figure 159. 
The response of the control, DMSO, was unexpectedly rising from baseline which could 
be indicative of two conditions: 1) DMSO is eliciting a dose response curve or 2) GABA has a 
slower than expected onset of action and successive doses of a constant concentration is required 
Figure 159. Jurkat E6-1 cells which were preincubated with compound for 180 seconds prior to activation 
with agonist GABA. A) Cells preincubated with increasing concentrations of compound before bein g 
exposed to a constant concentration of GABA EC100 or 30µM.  
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to elicit the maximal current response. These two possiblities were tested and are shown in Figure 
Figure 160. Jurkat E6-1 cells exposed to successive doses of a constant 
concentration of high GABA elicited a dose response curve. N=4  
Figure 161. Jurkat E6-1 cells exposed to increasing percentages of DMSO 
elicit a dose response. N=4 
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160 and Figure 161. Figure 160 reveals that successive doses, upwards of 20, are required to bring 
out a maximum current response to the same concentration of GABA. This would suggest either 
an altered binding profile for these receptors, activation of present GABAB metabotropic receptors, 
or the requirement of surface associated GABA to reach the maximum response. In any case, this 
attribute means that using previous methods, the baseline canot be accurately established in order 
to measure the potentiation caused by positive modulators. Figure 161 reveals another problem 
and that is the sensitivity of the Jurkat cells to DMSO. It would appear that amounts as low as 
0.004% DMSO is enough to potentiate a signal. This may be due to DMSO’s ability to dissove 
Figure 162. Jurkat E6-1 cells exposed to increasing concentrations of zinc 
chloride in constant concentration of GABA EC 100 or 30µM. Salt was 
diluted in ECS buffer. N=7 
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and permeabilize cell membranes 437. Another possibility is that the solvent increases the 
osmolarity, causing slight transient shrinkage, altering the current response. To determine whether 
the negative modulators would have an effect without DMSO; the water soluble, negative 
allosteric modulator zinc chloride was also tested, Figure 162. Without preincubation, the signal 
decreased from 100% to less than 50%.  
The expression of receptor subtypes found in the Jurkat cells as well as the amount of TSPO 
and VDAC has yet to be reported with consistency 298,325,438. It is also worthwhile to keep in mind 
that Jurkat E6-1 cells are a mixture of CD4+, CD8+, CD4+/CD8+, and CD4-/CD8-; all of which may 
express varying levels of GABAAR under differing conditions 
393. To determine the expression 






































































































Figure 163. The relative mRNA expression of GABAAR and TSPO associated 
proteins in inactivated vs activated (+) Jurkat E6-1 cells. Data analyzed using one 
way ANOVA, p>0.05. Statistical significance evaluated with 95% confidence, N=3. 
Jurkat cells were activated (+) by incubation overnight with PMA and PHA.  
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that the most significant changes after activation occurred in the expression of the increased α1, 
increased α6, and decreased β3 subunits. In addition, to a less extent, α3 and α5 also exhibited an 
increase in expression after activation. The amount of TSPO mRNA is comparable to the amount 
of GABAAR subunit which, though nonideal, is more favorable than having quanitites that far 
surpass the GABAAR transcripts. The extremely high amount of α6, coupled with the very low 
amount of α1 makes the Jurkat E6-1 cells a poor model of human T lymphocytes which, despite 
having inconsistent findings for detection, should have low expression of the α6 subunit and the 
highest expression of the α1 318,325. It is well known that cell characteristics can change over time 
with immortalized cell lines and the high amount of α6 mRNA expression may be indicative of 
the status of these cells. The Jurkat E6-1 cells have undergone much criticism for defective 
expression of several enzymes and proteins normally found in T-cells 439.  
GABA has been detected in human peripheral blood monocyte-derived macrophages 321 as 
well as in the macrophage and lymphocytes derived from human psoriatic skin 440. GABA 
secretion has been detected from stimulated mouse macrophages and T cells 317,320. However it has 
yet to be reported, to the extent of my knowledge, whether Jurkat cells endogenously produce the 
ligand GABA. By performing a three phase methanol/chloroform/water extraction, the water 
soluble metabolites of the Jurkat cell lysate were isolated. GABA was detected from this 
extraction, Figure 164. A next step would be to quantify the amounts of GABA produced and 
Figure 164. Detection of GABA in Jurkat E6-1 cell extract by triple quad LCMS-8040 
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under what conditions, such as activation of the cells or addition of a GABAAR modulator, in 
which production of the ligand can either be stimulated or inhibited. However, the method to create 
an LCMS protocol in order to quantify GABA was beyond the scope of this study.  
Though it has then been found that GABA is endogenously produced by Jurkat cells, it has 
yet to be determined whether it is exogenously secreted. If GABA is also secreted by these 
cultured, leukemic human T-lymphocytes then this would further prove that the neurotransmitter 
serves a signaling role. 
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In the attempt to find a more suitable model, murine splenocytes isolated from Ova 
sensitized Balb/c mice were considered. 
Figure 165. GABA current response of murine splenocytes isolated from male 
Balb/c mice. Mice were sensitized with OVA and were either unchallenged (S) or 
challenged in culture (S/C). N=4 per curve. 
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Spenocytes are a heterogenous mixture of different white blood cells purified from splenic 
tissue. The spleen has been described to have a similar structure to a large lymph node and acts as 
storage for red blood cells and lymphocytes. Thus cells isolated from the spleen can consist of T 
and B lymphocytes, dendritic cells, macrophages. The results of the automated patch clamp 
Figure 166. Musclimol current response of murine splenocytes isolated from 
male Balb/c mice. Mice were sensitized with OVA and were either unchallenged 
(S) or challenged in culture (S/C). N=4 per curve.  
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experiment on the mixture is seen in Figure 165. Cells were also exposed to the GABA analog 
muscimol, Figure 166. Muscimol is a non-addictive psychoactive constituent of Amanita muscaria 
Figure 167. Successive doses of GABA on murine splenocytes isolated f rom male 
Balb/c mice. GABA EC100 of 30µM. Mice were sensitized with OVA and were either 
unchallenged (S) or challenged in culture (S/C). N=2 per curve.  
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mushroom and is a potent GABAAR agonist that displays sedative-hypnotic and dissociative 
psychoactivity when taken and binds to the same site as GABA.  
It should be noted that since the splenocytes are heterogenous mixtures of leukocytes and 
the cells were not separated further, population density and morphological characteristics could 
favor a particular cell type. For example, the high population of lymphocytes makes it more likely 
that the cells trapped are either T or B cells; however, macrophages are large and though the 
popultion is low- the cells may be trapped more easily; at the same time, the morphology of 
dendritic cells could prevent them from being easily trapped and sealed with high resistance. 
Electrophysiological characterization of the separated homogenous cell types would be a 
worthwhile endeavor for the future.  
As evidence in Figure 165 and Figure 166, both GABA and muscimol elicited clear dose 
response currents. The current response following successive doses of GABA as well as the 
response of the cells to DMSO were also a concern. The results for these experiments can be seen 
in Figure 167. The murine splenocytes had an inconsistent response to repetive doses of GABA 
EC100. Whether this was a result of the mixed population of trapped cells, changes in receptor 
expression after the OVA challenge, or change in the population of cells after OVA challenge; it 
would appear that the cells require up to 10 repetive doses to reach a maximum response to GABA. 
However this signal rapidly diminishes and can slowly rise back (S/C) or promptly spike back (S) 
Figure 167. In any case, it would appear that the murine splenocytes suffer from the same problem 
as the Jurkat cells as a baseline cannot be accurately established to measure positive modulation. 
The DMSO sensitivity of the murine splenocytes was also evaluated, Figure 168. DMSO 
quantities as low as 0.001% elicit a signficant current response. Confirming the splenocytes 
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sensitivity for GABA, zinc chloride was utilized again as a water soluble negative allosteric 
modulator, Figure 169. Zinc inhibited channel activity, decreasing the signal from 100% to 50%. 
Figure 168. Increasing concentrations of DMSO on murine splenocytes isolated f rom 
male Balb/c mice. Mice were sensitized with OVA and were either unchallenged (S) or 
challenged in culture (S/C). N=2 per curve. 
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The expression of GABAAR in spleen cells from Balb/c mice has, to the best of my 
knowledge, not been found or published. However, the splenocytes from NOD mice have shown 
functional GABAAR
299 and the spleen cells of GAT1+/+ and -/- mice have exhibited expression of 
α1, α2, α5, β1, β2, δ, γ1, γ3 mRNA 2. Thus a qRT-PCR for the murine splenocytes of male Balb/c 
mice was performed, Figure 170. The results had a striking absence of the α1 receptor. The low 
quantities of the β3 subunit as well as the high expression of α2 and α5 corresponds well with the 
results previously published for the spleen cells of GAT1+/+ and -/- mice 2. The quantitites of α3, 
Figure 169. Murine splenocytes from male Balb/c mice exposed to increasing 
concentrations of zinc chloride. Mice were sensitized using Ova. N=2.   
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α4, α6, γ2, VDAC1 and TSPO were not reported previously in any murine splenocytes. The high 
amount of expressed γ2 subunit may represent that the mice may be a misleading animal model 
for studying the immunosuppressive effect of BZDs as the high quanities will provide further BZD 
binding sites than what is found expressed in humans. Furthermore, unlike what was observed in 
the Jurkat cells wherein most mRNA levels rose after PMA/PHA activation- the Ova challenged 
splenocyte cells trended downwards in GABAAR subunit mRNA expression. The α2, α6, and γ2 
subunit mRNA significantly decreased upon Ova challenge of the cells. Whether this is a species 
dependent characteristic for mRNA regulation or that the upregulation observed in Jurkat cells 
were the result of the immortalized status of the cell line is yet unknown. However, these two 
Figure 170. The relative mRNA expression of GABAAR and TSPO associated proteins in Ova 
sensitized and Ova sensitized and challenged (+) murine splenocytes. Spleen cells were isolated  
from male Balb/c mice which were Ova sensitized. Data analyzed using one way ANOVA, p>0.05. 
Statistical significance evaluated with 95% confidence, N=3. Cells were challenged (+) in culture 
overnight ex vivo with Ova. 
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cellular models had significant differences in subunit expression. Most concerning is the lack of 
the α1 mRNA.  
Due to the relative inconsistency of reporting for mRNA quantification in immune cells; it 
was adventageous to perform a qRT-PCR on primary human cells. To do this, human peripheral 
blood mononuclear cells (hPBMCs) were extracted from whole blood. The blood was fractionated 
and the mRNA of the white blood cells collected in the buffy coat was quantified, Figure 171. The 
overall yield of mRNA for 5mL of whole blood was low (40 µL of 102 µg/mL), however the 
quantity was sufficient to perform qRT-PCR. The results coorespond well with previously 
published PCR cDNA band intensity studies with the exception of the high expression of the α5. 



















































Figure 171. The relative mRNA expression of GABAAR and TSPO associated 
proteins in human peripheral blood mononuclear cells. Cells were isolated from 
whole blood extracted from a human female, Asiatic, 28 years of age. N=3.  
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of α1, α3, α4, β2, β3, γ2, δ, ε325 and the other study reporting consistent expression of α1 and δ, 
individual-dependent presence of α3, α6, and γ2, and PHA activated expression of β3 318. It would 
be prudent to compare the primer efficiency between our primers and those used by the two 
publications. 
 
6.3.4 CONCLUSIONS  
The expression pattern of GABAAR in Jurkat E6-1 cells and murine splenocytes represent 
a poor model of healthy human T-lymphocytes. Furthermore the regulation of mRNA expression 
after activation of the cells with PMA/PHA or Ova had opposing effects. The characterization of 
human immune cells after activation has yet to be consistently reported, and would appear to be 
dependent on the individual 318, creating further complications in choosing a representative cellular 
model. Primary human cells, preferably those of an invidual with atopy, would represent the 
optimal paradigm and an easy method of isolation has been performed and described herein.  
As mentioned in the discussion, there has been inconsistency in the reports of 
GABAAR expression in not only hPBMCs and murine splenocytes but also immortalized 
cell lines. Studies into the GABAAR expression in Jurkat cells, for example, one group 
found expression of α1, α3, α4, α6, β1, β2, β3, γ2, ε, and θ 325 while yet another study 
reported expression of α1, α3, α5, α6, β1, β2, β3, φ, and ρ2 298. Interestingly, the supplier 
of the cells for these two groups were the same (European Collection of Cell Cultures, 
ECACC) which should be assumed to be nearly identical cell samples.  In addition to the 
mixed reports on GABAAR expression, TSPO expression in Jurkat cells has also 
experienced similar controversy. TSPO expression has been considered a significant 
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biological marker for cancerogenesis in some tissues and is abundantly expressed in most 
malignant cells 441-443. Some studies have considered Jurkat cells as completely lacking 
expression of the TSPO and have used it as a negative control to show high specificity of 
TSPO-specific ligands. However, several studies have observed expression of TSPO in 
Jurkat E6-1 cells, under the pseudonym PBR 438, due to its upregulation in tumors and 
cancer cell lines and the role it appears to play in apoptosis regulation 444. Interestingly, 
it would appear that the Jurkat TSPO receptors, detected using immunoblot, have only a 
low affinity for classical TSPO ligands which explains its late discovery 445. Jurkat cells 
may then be a better model for testing BZDs as the binding affinity is lower than the 
normal TSPO receptor and would theoretically cause less interference. Whether this 
modified affinity is due to the previously unaccounted for presence of the GABA AR 
detected in our tests is still unknown but may explain the different character ization as 
most other TSPO receptors were studied in cancerous cell lines rather than both cancerous 
and an immunological cell.  
The slow increase in response to repetitive doses of GABA is an incredibly unusual 
and appears to be a unique feature of these immune cells. The differences in response 
from neuronal GABAAR is tantamount to differences in receptor subunit composition, 
subtype populations, unknown subtype variants, and/or surface expression. The slower 
rise and decay of the lymphocytic GABAAR was also observed in whole-cell patch-clamp 
recordings of macrophages 317. In addition, only 7 of the 10 macrophages patched elicited 
a GABA-evoked current. Which would suggest that, despite cell type, individual cells 
may have a varying level of expression of GABAAR. The currents diminished in 
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amplitude with repeated application of GABA, resembling desensitization or possibly 
endocytosis 446. 
A study of human activated T cells vs naïve T cells shows that there is differential 
expression of the GABAAR subunits. One study observed expression of α1, α4, β2, β3, γ1, and δ 
in resting cells and upon activation the β2 and γ1 were lost 323. A similar finding was reported with 
THP-1 cells where α1, α4, β2, γ1, and δ subunits were reported while study of primary human 
monocytes only detected the presence of the β2 subunit 447.  
Importantly, it cannot be ignored that any immunosuppressive effect observed from BZD 
may be the result of TSPO binding. Functional peripheral benzodiazepine receptor TSPO, has been 
observed to have immunosuppressive activity. TSPO expression has been observed in order of 
abundance in the following cells types: monocytes 448, polymorphonuclear neutrophils 449, B-cells, 
natural killer cells 448, CD4+, CD8+ 449, platelets, and erythrocytes 448. In addition, murine 
splenocytes have also exhibited ligand binding, particularly in the macrophage population but also 
in the T-cells which show 5-fold lower binding 450. It has also been observed that murine lymph 
node and spleen cells experienced inhibition of T and B cell stimulation by benzodiazepines 451. 
In addition, when diazepam and clonazepam were administered to pregnant mice, the offspring 
had significant inhibition of T and B cell proliferative response 452. This effect was enhanced using 
TSPO selective agonist Ro5-4864 453. Yet another study of long-term treatment with BZDs in rats 
has observed an increase of the percentage of T-lymphocytes and decrease in B lymphocytes and 
increase in corticosterone serum levels. Long-term treatment with BZDs decreased the number of 
apoptotic and necrotic cells 454. BZDs have also been shown to decrease mast cell and TNF-α 
production as well as suppress the activation of the IL-6 455-457. TSPO receptors are present locally 
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in the lung 458 and expression has been shown to be affected by cigarette smoke 459, suggesting that 
inhalation of therapeutics would have an effect. Interestingly, most recently there has been interest 
in developing drugs selective for TSPO. XBD173 appears to be an excellent non-sedative 
anxiolytic and antipanic agent that has high selectivity for TSPO.  
A study of TSPO specific PK11195 and Ro5-4864, mixed type diazepam, and GABAAR 
specific clonazepam; has found that these compounds all inhibited mitogen-driven proliferation of 
B- and T-cells in vitro as well as the suppression of IL-2 and IL-2 receptor expression 451. However, 
clonazepam was around half as active and Ro15-1788 failed to antagonize the actions of both 
diazepam and clonazepam which may suggest an altogether new receptor type that is both distinct 
from TSPO and from GABAAR. Interestingly, FG7142 and DMCM, anxiogenic inverse agonists, 
have also been observed to induced severe immunosuppression in rodents within 24hr 78. One 
study has also reported the differential effect of two GABAAR modulators alprazolam and 
clonazepam on the immune systems of stressed adult male rats. The study found that both 
compounds increased neutrophil count while decreasing lymphocytes, anti-SRBC titer, and IL-2 
level. Alprazolam was more effective than clonazepam and the toxic effects were exacerbated by 
stress. Stress is generally considered to be immunosuppressive and increases susceptibility to 
infections and cancer 460,461. Clonazepam has also been found to bind strongly to TSPO receptors 
in rat aortic smooth muscles compared to other BZDs, concentrated in mitochondria 462. Taking 
this evidence into account, dually targeting both GABAAR and TSPO may present a more effective 
means of asthma treatment than targeting either of them individually. 
Intriguingly, after injury, TSPO has a significant increase in expression suggesting that it 
is involved in the neuroimmunological response. TSPO has been used as a biomarker of brain 
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damage and neurodegeneration since expression levels under normal conditions are low 463. The 
selective expression of TSPO to locally damaged regions has been observed in Alzheimer’s, 
frontotemporal dementia, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis, 
and Parkinson’s 463. They have also been found in mast cells and macrophages 464-466. In addition, 
those with generalized anxiety disorder, social anxiety, PTSD, and panic disorder have reported 
reduced TSPO expression 463. High affinity phenylpurine TSPO ligand XBD173 was able to 
alleviate panic attack in rodents and humans with no sedative properties 467. Administration has 
had anxiolytic and anticonflict actions and is correlated with increases in allopregnanolone, 
pregnenolone, progesterone and THDOC 468.  
However, caution should be taken in targeting the TSPO protein as evidenced from 
alpidem, which was an approved TSPO ligand in 1991 France to treat anxiety. This compound 
caused severe and sometimes lethal liver damage and was withdrawn by 1994 469. Despite this, 
recently another TSPO specific compound called AC-5216 has been under review for its 
antianxiety and antidepressant-like effects 470.  
There is also the possibility that the α4 found expressed in the immune system are not 
assembled in the α4β3γ2 or the α4β3δ. It has been reported that a significant part of native 
GABAAR containing α4 does not contain either the γ or the δ subunit 471,472.  
Evidence that targeting the GABAergic system in immune cells has shown promise for the 
treatment of asthma. Oral GABA decreases IgE levels in Ova sensitized Balb/c mice and exhibited 
an increase in Th1 associated IFN-γ and a decrease in Th2 associated IL-4 473. This is particularly 
significant for allergic responses which are associated with IgE production and a Th2 response. 
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In conclusion, the highly variable levels and plasticity of expression would suggest that 
there is a dynamic regulation of the receptor subunit which is dependent on species, state of 
activation, cell type, and the individual. Although we have ascertained that GABA is endogenously 
produced, it has yet to be determined whether GABA is also exogenously secreted in human cells. 
If GABA is secreted then this would further prove that the neurotransmitter serves a signaling role 
that may allow T-cells to communicate not only among themselves but also with neuronal CNS. 
Furthermore, it would be interesting to determine whether the amount of GABA that is 
endogenously produced increases or decreases after activation and differentiation; as well as the 
effect that BZDs might have on the quantities of GABA produced. Elucidating this mechanism of 
possible autocrine/paracrine signaling may give valuable insight into understanding how 
coordination and cross-talk occurs between the immune and nervous systems.  
6.2 Implications of Findings  
The CNS is segregated from the rest of the body with the existence of the Blood-Brain 
Barrier (BBB) that facilitates ion balance, nutrient transport and blocks the entrance of harmful 
molecules. The BBB was first discovered after a series of landmark experiments. In 1885, Paul 
Ehrlich injected water-soluble dye into the circulatory system which stained all organs except the 
brain and spinal cord 474. Though at first, he mistakenly attributed this finding to the nervous 
tissues’ low affinity to the dye 475. Ehrlich’s student Edwin Goldman later injected trypan blue 
directly into the cerebrospinal fluid and successfully stained the brain but did not enter the 
periphery 476.  It was later found that basic aniline dyes crossed the BBB but acidic aniline dyes 
did not. An extensive review was published of the permeabilities which resulted in the discovery 
that passage through the barrier was dependent on electrochemical properties. Compounds with a 
positive or no charge at blood pH are capable of passing but those with a negative charge are 
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impermeable 477. Further study on the matter found more complex results that took into account 
the molecular weight, size, binding affinities, dissociation constants, lipid solubility, and charge 
478.  
The central nervous system was once previously considered to exist completely separately 
from the peripheral immune system. Typically, white blood cells in lymph nodes detect foreign 
pathogens, causing an immune response. These lymphatic vessels were never detected in the brain 
and thus it was assumed that the brain was entirely disconnected. However, the recent discovery 
of lymphatic vasculature in the CNS has led to a revolution in our understanding of 
neuroimmunology and neurodegenerative diseases associated with immune system dysfunction 
479. The necessary connection between the immune system and central nervous system would 
necessitate a balancing act to avoid overstimulation and inflammation in the brain; making 
communication between the two systems vital. How these two systems communicate has yet to be 
discovered but the presence of neurotransmitters in the immune system and their ability to mediate 
immunological response may be a hint to this mystery. 
It has long been understood that the CNS regulates the innate immune response, controlling 
cytokine production in the spleen. The action potential is transmitted by the vagus nerve to the 
spleen by release of the neurotransmitter acetylcholine 480. When this regulation is unrestrained, 
the cytokine cascades can be lethal, leading to sepsis 481. In addition, the newly discovered 
lymphatic vessels may play a role in neurological diseases with a strong immunological element 
such as MS, autism, and Alzheimer’s disease. Another study, by Jonathan Kipnis, has suggested 
that some compound exists that is released from the injured CNS and is transmitted to deep cervical 
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lymph nodes through lymphatic vessels where it activates the immune system 482. This may explain 
the presence of similar receptor ion channels which might aid in the cellular signaling.  
Interestingly, comorbity of asthma with psychological disorders is common with anxiety 
occurring in between 16-52% and mood disorders in 14-41% 483. However, whether asthma causes 
psychological problems or if psychological problems cause asthma has yet to be determined 484. 
Perhaps this is why, historically, asthma was seen as a psychological illness. 
A major question that has yet to be fully addressed is what is the role the immune system 
plays in psychiatric disorders? There are multiple observations that link immune dysfunction with 
depression: patients with depression have a higher incidence of immune abnormalities, depression 
is a common side effect of cytokine therapy, IL-1 administration induces depression-like sickness 
behavior, activation of the hypothalamic-pituitary adrenal axis (HPAA) with some cytokines, other 
cytokines activate the brain serotonergic systems. All of these points will be discussed in order 
below.  
Immune dysfunction has been observed in patients with depression for over a century. The 
earliest studies found that depression weakened the immune function in patients 485 but recent 
studies have found the opposite effect of depressed patients having heightened immune activation 
486. A review by Kronfol 487 notes that major depression is associated by positive acute-phase 
proteins and lower plasma concentrations of negative acute-phase proteins which is indicative of 
an inflammatory state. It has been suggested 488 that chronic depression is associated with chronic 
inflammation. This is consistent with reports that depressed patients have elevated concentrations 
of prostaglandins and cytokines 487,489.  
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Cytokine therapy has been used in the treatment of a variety of medical conditions 
including hepatitis C, multiple sclerosis, infections, leukemia, kaposi’s sarcoma, melanoma, 
myeloma, renal carcinoma and other forms of cancer. Cytokines are divided into two groups: the 
pro-inflammatory and the anti-inflammatory. The proinflammatory cytokines include the IL-1, IL-
6, and TNF which work to attract immune cells to the site of infection or injury and activate them 
to respond. The anti-inflammatory cytokines include the IL-10 and IL-13 which inhibit the 
synthesis of pro-inflammatory cytokines. The most common cytokines in these therapies utilize 
IFNα, IFNβ, IFNγ, and IL-2. Depression is most often associated with the treatment using IFNα 
and IL-2, it has also been observed with IFNβ but interestingly not with IFNγ 490,491. 
Administration of IFNα, IL-1 and IL-6 have been shown to effect brain serotonergic systems which 
have been implicated in major depressive disorder. A recent meta-analysis on the immunology of 
depressed patients was performed and found that major depression is associated with overall 
leukocytosis, increased CD4/CD8 ratios, increase in the circulating haptoglobin, prostaglandin E2, 
and IL-6 concentrations and reduced natural killer (NK)-cell cytotoxicity. It is interesting to note 
that the paper did not find consistent elevation of IL-1, the sole cytokine that induces depression-
like behavior in animals, in depressed patients 492.  
Sickness behavior is the observed behavioral changes that occur during the course of an 
infection. The changes include lethargy, depression, anxiety, loss of appetite 493, sleepiness 494, 
hyperalgesia 495, reduced grooming 496, and lowered abilities to concentrate 497. Sickness behavior 
can be induced in animals through the administration of endotoxin lipopolysaccharide (LPS) or 
the cytokine interleukin-1 (IL-1).  
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HPAA activation is one of the most consistent biological markers for depression (50-70% 
occurrence rate). So the fact that IL-1 potently activates the HPAA appeared to be further evidence 
of this theory 498. 
Most drugs used to treat depression inhibit serotonin reuptake despite lack of evidence that 
abnormalities in 5-HT cause depression 499. Theoretically, if low serotonin levels caused 
depression, antidepressants should rapidly alleviate symptoms. However, serotonin reuptake 
inhibitors can require more than a month to achieve efficacy 500. Despite these quandaries, 
serotonin reuptake inhibitors do alleviate depressed mood in many individuals. Some researchers 
have posited that the drugs increase neurogenesis and alleviation of depression may be a result of 
the long-term effects of the increased neuronal population 501,502. Recent estimates show that 
current antidepressants available on the market only work in 60% of patients 503. Thus continued 
pursuit of research into antidepressants is necessary. 
Accumulating evidence for the linkage between depression and immunological 
dysfunction has been increasing. Raz Yirmiya was the first psychobiologist to liken that the 
symptom markers of major depressive disorder and sickness behavior are identical. In an 
experiment using rats treated with cytokines, he found that they were less sensitive to the rewarding 
properties of a saccharin solution and sexually-active partner 504. This was able to be treated using 
chronic administration of antidepressant drugs. This has led to the theory known as “the cytokine 
hypothesis of depression” and proposes that depression could be the result of cytokine secretion 
due to activation or dysfunction of the immune system 504-507. Another version of the hypothesis, 
found that depression was associated with increased secretion of cytokines (particularly IL-1) by 
macrophages and that this process specifically is the cause of depression 508. This theory, it would 
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appear, has been elevated to the level of folklore status in the research community 486. Yet another 
version of the theory proposes that immune activation in the periphery induces the production of 
cytokines and their receptors in the brain 509. The activation of this response is believed to be 
initiated through stimulation of the vagus nerve which translates through the brain stem and into 
the forebrain 510,511. 
However, it has yet to be determined as to whether cytokines are a cause of major 
depressive disorder or the cause. And although depression has received most of the attention, 
anxiety has also been linked to inflammation. An elevated level of Il-6 is observed in people with 
anxiety independent of depression-like symptoms. This has been purported to be a possible 
explanation as to why anxiety increases the risk of other inflammatory conditions 512. Mice 
overexpressing IL-6 or TNF display an anxiogenic phenotype 513,514 and knockout of INF-γ 
enhances anxiety-like behavior in rodents 515. In addition, the inflammatory state in schizophrenia 
is also associated with increases in prostaglandin E2 and increase in cyclooxygenase-2 (COX-2) 
expression. Infection of pregnant mothers later resulting in offspring who developed schizophrenia 
has also often been reported 516,517. Even in animal models, an immune activation of the mother 
during the second trimester of pregnancy led to schizophrenia-like symptoms in the offspring 518. 
Another study found that increased IL-8 levels in human mothers was associated with a heightened 
risk of offspring developing schizophrenia 516. There is also a fivefold increase in risk of 
developing psychoses if the infection invades the CNS in early childhood 516,519-522. Another study 
has observed that unmedicated schizophrenia patients have a significantly higher number of 
monocytes than healthy controls 523. Although, the same problem appears with this theory as it is 
unknown whether anxiety causes inflammation or inflammation causes anxiety.  
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Inflammation is also observed in age-related neurodegenerative diseases, such as 
Parkinson’s disease (PD). Such diseases are characterized by loss of certain neuronal 
subpopulations, nigral dopaminergic neurons in PD, and the inflammatory response from the 
soluble factors secreted from injured neurons during degeneration appears to be an important factor 
in disease progression 524. Chronic activation of microglia has been implicated in 
neurodegenerative disorders 525 as the brain ages, the amount of proinflammatory cytokines CD80, 
CD86 and ICAM-1 rises 526 while the levels of anti-inflammatory cytokines IL-10 and IL14 drops 
527. In addition, with age comes the deterioration of the BBB ultimately leading to cognitive decline 
and dementia 528,529. 
An interesting phenomenon worthy of noting is the ability of psychological stress to trigger 
or exacerbate clinical symptoms in patients with asthma. This ability of stress in the mind, effecting 
the immune system is well documented. Children with asthma who experience an acute negative 
life event (death of a close family member) have a 2-fold increased risk of subsequent asthma 
attack while children with acute and chronic stress have a 3-fold increase in risk of attack in the 
two weeks following the acute event 530. Studies with asthmatic college students during periods of 
high stress (final exam period) found that around final exams, challenge with the allergens they 
were sensitized to resulted in a higher number of eosinophils in both the sputum and blood 531 . A 
similar study within high school students found that there is a reduction in Th-1 cytokines IFN-g 
and IL-2 but an increase in pro-inflammatory Th-2 cytokine IL-6 532. 
It has been theorized that the way stress amplifies the immune response involves the 
activation of the HPA axis. The process first begins when the hypothalamus secretes corticotropin-
releasing hormone (CRH). This triggers a release of adrenocroticotropin hormone (ACTH) in the 
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anterior pituitary gland. ACTH signals the zona fasciculate to stimulate the production of cortisol 
which binds to glucocorticoid receptor. The glucocorticoid receptor has been shown to regulate 
the expression of anti-inflammatory IL4, IL-5, and IL-13 on T-lymphocytes after activation from 
an allergen, leading to a shift to Th2-mediated immunity. Allergic diseases, such as asthma, 
rhinitis, aczema, and IgE-mediated food allergy, are characterized by a dominant Th2 response 533. 
The HPA axis can be potently activated in situations that necessitate high levels of social 
evaluation which elicit self-conscious emotions like shame which produces ACTH and cortisol 534. 
In children who experience both chronic and acute stress, a 5.5 fold reduction in glucocorticoid 
receptor mRNA was observed 535 suggesting that the down regulation leads to glucocorticoid 
resistance. Stress episodes before the development of the disease may then increase the 
susceptibility of the individual 536. It has been found that the presence of high doses of cortisol bias 
the immune system towards excessive Th-2 cytokine response which may result in severe and 
prolonged symptoms following exposure to a trigger 328. Thus, the effects of GCs and β2 agonists 
appear beneficial in the short-term, the long-term effects might perpetuate the increased 
vulnerability of the patient to allergens. In fact, in vitro and in vivo studies have found that GCs 
and β2 agonists potentiate IgE production 537,538. 
Adrenergic receptors expression levels also appear to be effected by psychological stress. 
These receptors present on T- and B-cells regulate the expression of IL-4, IL-5, IL-13, histamine 
release by activated mast cells, and recruitment and activation of eosinophils in the airways. In 
children experiencing both acute and chronic stress, there was a 9.5-fold reduction in mRNA levels 
of the β2-adrenergic receptor 535 making the B2 agonist drugs less effective. 
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Another interesting effect of stress effecting the immune system comes from the 
observation that during pregnancy, Th-1 related diseases such as RA and MS remit but exacerbate 
postpartum. It was found that during pregnancy there is an increase in secretion of cortisol, 
norepinephrine, and 1,25-dihydroxyvitamin D3 and a reduction in monocytic production of Th1 
type proinflammatory cytokines IL-12 and TNF-α. During pregnancy, cytokine production skews 
toward the Th2 type with an increase in IL4 and IL10 in particular 539 
The relationship between the immune system and the central nervous system is a still 
evolving field of study. Despite being segrated from the rest of the body by the BBB, the CNS still 
needs to be monitored for infection and/or trauma. Recent advances have observed how peripheral 
leukocytes such as CD4+ cells gain critical surface molecules which allow them to traverse the 
BBB, rendering them capable of accessing the CNS to participate in surveillance and clearance of 
antigens 540. A break-down in neural-immune interactions can result in unchecked inflammation 
in the CNS such as the autoimune demyelinating disorder, multiple sclerosis.  
Some things to take into consideration for the future. The observed effect of anesthetics 
such as BZDs on ventilary control has observed that in the use of an animal model; rodents required 
10-fold higher dosage to achieve the equivalent respiratory depression observed in humans 541. 
Furthermore, human, mouse and rats have a differential expression of GABAAR in T-lymphocytes. 
One study found that 5, 8, and 13 different GABAA subunit isoforms in human, mouse, and rat 
CD4+and CD8+ T cells, respectively. The BZD sensitive γ2 subunit was only detected in mice 
which may make mouse studies untranslatable to human.  
An i.p. injection has direct access to the vagal terminals in the peritoneum, is taken up by 
the lymphatic system and transported to the mesenteric lymph nodes, and then to the liver. Because 
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of this route, compounds are exposed to degradative enzymes and clear the liver, after which, it 
enters the bloodstream and is transported to the heart. In contrast, a substance injected via i.v. 
rapidly diffuses to the heart and then to the lungs, before distributing through the rest of the body 
542. The efficient and rapid diffusion of inhaled particles from the lungs into systemic circulation 
has been well studied 543 and thus makes an inhaled therapeutic an attractive option.  
Animal models have been indispensable to understanding and developing treatments for 
asthma, however these models ignore the complex facets of the disease. Access to patient tissues 
would greatly increase our understanding of the disease. 
In addition to asthma, there are many other immunological opportunites for designing new 
therapeutics through targeting GABAAR.  
GABAAR has been implicated in having an active role in the pathogenesis of psoriasis. 
Recent studies have found that there is a marked increase in the expressed GABA ligand and 
GABAAR in the involved skin of psoriatic patients 
440. There have also been reports that treatment 
with GABA analogues such as gabapentin and pregabalin have led to improvement in psoriasis 
544. In addition, oral pregabalin has been shown to ameliorate chronic polycythemia vera-
associated pruritus 545 and uremic pruritus 546,547 
In another study, a cell line P815 which are mast cells with mastocytoma were found to 
contain α1 and α2 subtypes while H9 cells, which are T-cells, were found to contain α1, α4, and 
β1 subunits. In these two cell lines, GABA appeared to modulate cytotoxicity of immune cells. 
The presence of GABA and GAD in these cell types may be a clue about autoimmune diseases 
such as stiff-man syndrome in which patients develop antibodies to GAD 548.  
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In addition, low doses of GABA were able to dramatically inhibit the development of 
proinflammatory Th1 responses and disease progression in non-obese prediabetic type 1 diabetes 
(NOD) mice 322. This may be a result of an observed arrest in T-cell receptor (TCR)-mediated T-
cell cycle progression by GABA 322. The arrest stalled cells in the G0/G1 phases but did not lead to 
cell apoptosis. This study also found that naïve T cells and activated T cells from the mice 
expressed α1, α2, β1, β2, and δ. Activation also resulted in the strong expression of γ3, the 
induction of which may suggest a specialized function in activated T cells.  
GABA also appears to play a role in autoimmune disorders. Multiple Sclerosis (MS) 
patients have a decrease in GABA serum levels during relapse 549 and in the mouse model of 
rheumatoid arthritis and obesity, orally administered GABA down-regulates the inflammatory 
response 362,550. It could be that the decrease in GABA serum is due to low production in the 
 284 
 
immune system and thus low inhibition of T cell activity, leading to higher levels of cytokine 
Table 16. Summary of the studies performed on GABA in the immune system. References (Ref.) are from 
1-14 are found in the text. 
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production and thus inflammation. 
 The role of GABA, and neurotransmitters in general, in the immune system and immune-
related diseases is still under study. A summary of studies performed on GABA in the immune 
system is shown in Table 16 2,317-319,321-325,364,447,548,551. Future work is necessary as the cross-talk 
between the immune and nervous system present the opportunity for the creation of new strategies 
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Research Project Highlights:  
 
 Development of 6 Stable Recombinant Cell Lines Containing GABAA Receptor 
Subtypes with long (>10 passages) term stability to determine subtype selectivity of 
drugs which can be utilized in large scale drug screening assays. 
 
 Utilization of neuronal iPSCs for drug screening on automated patch-clamp to provide 
the overall response from a native population of mixed GABAAR. 
 
 Development and optimization of high-throughput fluorescence-based assay for GABAA 
receptor in multiwell plate format using an eYFP on the Tecan Infinite M1000 which 
can be used in parallel with the stable recombinant cell lines.  
 
 The study of GABAAR found natively in white blood cells and characterization of their 
electrophysiological and kinetic properties contributed to $2 Million collaborative grant 
from the NIH to develop new asthma therapy with the Milwaukee Institute for Drug 
Discovery (MIDD). 
 
Graduate Teaching Assistant, 2011 to 2014 
 
 Instructed twenty-four different discussions and laboratory classes ranging in rudimentary to 




 Excellent reviews given through anonymous student surveys. 
 
UWM-RESEARCH FOUNDATION (non-profit corporation to support research and innovation at UWM by 
providing funding for scholarships and grants and fostering corporate partnership) –Milwaukee, WI 
 
Graduate Student Ambassador, 2014 to Present 
 
 Assessed the commercial potential and patentable technologies of research performed by 
graduate students across the UWM campus through personal interviews.  
 
 Organized events for graduate students to tour industry partners and present their 
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 GLCACS Student Research Presentation Award 2015 GLCACS 19th Annual Conference: 
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 Keith Hall Award Excellence in Graduate Research 2015 University of Wisconsin-Milwaukee, WI 
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 UWM Graduate Student Travel Award 2012 ACS 243rd National Meeting: San Diego, CA 
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SKILLS AND TECHNIQUES 
 
Specialization 
 Ion channels electrophysiology using cutting edge technology in automated patch-clamp 
 High-throughput assay development 
 
Biochemical 
 Mammalian cell cultures 
o HEK293T 
o iPSCs 
o Jurkat E6-1 
o HL-60  













o Stable cell line 
generation 
 Animal handling 
certification for mice 
o Rotorod 
o Drug dosing 
o Human tumor 
xenografts 





 Assay development and 
troubleshooting 
 High throughput 
screening 
 Tecan M1000  
 Microsoft Excel 





 Fluorescence based 
toxicity assays  
 qRT-PCR Thermocycler 
 SDS-PAGE gel  
 Agarose gel  
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Receptor and Coactivators. Premchendar Nandhikonda, Wen Z. Lynt, Megan M. McCallum, 
Tahniyath Ara, Athena M. Baranowski, Nina Y. Yuan, Dana Pearson, Daniel D. Bikle, 
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POSTER AND ORAL PRESENTATIONS 
 
1. Electrophysiological Assay of GABAA Receptor: Roles in Neuropharmacology & Immunology, Nina Y. 
Yuan, Dr. James M. Cook, Dr. Alexander Arnold. UWM Chemistry and Biochemistry 
Research Symposium, Poster presentation, May 2016.  
 
2. Electrophysiological Assay of GABAA Receptor: Roles in Neuropharmacology & Immunology, Nina Y. 




3. Electrophysiological Assay of GABAA Receptor: Roles in Neuropharmacology & Immunology, Nina Y. 
Yuan. Great Lakes Chapter Chinese American Chemical Society, Oral presentation, May 
2015. Winner of GLCACS Student Research Presentation Award. 
 
4. Electrophysiological Assay of GABAA Receptor: Roles in Neuropharmacology & Immunology, Nina Y. 
Yuan, Michael Poe, Chris Witzigmann, Dr. James M. Cook, Dr. Alexander Arnold. UWM 
Chemistry and Biochemistry Research Symposium, Poster presentation, April 2015. Winner 
of 1st place presentation Keith Hall Award for Excellence in Graduate Research. 
 
5. Development of High-Throughput Assays to Identify New Alpha Subtype-Selective GABAA Receptor 
Modulators to Treat Anxiety and Depression Disorders, Gordon Research Conference: Ion 
Channels (GRS), Oral Presentation, July 2014. 
 
6. Development of High-Throughput Assays to Identify New Alpha Subtype-Selective GABAA Receptor 
Modulators to Treat Anxiety and Depression Disorders, Nina Y. Yuan, Michael M. Poe, Chris 
Witzigmann, Dr. James M. Cook, Dr. Alexander Arnold. Gordon Research Conference: Ion 
Channels (GRC), Poster Presentation, July 2014. 
 
7. Development of High-Throughput Assays to Identify New Alpha Subtype-Selective GABAA Receptor 
Modulators to Treat Anxiety and Depression Disorders, Nina Y. Yuan, Michael M. Poe, Chris 
Witzigmann, Dr. James M. Cook, Dr. Alexander Arnold. Gordon Research Conference: Ion 
Channels (GRS), Poster Presentation, July 2014 
 
8. Automated Patch Clamp: High-Throughput Electrophysiological Assay for Neuropharmacology Research in 
Mammalian Cells, Nina Y. Yuan. UWM Neuroscience Workshop, Oral Presentation, July 
2014. 
 
9. Development of High-Throughput Assays to Identify New Alpha Subtype-Selective GABAA Receptor 
Modulators to Treat Anxiety and Depression Disorders, Nina Y. Yuan, Michael M. Poe, Dr. James 
M. Cook, Dr. Alexander Arnold. UWM Chemistry and Biochemistry Research Symposium, 
Poster presentation, April 2014. 
 
10. Identifying New Treatments for the Brain: Electrophysiological Assay and Generation of a Stable 
Recombinant Cell Line, Nina Y. Yuan, Michael M. Poe, Dr. James M. Cook, Dr. Alexander 
Arnold. Yao Yuan Biotech/Pharma International Symposium, Poster presentation, April 
2013.  
 
11. Identifying New Treatments for the Brain: Anxiolytic Neurochemistry and Electrophysiology, Nina Y. 
Yuan, Michael M. Poe, Dr. James M. Cook, Dr. Alexander Arnold. UWM Chemistry and 
Biochemistry Research Symposium, Poster presentation, April 2013. Winner of 1st place 
presentation Keith Hall Award for Excellence in Graduate Research. 
 
12. Uppers, Downers, All Arounders: Identifying New Treatments for the Human Brain, UWM Chemistry 
and Biochemistry Research Symposium and Recruiting, Oral presentation, April 2013. 
 
13. Benzodiazepine Specificity of GABAA Receptor Subtypes: High-Throughput Electrophysiological Assay 
with Transiently Transfected Cells, Nina Y. Yuan, Michael M. Poe, Dr. James M. Cook, Dr. 
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Alexander Arnold. ACS 243rd National Meeting, San Diego, CA, Poster presentation, March 
24-30, 2012. 
 
14. Benzodiazpine Specificity of GABAA Receptor Subtypes, Nina Y. Yuan, Dr. James M. Cook, Dr. 
Alexander Arnold. UWM Chemistry and Biochemistry Research Symposium, Poster 






The Study of GABAAR Found Natively in White Blood Cells and their Pharmacological Properties. Interpretation 
of Significance in Disease Models, Prevention, and Treatment  
 Study of Jurkat E6-1 cells have revealed the presence of the GABAAR in T-lymphocytes. These 
cells are responsive to GABA and their analog muscimol. In addition, the kinetic profile of these 
receptors differ from those found in our recombinant cell lines. These receptors are 
characterized by slow saturation kinetics. Splenocytes analyzed via patch-clamp also exhibit 
exceptionally high responses to the application of GABAAR ligands and immunocytochemistry 
has shown significant quantities of the receptor expressed on T and B lymphocytes and 
macrophages. 
 
Development of 6 Stable Recombinant Cell Lines Containing GABAA Receptor Subtypes  
 The generated cell lines show high expression of the proteins and expected electrophysiological 
response. Immunocytochemistry shows uniform expression of the receptors in the generated 
cell lines. Stability of expression over 15 passages has been confirmed by qRT-PCR. 
 
Construction of 6 Single Plasmid Systems for GABAA Receptor subtypes 
 Design of plasmids containing all three necessary components for a functional GABAAR (α, β, γ) 
with intention for genetically engineering stable mammalian cell lines using PhiC31 integrase 
gene and Cytomegalovirus immediate-early promoter to achieve high levels of expression in a 
HEK293T cell line. 
 
iCell Human Neuron Evaluation and GABAA Receptor Quantification via RT-PCR and Automated Patch 
Clamp  
 The use of human neurons derived from pluripotent stem cells, coupled with automated patch 
clamp, were assessed to determine relative efficiency and quality of data yield. In order to find 
this, cells were evaluated proteomically and genomically through their electrophysiological 
profile and their mRNA levels. Cells performed excellently on automated patch clamp. We 
concluded that screening compounds on recombinant cell lines to determine subtype selectivity 
in parallel with human-induced pluripotent stem cell neurons can provide a valuable and unique 
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perspective on the effects of GABAAR ligands. It was determined that coupling these two 
techniques can provide an excellent representation of the complexity arising from multiple 
subtypes expressed on a single cell.  
 
High-Throughput Fluorescence-Based Assay for GABAA Receptor  
 Using an Enhanced Yellow Florescent Protein which quenches in the presence of chloride ions, 
cells were transfected and the assay was optimized for use in a 96 and 384-well plate with our 
stable recombinant cell lines. Measurements were optimized to use a Tecan M1000. 
 
Methylglyoxal/Glyoxalase 1 Anxiety Project  
 Determination whether methylglyoxal acts as an agonist towards the GABAA Receptor. 
Transiently transfected cells containing the α1β3γ2 were assayed and resulted in a strong 
hyperpolarizing effect with a dose response curve. This proves that a Glo1 inhibitor is a 
potential candidate for modulation to treat anxiety. 
 
Pharmaceutical Company Proprietary Compound Testing-Collaboration  
 A short collaboration with a pharmaceutical company, testing their subtype selective compound 
to determine if the deuterated form changes its pharmaceutical properties. 
 
HZ-166 Testing Cook Compound 
 The project involved determination of instrument ability to measure specific subunit selectivity 
of alpha subtype-selective drugs. This was accomplished by testing receptor subtypes containing 
α1-6, β3, and γ2 with a novel benzodiazepine-based compound provided by Dr. James M. Cook 
(UWM) dubbed HZ-166. Measurements taken reveal similar results as those previously 
published using manual patch-clamp methods. 
 
Automated Patch Clamp IonFlux Assay Development and Troubleshooting 
 The objective of this study was the establishment of an automated (IonFlux, Fluxion) patch-
clamp assay capable of measuring the electrophysiological response of benzodiazepine-bassed 
compounds to the GABAA receptor in transiently transfected mammalian (HEK293T) cells.  
 
Determination of binding of inhibitors to Vitamin D Receptor-Coregulator  
 VDR, involved in cell proliferation and differentiation, is a pharmaceutical target for treatment 
of a variety of disorders with a concentration on cancer. Disruption of the transcription process 
with co-regulator inhibitors are a potential method to combat cancer progression and 
development. This project involved performing in vivo study performed on mice and in vitro 
determination of binding behavior of small molecule to protein using dialysis and subsequent 
fluorescence polarization to identify whether molecules were reversible or irreversible inhibitors. 
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